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Abstract 
Microencapsulation for Therapeutic Applications 
Nikhil O. Dhoot 
Margaret A. Wheatley 
 
 
 
  
Microencapsulation has proved to be a powerful technique in the field of drug 
delivery. A great deal of research is directed towards studying the use of various 
microencapsulation systems for that purpose. This study investigates the use of 
microencapsulation in alginate for protein delivery and delivery of gene therapy 
products for the treatment of spinal cord injury.  
 Liposomes were encapsulated in alginate to form a drug delivery system 
which allows for multiple control points for drug release. We found that the 
crosslinking ion has a marked effect on the release profile. PC/Chol and PC/PG/Chol 
liposomes encapsulated in Ca2+ crosslinked alginate released protein rapidly in the 
form of a burst which was eliminated by crosslinking the alginate with Ba2+. 
Liposome composition also plays an important role in the release from 
microencapsulated liposomes. DOPC and DOPC/Chol liposomes showed a delayed 
pulse of protein release which could be useful for vaccine delivery. Unextruded 
REV’s demonstrated the capability of obtaining protein release in a pulsatile manner 
after encapsulation in alginate. Our studies also showed that encapsulation in alginate 
made the liposomes leakier and this was the result of a co-operative effect of alginate 
and the crosslinking ions.    
 Fibroblasts that were genetically engineered to produce BDNF were 
encapsulated in alginate. In vitro studies showed that the encapsulated cells continue 
 xiv 
to grow, express the transgene and BDNF is released from the microcapsules in an 
active form. These encapsulated cells were transplanted into the injured spinal cord of 
rats that were not immune suppressed. We found that the encapsulated cells survived 
in vivo and continued to express the transgene. This showed that encapsulation 
protected the cells from the host immune system. The transplanted capsules evoked a 
non-specific immune response and also resulted in sprouting of axons in the 
transplant area. The axonal growth observed increased with time. Behavioral studies 
showed a recovery of function in the injured forelimb of the rats almost up to baseline 
levels over 5 weeks. Finally, we studied a peptide-alginate conjugate as a permissive 
surface for growth of neurons such that it could be applied in combination with the 
encapsulated cells. 
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1. INTRODUCTION 
1.1 Protein Delivery 
 The rapid growth in the field of biotechnology has led to the development of 
numerous recombinant protein drugs such as hormones and vaccines. These protein 
drugs are usually high molecular weight proteins and are very sensitive to 
environmental conditions. Most proteins cannot be delivered orally due to problems 
related to degradation in the acidic environment of the gastrointestinal tract. 
Moreover, the high molecular weight of these substances often results in poor 
absorption in to the blood stream when administered orally. The blood brain barrier 
presents a major hurdle in the delivery of proteins that are intended to be delivered to 
the brain or the central nervous system. The most common mode of administration of 
these therapeutic proteins is intravenous injections which are usually not well 
tolerated by the recipient. Also, most of these proteins have short half lives in the 
blood stream and need to be administered frequently in high doses to obtain 
therapeutic efficacy. Systemic administration in high doses can lead to side effects 
and can also be toxic. These difficulties in administration of protein based drugs 
provided the impetus for development of delivery systems that could deliver them to 
the body such that therapeutic levels of the drug could be maintained without 
resulting in undesirable side effects.  
 Drug delivery systems employing a polymer as an entrapment matrix form a 
major part of the different types of systems being studied. Release of protein from 
these matrices can be through various mechanisms such as diffusion through or 
erosion of the polymer matrix and sometimes through combination of different 
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mechanisms. Encapsulation of proteins in liposomes has also emerged as one of the 
widely investigated technologies for protein delivery. More recently, ex vivo gene 
therapy involving transplantation of cells that secrete the therapeutic product of 
interest has seen a tremendous growth during the past decade.  
1.2 Microencapsulated Liposomes for Protein Delivery 
 Liposomes are one of the most widely studied vehicles for delivery of proteins 
as well as other therapeutic compounds. Liposomes are very versatile drug delivery 
systems due to the large range of phospholipids available and the potential to prepare 
liposomes with varying characteristics using different combinations of phospholipids. 
They can entrap hydrophilic drugs in the central aqueous space as well as 
hydrophobic drugs within the bilayer. Also, they are believed to be non-toxic. The 
concept of using liposomes for drug delivery also involves systemic administration. 
However, since the drug is encapsulated inside the liposomes it would be protected 
from direct contact with the external environment until it is released from the 
liposome and slow permeation of the drug to the outside would result in extended 
release times and reduce the need for frequent administration. Despite these 
advantages, there is an obstacle in the use of liposomes for systemic drug delivery. 
Liposomes are subject to rapid elimination from the blood stream via uptake by the 
reticulo-endothelial system, often in times less than 24 hours, resulting in a loss of a 
major portion of the entrapped drug. Hence several strategies are being developed to 
protect the liposomes from rapid elimination. One such strategy involves entrapping 
the drug-containing liposomes in a polymer matrix such that the liposomes are 
protected from the host immune system. The drug in such a system would then be 
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released from the liposomes and then diffuse through the polymer matrix before being 
released in to the body. Polymers that have been used for this purpose include 
alginate1 and gelatin2. It has been shown that encapsulation of liposomes in alginate 
provides a promising means of achieving sustained protein delivery and also includes 
the possibility of achieving pulsatile release of the entrapped protein3. A pulsatile 
delivery system could be very useful in the administration of protein drugs such as 
vaccines and hormones.  
1.3 Ex vivo Gene Therapy for Spinal Cord Injury 
 Approximately 11, 000 people suffer from spinal cord injuries every year in 
the United States alone. These injuries result in a need for lifelong care and 
rehabilitation and the estimated costs for a quadriplegic patient’s lifetime has been 
estimated to exceed $1 million4. The devastating effects of spinal cord injuries are 
due to the death of neurons that cannot be replaced, the inability of the surviving 
neurons to regenerate their axons and an inhospitable environment produced by the 
injury. Several different strategies are being investigated for treatment of spinal cord 
injuries, one of the most promising ones being application of neurotrophic factors 
which have been shown to prevent death of neurons and stimulate the regeneration of 
injured axons5. Systemic administration is not effective because of the inability of the 
neurotrophic factors to cross the blood brain barrier. Ex vivo gene therapy has 
emerged as the leading strategy for delivering these factors effectively at the site of 
the injury. This strategy involves the transplantation of genetically engineered cells 
that produce a neurotrophic factor at the injury site. Ideally, the patient’s own cells 
would be modified and transplanted in order to prevent rejection. However, the 
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protocols for such modification are time consuming and expensive and this has led to 
the development of non-autologous grafts. This allows for the development of a 
genetically modified and highly characterized cell line (not from the patient) that 
would be readily available for transplantation. Transplantation of non-autologous 
cells requires the recipient to be immune suppressed which can cause complications 
such as infections, tumorigenesis of the transplanted cells and of the host and can 
reduce the effectiveness of the transplant. Encapsulation of the cells in a polymer 
matrix is a means of protecting them from the immune system of the host. Matrices 
such as collagen6 and Matrigel7 and hollow fibers of acrylonitrile-vinyl chloride8 and 
polyethersulfone9 have been used for this purpose.     
1.4 Alginate 
 Alginate is a naturally occurring linear polysaccharide extracted from brown 
seaweed. It is composed of 1-4 linked α-L-guluronic and β-D-mannuronic acid 
residues. Alginate can form hydrogels by reaction with divalent cations such as Ca2+, 
Ba2+, Sr2+ and more with the exception of Mg2+. Trivalent cations such as Al3+ and 
Fe3+ have also been used. The preparation of these hydrogels simply involves 
dropping a sodium alginate solution into a solution which provides the crosslinking 
cations and can be performed under very mild conditions and with non-toxic 
reactants. This makes it a very attractive choice as a matrix for the encapsulation of 
biologicals, including drug containing liposomes and cells. Liposomes encapsulated 
in alginate have been studied for protein delivery1, 3 and several different cell lines 
including pancreatic islets10 and genetically engineered fibroblasts11, 12 have been 
encapsulated in alginate for therapeutic applications. Moreover, alginate hydrogels 
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can be coated with polycations such as poly-L-lysine or poly-L-ornithine which can 
act as a rate-controlling, semipermeable membrane regulating the substances that go 
into and out of the hydrogel. The coating can be so designed that it allows diffusion 
of the therapeutic product to the outside but prevents the entry of immunogenic 
substances from the host immune system. Figure 1.4.1 shows a schematic of an 
alginate hydrogel (in the form of a microcapsule) with liposomes or cells 
encapsulated in it and coated with a semipermeable membrane.  
 Along with preventing elimination from the body in a short period of time, 
encapsulation of liposomes in alginate provides us with three points of control for the 
release of drug: (A) release of the drug from the liposome can be controlled by 
varying the type or composition of the liposome; (B) diffusion of the drug across the 
alginate matrix can be controlled by varying the concentration and type of alginate or 
by addition of excipients and (C) diffusion of the drug across the semipermeable 
membrane can be controlled by varying the characteristics of the coating. 
 Encapsulation of cells in alginate provides protection of the non-autologous 
cells from the host immune system and if the cells can be protected effectively, it can 
eliminate the need for immune suppression of the host. Moreover, the alginate 
hydrogel can be coated with proteins such as laminin which can provide a favorable 
surface for regenerating tissue to grow on.     
1.5 Statement of the Problem 
 The aim of this thesis was to evaluate the use of microencapsulated liposomes 
and genetically engineered cells encapsulated in alginate as potential systems for 
delivery of therapeutic proteins. The primary objective of encapsulating liposomes in  
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Figure 1.4.1 Schematic representation of microencapsulation of liposomes/cells 
in alginate 
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with a rate-controlling, semipermeable membrane would protect them from the 
immune system of the host while allowing outward diffusion of the therapeutic 
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alginate was to develop a versatile system for the delivery of proteins with the 
possibility of obtaining pulsatile release using a combination of liposome technology  
and microencapsulation. Also, it was aimed at determining the effect of various 
parameters of the system on the ability to modulate drug release. The primary goal of 
encapsulating genetically engineered cells in alginate was to provide a delivery 
system that could deliver a neurotrophic factor at the site of a spinal cord injury. It 
was also a goal to establish the potential of the system to allow the encapsulated cells 
to survive in vivo in the absence of immunesuppression and to investigate if the 
BDNF secreted was able to promote regeneration of axons at the injury site. The 
specific goals of this thesis were as follows: 
1. To encapsulate liposomes in alginate microcapsules and to optimize the 
encapsulation procedure. The aim is to develop alginate microcapsules which 
are stable over a long period of time and which could be used as drug delivery 
vehicles for modulated release of therapeutic products.  
2. To determine the effect of different types and compositions of liposomes and 
different crosslinking ions on release profiles that can be obtained using the 
microencapsulated liposome system. This would be useful to determine the 
system suitable for a particular application e.g. a pulsatile release system for 
the delivery of vaccines or hormones. 
3. To investigate the possibility of interaction between the liposomes and 
alginate and to determine the mechanism of any such interaction. 
4. To encapsulate recombinant fibroblasts that are genetically modified to 
express BDNF in alginate microcapsules and to study the growth of and 
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transgene expression in the encapsulated cells in vitro. The objective here 
would be to determine if encapsulation hindered the growth of the cells and 
the expression of the therapeutic product of interest and to test whether the 
product secreted was active. It was also aimed to optimize the encapsulation 
that would allow survival of and transgene expression in the encapsulated 
cells over a sufficient period of time for therapeutic effectiveness after 
transplantation. 
5. To develop in vitro methodologies for creating an environment that is 
permissive for the growth of neurons in contact with the capsules using a 
capsule coating such as laminin, a growth permissive substrate. The aim is to 
determine the effect of a laminin-coated alginate substrate on the growth of 
neurons in vitro. One of the objectives was to develop alternative methods of 
creating a growth permissive microcapsule surface 
6. To test the in vivo efficacy of the encapsulated cells with or without growth 
permissive coating when transplanted into the injured spinal cord. The aim 
would be to obtain information about the host immune response, neuronal 
growth in the transplant, survival of the encapsulated cells, expression of the 
transgene and the effect of the growth permissive surface 
7. To test functional recovery in the animals receiving transplants of the 
encapsulated cells. The aim would be to determine if the injured forelimb 
showed any recovery of function over a period of time after transplantation of 
the encapsulated cells. This would be achieved by behavioral tests on the 
animals which would examine the injured forelimb for functional use. 
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2. BACKGROUND AND LITERATURE REVIEW 
2.1 Controlled Drug Delivery 
 Over the past few decades, the rise of modern pharmaceutical technology and 
the amazing growth of the biotechnology industry have revolutionized the approach 
to drug discovery and development. The close association of people from various 
fields such as chemistry, biology, medicine and engineering in drug development 
research has led to the uncovering of the cellular and molecular basis for the action of 
many drugs. There is a vast database of scientific knowledge available concerning, 
for example, the interactions between molecules and their receptors, the regulation of 
enzymes and hormones in the human body, and the effects of various chemicals on 
different types of cells13. The utilization of this knowledge has led to the development 
of revolutionary classes of therapeutic and prophylactic agents. Recombinant protein 
manufacture is one of the most prominent examples of the use of modern technology 
for drug development. Today, even more complex molecules such as chimeric 
antibodies, gene-based drugs, antisense oligonucleotides and virus-like particles are 
emerging as viable drug candidates. New clinical approaches involve molecules as 
well as genetically modified cells.  
 The most common mode of administration of drugs is in the form of pills or 
injections. These methods of administration meet the requirements of efficacy for 
several drugs. However, these methods are inadequate for many new drugs such as 
recombinant proteins, which have short half-lives, poor permeability in membranes 
and are severely toxic when delivered systemically in large doses. To overcome these 
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difficulties, new modes of administration have been the focus of a great deal of 
research over the past few decades.  
 Similar to drug development research, the development of drug delivery 
systems involves an interdisciplinary approach involving contributions from the fields 
of chemistry, material science, engineering, pharmacology and other biological 
sciences. A controlled release drug delivery system should be able to achieve the 
following benefits: (1) maintenance of optimum therapeutic drug concentration in the 
blood with minimum fluctuation; (2) predictable and reproducible release rates for 
extended duration; (3) enhancement of activity duration for short half-life drugs; (4) 
elimination of side effects, frequent dosing and wastage of drug; and (5) optimized 
therapy and better patient compliance14.  
Drug delivery systems involving the use of polymers are the most widely 
studied and biocompatible polymers have become the focus of such research. 
Polymers have long been used in experimental drug delivery systems to provide 
controlled release of small organic molecules15 and macromolecules16. A number of 
controlled release drug delivery systems have been developed using polymers and 
some of them are already in commercial production (Table 2.1.1).     
Polymeric materials generally release drug by one of the following mechanisms17: 
1. Diffusion 
2. Chemical Reaction  
3. Solvent activation 
Diffusion controlled drug delivery systems are of two types namely, reservoir systems 
in which a drug core is surrounded by a polymer film, or matrix systems where the  
 11 
Table 2.1.1 Commercially available controlled release systems 
(adapted from ref. 13) 
                                                              
Drug/Polymer Trade Name Indication 
Estradiol/poly[ethylene-co-
(vinyl acetate)] 
Estraderm®, Ciba 
Pharmaceutical Co. 
Estrogen replacement 
therapy 
BCNU/poly[carboxyphenoxy-
propane-co-(sebacic acid)] 
Gliadel®, Rhone-Poulenc 
Rorer 
Recurrent glioblastoma 
multiforme 
Leuprolide Acetate/poly(DL-
lactide-co-glycolide) 
Lupron Depot®, Takeda 
Chemical Industries 
Endometriosis 
Levonorgestrel/silicone 
elastomer 
Norplant®, Wyeth-Ayerst 
Laboratories 
Implantable 
contraceptive 
Nitroglycerin/ poly[ethylene-
co-(vinyl acetate)] 
Transderm-Nitro®, 
Summit Pharmaceuticals 
Prevention of angina 
Pilocarpine/ poly[ethylene-
co-(vinyl acetate)] 
Ocusert®, Alza 
Corporation 
Glaucoma Therapy 
Progesterone/ poly[ethylene-
co-(vinyl acetate)] 
Progestasert®, Alza 
Corporation 
Intra-uterine 
contraceptive device 
 
 
 
drug is uniformly distributed throughout a polymer matrix. One of the first clinically 
used controlled release systems was Ocusert®, a reservoir system for the delivery of 
pilocarpine to the eye and designed to improve glaucoma therapy17. Chemical control 
of drug release is achieved by regulating degradation of the polymer which results in 
regulation of release of drug entrapped in the polymer matrix. Alternatively, the drug 
could be attached on the polymer backbone and controlled release could be obtained 
by regulating the cleavage of the drug from the polymer backbone. The solvent 
activation mechanism of drug release involves drug release due to swelling of the 
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polymer or by creation of pores due to penetration of water as a result of osmotic 
pressure.  
The other widely studied type of drug delivery systems involves the use of 
vesicles. Vesicles are microparticulates or colloidal carriers composed of substances 
such as proteins, lipids, carbohydrates or synthetic polymers. They exhibit several 
advantages over polymeric systems in terms of altered pharmacokinetics and 
biodistribution and make possible potentially higher drug loading17. Phospholipid 
vesicles, called liposomes, are the mostly widely studied of these vesicles and will be 
discussed in more detail further in this thesis.  
2.2 Protein and Peptide Delivery 
 For several years, large molecules such as proteins were not considered 
feasible candidates for controlled release systems because they were considered too 
large to slowly diffuse through most polymeric materials. Large molecules could 
diffuse through highly porous gels such as polyacrylamide but in these cases the 
diffusion was generally too rapid and caused tissue damage. The uncovering of the 
fact that solid matrices of hydrophobic polymers containing a powdered form of 
macromolecules enabled controlled delivery for up to a period of 100 days greatly 
changed this17. Examples of such polymers include non degradable ethylene-vinyl 
acetate copolymer, degradable lactic acid-glycolic acid copolymers. Also, hydrogels 
of synthetic polymers such as poly(hydroxy ethyl methacrylate) and poly(vinyl 
alcohol) and natural polymers such as alginate, chitosan, collagen and gelatin have 
been found to be useful in delivery of proteins and peptides and are the focus of 
several research studies for the same. However, it should be noted that the hydrogel 
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formulations release these macromolecules over shorter periods of time as compared 
to the hydrophobic polymer matrices. The release mechanism generally involves 
diffusion of the polypeptide through a complex pore structure in the polymer matrix. 
The factors influencing the rate of release include protein particle size, loading, 
protein solubility and molecular weight, polymer composition and the dimensions and 
shape of the matrix18-20. The first Food and Drug Administration (FDA) approved 
peptide delivery system, Lupron Depot®, was an injectable polylactide-coglycolide 
microsphere formulation of leuprolide acetate used for the treatment of prostrate 
cancer and capable of delivering a sustained therapeutic level for one month17. 
Polymeric systems are now being used to study the release of several proteins such as 
insulin, growth factors and angiogenesis inhibitors21. Liposomes have also been 
studied for the delivery of proteins and will be discussed further in this dissertation.  
 Some of the most important factors to be considered in the course of 
designing delivery systems for proteins are the methods of delivery (whether invasive 
or non invasive), the stability of the protein (in vitro as well as in vivo), retention of 
biological function of the protein in the formulation (on the shelf as well as post-
delivery) and the dosage of the protein required for therapeutic efficiency. These 
factors determine the parameters of the controlled release formulation such as the 
polymer to be used, the method to be employed, excipients to be used and the amount 
of protein to be loaded to obtain therapeutic levels of activity. Loss of biological 
activity and change in immunogenicity as a result of protein aggregation or 
denaturation are the most important challenges faced in protein delivery. Stabilization 
approaches being developed in protein chemistry such as modification of sulfhydryl 
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residues to prevent aggregation, lyophilization, using appropriate additives and 
specific polymer compositions that prevent such behavior will go a long way towards 
the success of protein delivery systems22-24. Reference 25 provides a very 
comprehensive overview of the design and development strategies involved in the 
formulation of protein delivery systems. Table 2.2.1 shows some of the polymers 
being used in the development of protein delivery systems.   
 
 
Table 2.2.1 Biodegradable Polymers for controlled delivery of proteins 
(adapted from ref. 25) 
 
Materials Degradation Mechanism 
Starch Amylase 
Alginate pH, Enzymes, Alginase 
Collagen Collagenase 
Proteins Enzymes, Proteases 
Polyanhydrides Hydrolysis 
Polyesters (Polylactides) Ester hydrolysis, Esterases 
Poly (ortho esters) Ester hydrolysis, Esterases 
Polyiminocarbonates Hydrolysis 
Polycaprolactones Hydrolysis 
Polyamino acids Enzymes, Proteases 
Polyphosphazenes Hydrolysis, Dissolution 
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2.3 Liposomes 
2.3.1 Composition and Properties 
 Liposomes are artificial membranes composed mostly of phospholipids. 
Liposomes are spontaneously formed when phospholipids are placed in an aqueous 
environment and were first described by Bangham and Horne in 196426. Liposomes 
were first used as models of biomembranes to study dynamic properties of 
biomembranes such as phase transition and fluidity27 and also to study solute 
sequestration and diffusion characteristics28. These studies led to the development of 
the concept of liposomes as a drug carrier and in 1970, animals were injected with 
liposomes containing various therapeutic agents29, 30.  
 Phospholipids are amphipathic molecules composed of a polar headgroup and 
two nonpolar, hydrocarbon (acyl) chains. Figure 2.3.1 shows an example of a 
phospholipid where R represents the headgroup. Phospholipids are named according 
to the headgroup and the acyl chains. For example, phospholipids with a choline 
(OCH2CH2N+(CH3)3) headgroup, are called phosphatidylcholines and those with an 
ethanolamine (OCH2CH2N+H3) headgroup are called phosphatidylethanolamines. 
Another common group of phospholipids called phosphatidylglycerols have a 
glycerol (OCH2CHOHCHOH) headgroup. When both acyl chains are fully saturated 
16 carbon chains (palmitate) and the headgroup is choline, then the phospholipid is 
called dipalmitoylphosphatidylcholine. If both the acyl chains were 18 carbon chains 
with one double bond (oleate) and the head group were ethanolamine then the 
phospholipid would be called dioleoylphosphatidylethanolamine. The headgroup can 
impart a charge on the phospholipid. Of all the phospholipids isolated from natural  
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Figure 2.3.1 General structure of a phospholipid 
 
 
 
sources, only phosphatidylcholine and phosphatidylethanolamine and sphingomyelin 
are neutral at pH 7 whereas the rest have a negative charge. Stearylamine has a 
positive charge and is used in some preparations.  
 Phospholipids isolated from natural sources have acyl chains of unequal 
length and varying degrees of unsaturation. However, the chain length and degree of 
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unsaturation can be controlled in synthetically derived phospholipids. For example, 
the acyl chains in egg phosphatidylcholine are approximately one-thirds palmitoyl, 
one-thirds, oleoyl and the rest are various other acyl chains. However, synthetic 
phospholipids such as dipalmitoylphosphatidylcholine will contain upwards of 99% 
palmitoyl chains. The length and degree of unsaturation greatly affects the phase 
transition temperature (Tc), the temperature at which the lipid goes from a rigid “gel” 
phase to a liquid-crystalline or fluid phase. In general, increasing the degree of 
unsaturation lowers the phase transition temperature whereas increasing the chain 
length increases the phase transition temperature. Table 2.3.1 lists some natural and 
synthetic phospholipids, their charges and their phase transition temperatures.  
 Due to the amphipathic nature of phospholipids, they aggregate spontaneously 
in an aqueous environment and form structures with a hydrophobic interior and a 
hydrophilic surface31. These are mostly in the form of a bilayer wherein a large 
proportion of the lipid surface area is in the lipid bilayer and inaccessible to the 
aqueous environment. Figure 2.3.2 shows a cross sectional view of a single bilayer 
liposome which consists of an aqueous core and a hydrophobic bilayer. Hydrophilic 
molecules can be entrapped in the aqueous core whereas hydrophobic molecules can 
reside in the hydrophobic bilayer region. This makes liposomes useful for delivery of 
hydrophilic as well as hydrophobic molecules.   
 Liposomes can be prepared from different phospholipids and also from 
mixtures of phospholipids. The permeability of liposomes is relatively low when the 
temperature is below the Tc of the liposomes32.  This property of liposomes makes the 
transition temperature a very important parameter in the design of liposomes as drug  
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Table 2.3.1 Some of the phospholipids used in liposomes 
 
Phospholipid Charge at 
pH 7.0 
Phase Transition 
Temp (°C) 
Dilaurlyloyl phosphatidylcholine (C12:0) 0 -1 
Dimyristoyl phosphatidylcholine (C14:0) 0 23 
Dipalmitoyl phosphatidylcholine (C16:0) 0 41 
Distearoyl phosphatidylcholine (C18:0) 0 55 
Dioleoyl phosphatidylcholine (C18:1) 0 -20 
Dipalmitoyl phosphatidylethanolamine 0 63 
Dipalmitoyl sphingomyelin 0 41 
1-Myristoyl-2-palmitoyl phosphatidylcholine 0 27 
1-Palmitoyl-2-myristoyl phosphatidylcholine 0 35 
Egg phosphatidylcholine 0 ~ -5 
Beef brain sphingomyelin 0 32 
Egg phosphatidylglycerol -1 ~ -5 
Dioleoyl phosphatidylglycerol -1 -18 
Dipalmitoyl phosphatidic acid (pH 6.0) -1 67 
Dipalmitoyl phosphatidylserine  -1 54 
Phosphatidylinositol -1 - 
Dicetylphosphate -1 - 
Dipalmitoyl phosphatidic acid (pH 9.0) -2 58 
Stearylamine +1 - 
 
 
 
  
 19 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3.2 Cross sectional view of a liposome 
(adapted from ref. 33) 
 
 
 
carriers. The transition temperature is greatly affected by the type and proportions of 
the different phospholipids that make up the liposome. Using mixtures of synthetic  
lipids, liposomes of different transition temperatures and hence different 
permeabilities to entrapped compounds under physiological conditions can be 
designed. Mixtures of lipids having the same headgroup but differing in only two 
methylene groups in the acyl chains can result in a phase transition temperature 
between the individual transition temperatures of the two lipids34. However, care 
must be taken while mixing lipids differing by more than four methylene groups in 
the acyl chains since it can lead to phase separation in the bilayer resulting in distinct 
gel phases and fluid phases in different areas of the liposome. This can cause several 
undesired effects such as increase in bilayer leakiness, opsonization and aggregation 
of the vesicles and in some cases can also catalyze membrane fusion35.  
Hydrophobic 
bilayer 
Aqueous core
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 Charged phospholipids can be used in the preparation of liposomes to impart 
to them a net charge. One advantage of charged liposomes is that they are less prone 
to aggregation due to electrostatic repulsion. For lipids with similar chains and 
different headgroups, phase separation can result if the transition temperatures of the 
lipids differ by more than 10ºC. In the case of charged lipids, phase separation can 
also occur in divalent or polyvalent electrolytes or in acidic solutions35.  
 Cholesterol is an important component of eucaryotic membranes and is often 
used in liposome preparations. When added to liposomes, cholesterol becomes 
intercalated within the lipid bilayer with the hydroxyl group near the polar 
headgroups32. The presence of cholesterol reduces the fluidity of the hydrocarbon 
chains when they are in the liquid-crystalline phase and makes the liposomes less 
permeable36. Also, it has been suggested that cholesterol can increase the fluidity of 
the lipid bilayer below the phase transition temperature via a disruption of the order 
of the hydrocarbon chains. Cholesterol also affects the phase transition temperature of 
the liposomes. In general, addition of cholesterol reduces the phase transition 
temperature.        
2.3.2 Classification and Methods of Preparation 
 Liposomes are usually classified based on their size and morphology. The four 
most common types of liposomes are: (1) Small unilamellar vesicles (SUV’s) which 
consist of one bilayer and are up to 100 nm in size; (2) Large unilamellar vesicles 
(LUV’s) which are again made up of a single bilayer but range in size from 100 nm 
up to several microns in diameter; (3) multilamellar vesicles (MLV’s) which 
comprise of several concentric bilayers with several aqueous compartments in 
 21 
between and (4) multivesicular vesicles (MVV’s) which are made up of several 
individual vesicles inside a large vesicle. Both MLV’s and MVV’s can be up to 
several microns in diameter. Several methods are available for the preparation of the 
different types of liposomes. In general, all methods include the steps of lipid film 
hydration followed by formation of the lipid bilayer and then removal of unentrapped 
material. The most common method employed for the preparation of SUV’s is 
sonication37 (either by a probe sonicator or a bath sonicator). Other methods of 
preparing SUV’s have also been described such as high pressure extrusion38 or 
homogenization of MLV’s39, rapid injection of an ethanolic solution of a lipid into an 
aqueous solution40, or by transiently increasing the pH of aqueous phospholipid 
dispersions41. Due to the small size of SUV’s, their clearance from systemic 
circulation is greatly reduced and they have a better chance of delivering therapeutic 
agents to tissues other than the RES. However, on the other hand, due to the small 
size, they have a very low capacity of drug entrapment. LUV’s can be prepared by 
methods such as removal of detergents42, solvent infusion43, and reverse phase 
evaporation44. Reverse phase evaporation is one of the most commonly employed 
methods used to prepare LUV’s and has been modified to entrap large amounts of 
drug44. Vesicles produced by reverse phase evaporation are also referred to as reverse 
evaporation vesicles (REV’s). Since the interior of LUV’s is not occupied by internal 
lamellae, there is a great amount of space for incorporation of drug. However, a 
single bilayer enclosing a large space means that the LUV’s are more fragile and also 
have an increased permeability to small solutes. The most common method for 
preparing MLV’s is by simple hand-shaking or stirring of aqueous phospholipid 
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dispersion28. This however gives very low entrapment efficiency and a method called 
the dehydration-rehydration method has been described for preparation of MLV’s 
with better entrapment efficiency45. The large size of MLV’s is a major drawback for 
their use in parenteral administration because they are very rapidly taken up by the 
RES. However, the same effect has been utilized to deliver substances to the liver and 
the spleen46. Most methods of liposome preparation result in vesicles having a wide 
size distribution. Since liposome size is an important factor in the stability and tissue 
distribution in vivo, extrusion through polycarbonate membranes is routinely used to 
obtain a more uniform size distribution in the liposome preparation38, 47.  
2.3.3 Stability of Liposomes 
 Liposomes can become stable either through physical or chemical processes. 
Chemical stability is directly dependent on the composition of the liposomes. The 
most common processes of chemical degradation are lipid peroxidation and 
hydrolysis48. These problems can be overcome by storing the liposomes under an 
inert gas such as nitrogen or argon, or by using antioxidants like α-tocopherol in the 
liposome preparation. Some of the physical processes that lead to a loss of liposome 
stability are loss of bilayer components due to desorption, leakage of entrapped 
material, vesicle fusion and vesicle aggregation. Addition of chelating ions such as 
EDTA to bind ions that induce aggregation, or by including a small amount of 
charged lipid in the liposome preparation to create electrostatic repulsion can reduce 
the tendency of the liposomes to aggregate. Use of lipids with high transition 
temperatures or by storing liposomes at low temperatures reduces their permeability 
thus preventing loss of contents due to leakage. Inclusion of cholesterol also increases 
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the stability of liposomes above their transition temperature. The type of liposome 
also plays an important role in determining stability. MLV’s have been shown to leak 
their contents to a much lesser degree than LUV’s49. The small radius of curvature of 
SUV’s results in an outer monolayer with a surface area almost twice that of the inner 
layer and almost 70% of the lipid is in the outer monolayer. The resulting 
thermodynamic constraints make SUV’s more prone to aggregation/fusion50. 
2.4 Liposomes in Drug Delivery 
 Liposomes have widely been investigated for the delivery of 
chemotherapeutic agents for treatment of cancer, antimicrobial agents for treatment of 
bacterial, fungal, viral and parasitic diseases and also for use as immunological 
adjuvants for the delivery of vaccines. More recently they have been studied for the 
delivery of genes and also for delivery of entrapped DNA. Liposomes composed of 
different phospholipids, modified for steric stabilization or for targeting and lipid 
complexes have been investigated for these purposes. Table 2.4.1 lists some of the 
liposome based products developed or under development. This list is not exhaustive 
and a more detailed description of the different liposome based drug delivery 
approaches can be found in Reference 51. 
There are several advantages and disadvantages to liposomes in their use as a drug 
delivery system52.  
Advantages: 
(1) Since the drug is entrapped in the liposomes and released over a period of 
time, toxic effects of drugs are greatly reduced when compared to systemic 
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administration of free drug. Moreover liposomes themselves are made of non-
toxic materials that the body can metabolize.  
(2) The gradual release of drug from the liposomes also gives rise to longer 
lasting effects. 
(3)  Both hydrophilic as well as hydrophobic drugs can be entrapped in 
liposomes. 
(4) The different types of liposomes that can be prepared by varying size, 
morphology, composition offers a great deal of versatility. 
(5) Liposomes usually do not alter or interact with the drug in any form. 
(6) The property of liposome uptake by the RES can be utilized to deliver drugs 
to the liver and spleen. Moreover, specific antibodies can be conjugated on to 
the surface of the liposomes in order to target them to specific organs. 
Disadvantages: 
(1) As discussed earlier, liposomes tend to aggregate or lose entrapped drug 
during storage. 
(2) They cannot be sterilized by irradiation or by heat. 
(3) Liposomes can be taken up by the RES before reaching their target organ. 
(4) High density lipoproteins tend to interact with liposomes in vivo leading to a 
loss of encapsulated species. 
(5) Liposome preparation techniques are difficult to scale up using traditional 
methods. 
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Table 2.4.1 Liposome-based products developed or under development 
(adapted from ref. 51) 
AmBisome®, Daunoxosome®, Doxil®. Amphotec®, ABELCET® are FDA approved 
 
Product Drug Target Disease 
Liposomal nystatin, Aronex 
Pharmaceuticals 
Nystatin Systemic fungal 
infections 
Liposomal tretinoin, Aronex 
Pharmaceuticals 
All-trans retinoic acid Leukemia 
Newcastle disease vaccine, 
IGI, Vineland Laboratories 
Newcastle disease virus 
(killed) 
Newcastle disease 
(chicken) 
AmBisome®, NeXstar 
Pharmaceuticals  
Amphotericin B Systemic fungal 
infections 
Daunoxosome®, NeXstar 
Pharmaceuticals 
Daunorubicin Advanced Kaposi’s 
sarcoma, breast cancer 
and other solid tumors 
E. coli 0157:H7 vaccine, 
Novavax  
E. coli 0157:H7 (killed) E. coli 0157 infection 
Doxil®, SEQUUS 
Pharmaceuticals 
Doxorubicin Kaposi’s sarcoma, 
refractory ovarian, 
recurrent breast, 
prostrate and primary 
liver cancers 
Amphotec®, SEQUUS 
Pharmaceuticals  
Amphotericin B Systemic fungal 
infections 
ABELCET®, The Liposome 
Company 
Amphotericin B Systemic fungal 
infections 
HAV/HBs-IRIV combined 
vaccine, Swiss Serum and 
Vaccine Institute 
HAV, genetically 
engineered Hepatitis B 
antigens 
Hepatitis A and B 
Hepatitis A and 
B/diphtheria/tetanus/influenza 
supercombined vaccine, 
Swiss Serum and Vaccine 
Institute 
Inactivated HAV virons, 
HBs, diphtheria and 
tetanus toxoids, 
hemagglutinin and 
neuraminidase from 
influenza strains 
Hepatitis A and B, 
diphtheria, tetanus and 
influenza 
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2.5 Microencapsulation 
 Microcapsules and microspheres have found extensive use in the field of drug 
delivery. Microencapsulation is an interdisciplinary field that requires knowledge of 
polymer science, emulsion technology (in most cases) and an understanding of drug 
and protein stabilization53. Encapsulation is a very standard practice in the food, 
consumer products and cosmetics industries. Flavors have been encapsulated since 
the 1930s, vitamins since the 1940s and ink for carbonless paper since 195653. The 
concept of using semipermeable microcapsules for the delivery of therapeutic 
biological reagents was pioneered by T. M. S. Chang almost 40 years ago54 and over 
the years a wide range of drugs such as steroids, vitamins and antibiotics has been 
encapsulated53.  
 Both natural and synthetic polymers have been used to encapsulate drugs. 
Polysaccharides, such as cellulose and starch have been used in the delivery of 
vitamins55 and antiparasitics56. Another polysaccharide, alginate has been widely used 
in the delivery of several drugs and proteins and will be discusses in detail further in 
this thesis. Collagen has also been studied in the development of drug delivery 
systems57. Albumin microspheres have been shown to be effective for delivery of 
adriamycin to tumors in rat models58. A lot of research work has also been devoted to 
the development of synthetic polymers. These polymers can be non-biodegradable 
such as ethylene-vinyl acetate which has been successfully shown to deliver 
contraceptive steroids over extended periods of time17 or biodegradable such as poly-
lactic acid, poly-lactic-co-glycolic acid which have been used for delivering several 
therapeutic agents including proteins. Other examples of polymers used in the 
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development of drug delivery systems include poly(carboxyphenoxypropane-co-
sebacic acid), gelatin, ethylcellulose, polyvinylalcohol, chitosan, whey protein, 
agarose, and several other polymers. Polymers used to make drug delivery systems 
should have the following characteristics: 
(1) They should be non-toxic 
(2) Degradation products, if any, should be non-toxic and should be readily 
removed from the body 
(3) The polymer and the method of preparation should not affect the drug.  
 Among the several different methods of microencapsulation, the most 
common ones are solvent evaporation, coacervation, interfacial polymerization, spray 
drying and ionotropic gelation59.  
 Microcapsules offer several advantages in their use as drug delivery systems. 
The most important advantage being that the kinetics of drug release can be altered by 
changing the properties of the microcapsule. The delivery of drugs can be varied from 
several days to several months60. Also, the surface of the microcapsules can be 
modified by attaching ligands such as antibodies which would enable them to target 
specific organs and sites in the body61. Most of the disadvantages of 
microencapsulation are a result of the manufacturing methods. Most methods utilize 
organic solvents which can affect the drug or denature proteins and also be harmful in 
vivo if any residual solvent remains behind in the microcapsules. Sterilization of 
microcapsules also poses a problem. Although gamma irradiation could be used, it 
could cause degradation of the polymer and or drug entrapped in the microcapsule. 
 Properties of proteins such as structure, stability, activity and half-life are very 
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important for them to be effective as therapeutic agents. Proteins may degrade, 
denature or lose activity in the presence of organic solvents. Problems such as 
aggregation and loss of activity due to denaturation have been reported62. Hence it is 
desirable to avoid any exposure to organic solvents as much as possible. Water 
soluble polymers such as alginate, chitosan have been investigated in the 
encapsulation of proteins63, 64. Alginate is anionic and forms a hydrogel in the 
presence of multivalent cations. Also, some water soluble polymers with –OH groups 
can be crosslinked with agents such as glutaraldehyde to form hydrogels65. These 
types of hydrogels are formed under fairly mild conditions and the problems of 
denaturation of proteins can be avoided.  
2.6 Alginate 
   Alginate is a water soluble linear polysaccharide extracted from brown 
seaweed and is composed of alternating blocks of 1-4 linked α-L-guluronic and β-D-
mannuronic acid residues. Depending on the source of the alginate, the molecules can 
be composed of three types of blocks: polymannuronic acid blocks (MM), 
polyguluronic acid blocks (GG) and mixed blocks (MG). Also, the amount of each 
component (M and G) varies with the source of the alginate. Figure 2.6.1 shows the 
structures of mannuronic and guluronic acid residues and Figure 2.6.2 shows the 
binding between the mannuronic and guluronic acid residues in alginate. Table 2.6.1 
lists the various sources of alginate and compositions of the alginates obtained from 
those sources.  
  It has been shown that in aqueous solutions, alginates are highly hydrated  
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A. Mannuronic Acid 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B. Guluronic Acid 
 
 
 
Figure 2.6.1 Components of alginate (adapted from ref. 66) 
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Table 2.6.1 Compositions of alginates obtained from different sources 
(adapted from ref. 66) 
 
Species M content (%) G content (%) M/G ratio 
Macrocystis pyrifera 61 39 1.56 
Ascophyllum nodosum 65 35 1.85 
Laminaria digitata 59 41 1.45 
Laminaria hyperborea 31 69 0.45 
Ecklonia cava 62 38 1.6 
Eisenia bicyclis 62 38 1.6 
 
 
 
polyelectrolytes in the extended ribbon conformation66. X-ray diffraction studies and 
polarized infrared spectroscopy have provided information on the crystalline structure 
of polymannuronic acid and polyguluronic acid segments.  
 Polymannuronic acid is a flat ribbonlike molecule (Figure 2.6.3A), the 
conformation of which appears to be stabilized by the formation of an intramolecular 
hydrogen bond between the hydroxyl group on C3 of one unit and the ring oxygen of 
the next unit68. The shape of the polyguluronic acid chain is quite different from that 
of polymannuronic acid. 
 Polyguluronic acid is a buckled, ribbon like molecule (Figure 2.6.3B). This 
conformation is stabilized by an intramolecular hydrogen bond between the hydroxyl 
group on C2 and the oxygen atom of the carboxyl group in the next unit68.  
 Probably the most important property of alginates is their ability to form gels 
by reaction with divalent cations such as calcium. These gels which are similar to  
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Figure 2.6.3 Conformation of poly(uronic) acids in alginate 
(adapted from ref. 66) 
 
 
 
solids in retaining their shape and in resisting stress, are 99-99.5% water with the rest 
being alginate. It was initially suggested that crosslinks were caused either by simple 
ionic bridging of two carboxyl groups on adjacent polymer chains with calcium ions 
or by chelation of single calcium ions by hydroxyl and carboxyl groups on each of a 
pair of polymer chains69. It was also suggested that a cooperative association of either 
A. Flat, ribbon like 
polymannuronic acid chain 
B. Buckled, ribbon like 
polyguluronic acid chain 
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polymannuronic acid or polyguluronic acid segments is involved in the formation of 
the crosslinked network of polymer chains. This current proposed structure of 
alginate in which calcium ions are bound between the associated segments of polymer 
chains is shown in Figure 2.6.4. Circular dichroism studies showed that the calcium 
ions react preferentially with the polyguluronic acid segments70. It was also suggested 
that the alternating segments likely play no role in the gelation except to join the 
associated segments to form a three dimensional network. Based on coordination 
geometry, Grant et al71 suggested the “egg box model”, in which the polyguluronic 
acid segments associate into aggregates with interstices into which the calcium ions 
fit.  
In principle, any multivalent cation can cause gelation of alginate. Aluminum72, 
barium73 and zinc74 have been used to form alginate gels. Magnesium is one 
exception to this rule. The differences in affinity of cations to alginates has been 
studied by Haug75. The mechanical rigidity of the gels reflected the degree of 
affinity76. The affinity of cations to alginates is in the following order: 
Pb > Cu > Cd > Ba > Sr > Ca > Co, Ni, Zn > Mn 
Alginates also form strong complexes with polycations such as chitosan77, polyamino 
acids10, polyethyleneimine78 or polyacrylamide79.  
 Numerous studies have shown that the chemical structure, molecular size, as 
well as the gel forming kinetics and the cation have a significant impact on several of 
its functional properties including porosity, swelling behavior, stability, 
biodegradability, gel strength and the gel’s immunological characteristics and 
biocompatibility80, 81. The pore size of hydrogels formed by crosslinking alginates can  
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A. Current proposed structure of alginate gels 
 
 
 
B. Eggbox model for crosslinking of alginate with calcium ions 
 
Fig 2.6.4 Structure of alginate gels (adapted from ref. 66) 
 
 35 
vary greatly. Proteins as large as fibrinogen diffuse easily out of calcium alginate 
microcapsules80 (almost 100% over 15 hours). Only very high molecular weight 
enzymes and whole cells are completely immobilized in calcium alginate gels82. 
2.6.1 Alginate in Drug Delivery and Cell Encapsulation 
 The gelation method for alginate involves dropping alginate solution into an 
aqueous solution of multivalent cations. This process can be carried out under an 
extremely mild environment and uses non-toxic reactants. For this reason, alginate 
has been extensively studied for protein delivery and in fact is the polymer of choice 
for cell encapsulation. The release of drug can be easily regulated by controlling the 
properties of the alginate gel such as alginate concentration and crosslinking ion74, 83. 
 Moreover, the ability of alginate to react with polycations provides another 
interesting means of controlling the release of drug from alginate gels. Alginate gels 
can be coated with cationic polypeptides such as poly-L-lysine and poly-L-ornithine. 
These coatings are rate controlling and can be designed to be size-selective. The 
properties of the coating can be controlled by varying the parameters of the coating 
process such as the coating material, its molecular weight, the concentration of the 
coating solution and the coating time84, allowing the design of coatings with different 
molecular weight cut offs and with different release rates. In the case of cell 
encapsulation for therapeutic drug delivery, this coating can be so designed that it 
allows the therapeutic product to diffuse out of the gel but does not permit 
immunogenic substances from the host environment to enter the gel and interact with 
the cells.   
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 Alginate hydrogels have been the focus of several studies including delivery 
of drugs such as diclofenac sodium85, flurbiprofen85, prednisolone86, vancomycin87, 
theophylline88 and proteins such as melatonin74, heparin89, bovine serum albumin90, 
different types of growth factors including nerve growth factor91 and vaccines92. 
Reference 63 is a comprehensive review of applications of alginate gels in protein 
delivery. There has also been some work on developing conjugates of alginate with 
drugs such as daunomycin93.   
 Due to the mild encapsulation method, alginate has become the polymer of 
choice for cell encapsulation. In 1980, Lim and Sun10 successfully applied an 
alginate-poly-L-lysine encapsulation system to transplantation of pancreatic islets in 
rats. Since then, several different cell lines have been encapsulated in alginate gel 
systems for a wide range of therapeutic applications like delivery of hormones94, 95, 
angiogenesis inhibitors96, 97, neurotrophic factors11 and antibodies98. These include 
islet cells10, genetically modified fibroblasts11, 94, 95, rat hepatocytes99, hybridoma98, 
293-producer cells96 and baby hamster kidney cells97.  
 More recently, alginates are also being used in tissue engineering applications 
such as wound healing100, 101 and scaffolds for tissue repair102.     
2.6.2 Biocompatibility of Alginates 
 Alginate is used extensively in the food industry as a thickener, emulsifier and 
as a stabilizer. Alginates are included in a group of compounds that are generally 
regarded as safe (GRAS) by the FDA . The biocompatibility of alginates has been 
studied by several investigators. One study indicated that incorporating 5 to 15% 
alginate in the diet of purebred beagle dogs for a period of one year caused no 
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harmful effects66. Another study indicated that the administration of 5 g/kg body 
weight to rats within a 24 hour period caused no mortalities or signs of toxicity66. It 
has also been observed that the subcutaneous injection of mice with alginic acid 
caused no carcinogenic activity103. One study shows that alginate induces very little 
in vitro cytotoxicity in cell cultures and animal toxicity experiments have shown that 
alginate is well tolerated at doses up to 500 mg/kg104. Numerous other studies have 
attested to the high level of safety of alginates in food use66. However, there exists 
some contradiction in literature with respect to the biocompatibility of grafts of 
alginate. Some studies have shown that grafts of alginates show insufficient 
biocompatibility resulting in fibrotic overgrowth of the capsules and subsequent 
necrosis of encapsulated islets105. There have been several efforts to solve this 
problem. Some investigators have identified mannuronic acid to be the major initiator 
of the foreign body reaction106 whereas others have found guluronic acid to be 
responsible for the fibrotic overgrowth107.  It was noted that these studies were 
performed with crude alginates which are known to contain contaminants that can 
provoke an inflammatory reaction. A method to purify alginates involving a number 
of filtration, precipitation and extraction steps has been described in an attempt to 
improve their biocompatibility108. Grafts of purified alginate showed a great reduction 
in fibrotic overgrowth. However, the graft function was always limited from 6 to 20 
weeks for encapsulated islets which was the case with crude alginates also. Thus 
although the biocompatibility of alginates is improved by using the purified form, it 
has been suggested that the failure of grafts could be a result not only of the chemical 
composition but of imperfections of a more physical nature109.    
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2.7 Vaccine Delivery 
 The invasion of the human body by foreign bacteria or virus gives rise to a 
humoral immune response in the form of antibodies which bind to the bacteria or 
virus and mark them for destruction by phagocytes. Protection against these foreign 
organisms also depends on immunological memory. A primary humoral response 
occurs when the body is first exposed to a particular antigen. The primary response is 
characterized by a lag period which corresponds to the time required for the B cells 
specific to that antigen to replicate, differentiate and produce antibodies against the 
antigen. Some cells, known as memory cells, do not differentiate to produce 
antibodies but remain in circulation for as long as 20 years and are capable of 
producing a secondary immune response when challenged with the same antigen. 
 Vaccines contain parts of the bacteria or virus required for identification by 
the immune system. There is no difference in immunity acquired either by 
vaccination or by actual infection. In addition to generating antibodies against the 
antigen, vaccines do not cause symptoms of the disease and they help to establish an 
immunological memory110. 
 The most common method of immunization is a strict schedule of injections. 
Most vaccines require primary immunizations followed by a booster for optimum 
response111. According to the World Health Organization, more than 30% of the 
patients do not return for the booster injection, which leads to loss of effective 
antibody titers. In third world countries, more than a million children die each year 
from vaccine preventable diseases111. 
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 Recent advances in recombinant DNA technology have made possible the 
creation of a new generation of chemically defined subunit vaccines. Although these 
subunit or peptide based antigens could overcome many of the difficulties associated 
with live or attenuated vaccines, they tend to be poorly immunogenic and the 
concomitant administration of a substance with adjuvant activity is required112. Two 
commonly used adjuvants are Freund’s adjuvant and alum. However, chronic 
inflammation at the injection site makes Freund’s adjuvant unsuitable for human use. 
Alum, which is the only adjuvant approved for human use, greatly reduces the 
inflammatory reaction but most peptide based antigens adhere very poorly to alum113. 
Also there has been recent concern about the involvement of alum in disorders such 
as Alzheimer’s disease, Parkinson’s dementia, and osteomalacia114.  
 An ideal adjuvant or delivery system for vaccines would be such that it would 
release the primary and the booster doses of the antigen at predetermined points in 
time or at least maintain such therapeutic levels of antigen in the blood so as to 
develop an effective immunological memory. Some such approaches involve the use 
of liposomes and microcapsules and will be discussed in the following sections.     
2.7.1 Liposomes in Vaccine Delivery 
 Among the alternate immunoadjuvants being studied, liposomes have 
received the most attention because of their low toxicity, effective adjuvant properties 
and the ability to target specific antigen-presenting cells such as macrophages115. 
Macrophages are an important component of the antigen presenting system and play a 
fundamental role in the production of T cell dependent humoral immune response. It 
was expected that targeting the vaccines to macrophages via use of liposomes would 
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induce immunogenicity and evoke a suitable immune response. Several subunit and 
peptide vaccines such as tetanus toxoid, cholera toxin and tumor associated antigen 
have been tested and the humoral response elicited by the liposome based vaccines 
have generally been higher than those obtained with vaccines alone116-118. However, 
these immune responses have always been lower than those evoked by the vaccines 
administered with adjuvants such as Freund’s adjuvant or alum119. This has been 
attributed to the inherent instability of liposomes in vivo where they are rapidly 
destroyed30. Another approach has also been studied, in which antigenic peptides 
were anchored to the liposome either by covalent attachment or via a transmembrane 
segment120. Antibody titers obtained by this approach were much higher when 
compared to those obtained with free antigen and empty liposomes or only free 
antigen. 
2.7.2 Microcapsules in Vaccine Delivery 
 Early studies showed that a single micropellet of ethylene-vinyl acetate 
copolymer containing bovine serum albumin induced antibody responses in mice for 
more than six months and was comparable to the to the antibody levels obtained after 
two injections of the same amount of BSA in Freund’s adjuvant. The prolonged 
production of antibodies was consistent with the prolonged release of BSA from these 
matrices121. Since then, the nonbiodegradable ethylene vinyl acetate copolymer has 
been replaced by biodegradable polymers such as PLGA in these studies. Several 
studies have been carried out with PLGA polymers of different compositions 
(different lactic and glycolic acid content) in an effort to utilize them for vaccine 
delivery. Special efforts have been aimed at developing gentle and efficient means of 
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microencapsulation using PLGA since most conventional methods used harsh organic 
solvents. Also, different sizes of PLGA microcapsules and microcapsules with 
different release rates have been studied122. For example, tetanus toxoid encapsulated 
in PLGA microspheres produced high levels of antibodies for more than 24 weeks. 
These antibody levels were four to five times higher than those obtained after 
administration of the toxoid in solution. Subcutaneous injection of diphtheria toxoid 
in poly lactic acid microspheres elicited an immune response comparable to a three 
injection schedule111.  
 Such biodegradable polymer systems would be particularly attractive for 
vaccine delivery if the polymer or its degradation products had adjuvant properties. 
Poly-L-tyrosine and its derivatives- a polymer consisting of tyrosine or a tyrosine 
derivative connected by hydrolysable iminocarbonate bonds- have been synthesized 
to this end. The release of BSA from a single tyrosine based iminocarbonate pellet in 
mice gave rise to higher antibody titers than those obtained with release of BSA from 
a polyiminocarbonate (without tyrosine) pellet123. 
 Alginate has also been used to study delivery of vaccines. Intranasal 
administration of ovalbumin containing alginate-poly-L-lysine beads in mice induced 
high serum levels of antigen specific antibodies whereas intranasal administration of 
unencapsulated ovalbumin elicited no immune response124. A potential method of 
delivering heat killed Bacillus Camette Guering (BCG) encapsulated in alginate 
microbeads (5-15 µm in size) has also been described125. In the area of veterinary 
vaccines, alginate beads have been studied to deliver oral vaccines to different species 
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of animals63. The advantage of oral vaccination is that large number of animals can be 
vaccinated very conveniently.      
2.8 Microencapsulated Liposomes 
 The uptake of liposomes by the RES limits the duration for which the 
liposomes circulate and can release the entrapped drug into the blood stream. In case 
of vaccine delivery, prolonging the release of the vaccine into the blood stream would 
help in evoking a stronger immune response and also in developing an effective 
immunological memory. Several approaches are being studied to protect liposomes 
from rapid elimination in the human body. One of the most popular approaches being 
studied is the use of PEG-liposomes made of polyethylene glycol (PEG)-phospholipid 
conjugates126. Another way of protecting the liposomes from the immune system is to 
encapsulate the drug-containing liposomes in a polymer matrix in the form of a 
microcapsule1. Such “microencapsulated liposome” systems have been studied by 
several investigators for different purposes including pulsatile release of bioactive 
molecules1, 3, 127-130 and sustained release of acetylsalicylic acid131. Liposome 
composed of phospholipids such as phosphatidylcholine*, phosphatidylglycerol* 
have been used in such systems in conjunction with polymers such as alginate1, 3, 127-
130 and acacia-gelatin131, 132. A collagen matrix has been used to entrap liposomes for 
delivering insulin and growth hormone133. Liposomes have also been encapsulated in 
nylon and nylon-gelatin microcapsules using interfacial polymerization134. However, 
the process of preparation caused disruption of the liposomes causing a very rapid 
release of the entrapped drug.  
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 Alginate is again the polymer of choice because of the similarity of liposomes 
to cells and the mild encapsulation conditions employed. Liposomes were first 
encapsulated in alginate by Wheatley et al1. The alginate capsules were coated with 
poly-L-lysine and polyvinyl amine. A small amount of myoglobin was released from 
the microencapsulated liposomes during the first 7 days following which a large pulse 
of release was observed at around day 13. A slightly modified system for pulsatile or 
delayed release was devised by coating the liposomes with phospholipase A2 before 
encapsulating in alginate127. The timing of the pulse as well as the rate of release 
could be controlled by the amount of phospholipase, molecular weight of the poly-L-
lysine coating and the liposome composition. Also it was shown that, in such a 
system, horseradish peroxidase retained up to 40% of initial activity after 30 days at 
37°C. In solution, the enzyme lost its activity in a few days at 37°C.   
Microencapsulated liposome systems have been shown to extend in vivo drug 
retention times and also to elicit higher immune responses as compared to liposomes 
alone129, 130. In an in vivo rat model, BSA was released from liposomes encapsulated 
in alginate over a period of 80 days and produced high levels of antigen specific 
antibodies up to 150 days129. The maximum levels induced were about 3-4 times 
those induced by BSA in liposomes or in saline. In another study, a significantly 
higher immune response was observed by the release of Hepatitis B surface antigen 
(HBsAg) from liposomes encapsulated in alginate than that obtained with HBsAg in 
liposomes alone130.  
 One of the most interesting aspects of encapsulation of liposomes in a 
polymer matrix is that it provides two points of control for drug release; the first 
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being the release of drug from the liposomes into the polymer matrix and the second 
being the diffusion of drug across the matrix and into the surrounding medium. The 
overall rate of release can be controlled by modifying the properties of these control 
points. In the case of alginate, the ability to coat the microcapsule surface with a rate 
controlling, size selective membrane of polypeptides provides an additional control 
point.     
2.9 Ex vivo Gene Therapy 
 With the advent of the human genome project, important disease related genes 
are being cloned in increasing numbers. Examples include genes for Huntingdon’s 
disease135, myotonic dystrophy136, Fragile-X mental retardation137 etc. Some of the 
cloned human genes are already in human gene therapy clinical trials, including those 
for diseases that are genetic in origin such as severe combined immunodeficiency138 
and familial hypercholesterolemia139, as well as disorders such as cancer140 and HIV 
infections141. It seems to be a certainty that gene therapy, in the sense of genetic 
modification of tissues will play a major role in future medical approaches in treating 
previously untreatable diseases.  
 The most common form of gene therapy, called ex vivo gene therapy, involves 
transplantation of cells that are genetically modified to secrete the therapeutic product 
of interest. There are several challenges facing this kind of therapy. One of the most 
important challenges is the problem of cost. Most of the clinically approved protocols 
depend on genetic modification of the patient’s own cells (autologous) which are then 
transplanted (autologous transplant) in order to avoid immune rejection142. However, 
such protocols are extremely complicated involving isolation of cells from the patient, 
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their propagation in vitro, their genetic modification and subsequent characterization 
before transplantation and are labor-intensive143 and expensive. Prohibitively high 
costs and time required for genetic modification of autologous cells for every 
individual has rendered their use unrealistic. This has led to the development of 
effective non-autologous strategies for gene therapy144. The reasoning was that if a 
standard established cell line could be engineered to secrete a desired gene product 
and could be implanted in different patients requiring the same treatment, there would 
be no need to carry out patient-specific genetic modification. Various cell lines have 
been have been genetically modified to secrete a wide range of therapeutic products. 
These cell lines include fibroblasts8, 12, 95, 145, 146, baby hamster kidney cells97, 147, 148, 
hybridoma149, 293-producer cells96, 150, neuronal cells151 and neural stem cells152.  
These non-autologous cellular therapies, however, can induce strong immune 
responses and require strict immunosuppression protocols. These immunosuppression 
protocols can compromise the health of the host by causing infections and 
tumorigenesis of the transplanted cells and those of the host and can reduce the 
effectiveness of the transplant. One method of foiling the immune response and to 
prevent rejection of the graft is to encapsulate the graft cells in a permselective 
matrix, which would allow free diffusion of the growth factors, cell nutrients and 
waste products but would prevent the components of the host immune system from 
getting through. In addition, the encapsulation system should be such that it permits 
the expression of the therapeutic product over a prolonged period of time. Several 
kinds of such immune-protective or immunoisolation systems have been investigated. 
Matrices such as collagen6, 153, 154 or Matrigel7 have been used for transplantation of 
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nerve growth factor-secreting cells in to the injured spinal cord. Hollow fibers of 
acrylonitrile-vinyl chloride copolymer8, polypropylene148 and polyethersulfone9, 155, 
156 have been used to encapsulate cells that are genetically modified to produce 
neurotrophic factors and have been used as transplants in the spinal cord. Once again, 
due to the advantages discussed previously, alginate has been one of the most widely 
used polymers in the encapsulation of cells for gene therapy. Fibroblasts producing 
porcine growth hormone and encapsulated in alginate were transplanted into the 
peritoneal cavity of midget Tao-Yuan swine and a significant growth improvement in 
these animals was demonstrated over a period of 32 days12. Fibroblasts producing 
human growth hormone were shown to secrete significant amounts of the product up 
to one month after encapsulation in alginate95. Alginate-encapsulated genetically 
engineered cells have also been studied for the treatment of hemophilia B157 and 
malignant brain tumors150 in animal models. More recently, baby hamster kidney 
cells97 and 293-producer cells96 that were genetically engineered to produce 
endostatin (an endogenous specific inhibitor of tumor-related endothelial cell 
proliferation) were encapsulated in alginate. Transplantation of these cells into mice97 
and rats96 reduced tumor growth by more than 70% in both animal models. These 
examples prove the promise of ex vivo gene therapy and that alginate encapsulation 
could play a very important role. 
2.10 Spinal Cord Injury 
 Each year in the United States alone, approximately 11,000 people sustain a 
severe spinal cord injury. Most of these injuries are the result of vehicular accidents, 
falls, interpersonal violence or sports-related injuries4. A majority of these injuries 
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occur in young people who are otherwise completely healthy. These injuries not only 
have severe personal and social consequences, but also require lifelong care and 
rehabilitation and the estimated costs for a quadriplegic patient’s lifetime has been 
estimated to exceed $1 million4. Development of therapeutic strategies to treat such 
injuries has received a great deal of attention and is considered of utmost importance.  
 The devastating effects of spinal cord injuries are due to the death of neurons 
that cannot be replaced, the inability of the surviving neurons to regenerate their 
axons and an inhospitable environment produced by the injury. It was earlier believed 
that axonal growth was not feasible and that SC injuries were untreatable due to the 
reasons mentioned above. However, over the years, evidence has accumulated 
proving the ability of neurons to grow under conditions conducive to their growth. 
 The complete inability of regenerating fibers to traverse lesions in the spinal 
cord is a puzzling phenomenon. The injured axons cannot grow into and cross the 
lesion as a result of which they cannot reach their targets to form a connection and 
restore function158. On the other hand, it is commonly known that a lesion in the leg 
or the arm does not necessarily lead to permanent disability. In the peripheral nervous 
system, sensory axons can grow to innervate the skin restoring cutaneous sensation 
and motoneurons can regrow axons to innervate skeletal muscles allowing controlled 
movements. This discrepancy between the peripheral nervous system and the central 
nervous system observed in adult mammalian species is not seen in lower vertebrates 
or invertebrates. In a simple animal such as the medicinal leech, a complete 
transaction of the spinal cord is followed by growth and reconnections that are 
amazingly precise158. Similarly, transection of the optic nerve in frogs and fish and 
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the spinal cord in chicks is followed by regeneration leading to functional recovery159. 
The adult mammalian central nervous system displays an almost complete failure to 
regenerate. It has been long recognized through demonstration by Ramon and Cajal, 
that proximal axon stumps show an initial regenerative attempt (sprouting), 
suggesting they are capable of regrowth. However, this early sprouting is always 
followed by an arrest of growth, retraction of the fibers, and formation of a retraction 
neuroma160. A lot of work has been devoted towards investigating the reasons for this 
inability of the spinal cord to regenerate after an injury and several factors have been 
implicated. It is thought that central glial cells such as astrocytes and 
oligodendrocytes may not provide appropriate physical guidance or chemical factors 
to support successful axonal growth160. It has been demonstrated that growth 
inhibitory molecules are present on the surface of oligodendrocytes of the mammalian 
central nervous system, both in tissue culture and in rats161. There is also evidence 
that there are growth inhibiting molecules associated with the central myelin162. In 
addition, reactive astrocytes, microglia and invading macrophages are also observed 
at the lesion site162. Lack of trophic support and a loss of neurons as a result of 
retrograde cell death have also been thought to hinder central nervous system 
regeneration163. Scar tissue, also referred to as the glial scar, builds up at the site of 
the injury and there is evidence that the dense structure of this scar may physically 
obstruct growing axons and may contain growth inhibiting molecules164.  
 Understanding these reasons and mechanisms has led to the development of 
several different strategies to treat spinal cord injuries and these are discussed in the 
following section.             
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2.11 Approaches to Treatment of Spinal Cord Injuries 
     Several different therapeutic strategies are being developed to treat spinal 
cord injuries. These approaches include application of growth factors, antibodies to 
growth inhibiting molecules, cell transplants, ex vivo gene therapy approaches 
including encapsulated cells. Some of these approaches are discussed below. 
2.11.1 Neurotrophic Factors 
 Axotomy is thought to deprive the injured neurons of target derived 
trophic factors including a group of factors called neurotrophic factors. The 
importance of nerve growth factor (NGF) for supporting survival and growth in the 
peripheral nervous system is well documented. Its role in central nervous system 
injury was first tested in 1963165. It is now known that NGF is just one of a large 
family of factors including brain-derived neurotrophic factor (BDNF), neurotrophin-3 
(NT-3), ciliary neurotrophic factor (CNTF) and glial cell line-derived neurotrophic 
factor (GDNF). The potential therapeutic value of these factors has received 
widespread attention in the recent past166. Application of these trophic factors to 
hemisections or complete transactions of the adult spinal cord in rats has been shown 
to prevent the atrophy of rubrospinal neurons167 and to increase the sprouting in the 
corticospinal168 and the rubrospinal169 tracts. It has also been suggested that 
combination therapies involving delivery of more than one of these factors might hold 
more promise170. However, these neurotrophic factors are proteins that cannot cross 
the blood brain barrier which renders systemic administration unusable. Therefore, 
the challenge lies in delivering these factors effectively to the site of the injury. The 
most promising way to deliver these factors locally is to transplant cells that are 
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genetically engineered to produce these factors at the site of the injury and this is 
discussed a little further in this section.      
2.11.2 Antibodies to Growth-inhibiting Molecules 
 As discussed before, some growth-inhibiting molecules have been implicated 
in the difficulty faced by injured spinal cord neurons to regenerate. Schwab et al162, 164 
have identified and isolated some growth inhibiting factors associated with 
oligodendrocytes and the myelin of central axons. Two protein fractions from these 
have been isolated and an antibody, IN-1, developed against these proteins has been 
shown to effectively combat their inhibitory activity in culture171 and was found to 
support much more significant growth of the corticospinal tract as compared to 
untreated controls in case of spinal cord injury in adult rats161. Also, application of 
these antibodies has been shown to result in improvements in specific locomotor 
functions172. An approach using the IN-1 antibody in combination with NT-3 
increased the regeneration seen in the corticospinal tract even further173.    
2.11.3 Cellular Transplants 
 This section will discuss the transplants of different types of cells (not 
genetically engineered) used to promote regeneration and functional recovery in the 
injured spinal cord. Ex vivo gene therapy applied to spinal cord injuries will be 
discussed in detail in the next section.  
 Transplantation is one of the principal therapeutic strategies that has captured 
the imagination of scientists working in repair of central nervous system injury174. 
The initial transplantation approach to spinal cord repair focused on the use of fetal 
grafts and peripheral nerves. However, there has been an increasing realization of the 
 51 
need for alternative transplant sources, motivated not only by ethical issues but also 
by practical limitations related to the availability and quality of the tissue for 
grafting174. 
 The use of peripheral nerves transplanted into an injured spinal cord model 
provided evidence that adult central axons have the capacity to regenerate over long 
distances175. Aguayo et al176 demonstrated that a graft of peripheral nerve could 
provide a bridge along which CNS axons could grow. The conclusion from these 
experiments was that the substrate provided by the piece of peripheral nerve allowed 
axons to grow. The substrate consisted of the degenerated axons, extracellular matrix 
material and Schwann cells. However, in transplants of peripheral nerves growth 
generally stops close to the distal end of the transplanted nerve and axons rarely 
penetrate far in to the central nervous system. Also, another problem for significant 
functional recovery is that most of the regenerating axons come from neurons with 
cell bodies close to the point of transection.   
 The role of Schwann cells in supporting peripheral nerve regeneration is well 
established. These cells provide guidance tubes for regenerating peripheral axons and 
secrete a number of neurotrophic factors, extracellular matrix components and cell 
adhesion molecules177. These cells were studied for spinal cord transplants with the 
view that they would act in a similar fashion to guide and support growing axons in 
the spinal cord. Grafts of cultured Schwann cells or a collagen matrix containing 
Schwann cells into the injured spinal cord have been shown to increase axonal 
sprouting178. It has also been found that Schwann cell survival is improved and the 
glial scar is reduced when the Schwann cells are grafted immediately after the lesion 
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is made179. Delay in grafting of Schwann cells leads to less satisfactory results. 
Biocompatible artificial guidance channels seeded with Schwann cells have also been 
studied177. Growth of axons into these guidance channels did occur after complete 
transection, however, as with peripheral nerves, these processes mainly arose from 
local cells within the spinal cord rather than long tracts. 
 Transplants of embryonic rat brain or spinal cord tissue have been shown to 
survive and differentiate in the damaged spinal cords of newborn and adult host 
rats180. Transplants of brainstem containing particular cell groups can provide a 
source of neurotransmitters for the transected spinal cord. The transplants can act as a 
bridge through which regenerating axons can grow, and fetal transplants may reduce 
scar formation at the host-graft interface181. The implantation of fetal neural tissue 
into the neonatal spinal cord has been very successful with extensive regeneration 
into and beyond the injury site with considerable functional recovery182. However, 
fetal transplants into the adult spinal cord have not been as successful183. Although 
the host neurons can grow into the donor tissue, they cannot grow through it and the 
donor tissue does not extend into the host tissue for more than a few millimeters. This 
does not act like a true bridge and gives rise to minimal functional improvements. 
Although fetal tissue transplants has generated considerable interest in other types of 
central nervous system damage like Parkinson’s disease, there are considerable 
ethical, legal and practical difficulties in obtaining compatible donor tissue making 
this type of therapy less likely.    
 Neurons from the olfactory mucosa are the only neurons that are borne after 
birth and continue dividing throughout adult life. The growth of axons from these 
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neurons is supported by specialized cells called olfactory ensheathing cells. These 
cells are similar to Schwann cells but unlike Schwann cells, these ensheathing cells 
can accompany the axons into the central nervous system. Li et al184 reported that 
these ensheathing cells cultured from an adult rat olfactory bulb could support 
regeneration of corticospinal axons after a localized lesion in adult rats.. The fact that 
the axons grew through the lesion and some functional recovery was observed was 
also very encouraging. A great advantage of this approach is that cells from the 
patient’s own olfactory mucosa could be cultured and used, thus eliminating problems 
of rejection or immunosuppression.    
 Embryonic stem cells have been isolated from different species including 
humans. These cells are unique in their ability to generate all phenotypes including 
neural cells. They can be maintained in culture and used as a source of neural cells. 
Pleasure et al185 prepared neurons from the clonal NT2N cell line by treatment with 
retinoic acid. When these neurons were implanted in to the spinal cord of mice, they 
integrated with the host, survived for months and developed into mature neurons and 
with neurite outgrowth. Although, this is a very new approach, it is seen that 
embryonic stem cells have the potential to be used in spinal cord injury since they can 
be readily obtained and grafted.     
2.11.4 Ex vivo Gene Therapy for Spinal Cord Injuries 
 One of the most promising and rapidly growing approaches to treatment of 
spinal cord injury is the transplantation of genetically engineered cells which secrete 
the therapeutic product at the site of the spinal lesion. The therapeutic products in this 
case are the neurotrophic factors which pose the challenge of delivering them to the 
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site of the injury because of their inability to cross the blood brain barrier. Schwann 
cells that were genetically modified to secrete higher than normal levels of BDNF led 
to an increase in regeneration of brainstem neurons across a complete transection in 
adult rats186. The most common cell line that has been genetically engineered to 
deliver these neurotrophic factors are fibroblasts. Primary rat fibroblasts have been 
genetically modified to produce NGF. After transplantation in to the injured spinal 
cord of adult rats, robust growth of sensory, noradrenergic, and motor neurites was 
observed6. It has also been shown that partial functional recovery was achieved in 
adult rats with dorsal cord lesions after treatment with grafts of NT3-secreting 
fibroblasts187. Interestingly, it has been found that such genetically modified cells 
have been found to increase sprouting even when transplanted months after the 
lesion. Such an approach could be used to produce different types of neurotrophic 
factors such as NGF, BDNF, NT-3, CNTF and GDNF. Liu et al188 genetically 
engineered primary rat skin fibroblasts to produce BDNF. When these modified cells 
were transplanted into a partial cervical hemisection of adult Sprague Dawley rats, 
rubrospinal tract regeneration was observed up to 2 months after lesion and 
transplantation. Anterograde and retrograde tracing techniques showed that a 
significant number of the neurons regenerated axons through the transplants and 
penetrated several segments into the spinal cord. Behavioral tests demonstrated a 
significant recovery of forelimb usage following the transplantation of the BDNF-
producing cells. The same laboratory has also used genetically modified neural stem 
cells to deliver NT-3 to the injured spinal cord152. They demonstrated that these 
neural stem cells survived and produced NT-3 after transplantation into the injured 
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spinal cord of adult rats. They also observed that the transplanted neural stem cells 
differentiated into neuronal and glial phenotypes and also migrated for long distances. 
As can be seen from the above examples, the most likely scenarios for clinical 
applications would involve grafting of non-autologous transplants (allografts) into the 
injured SC. These non-autologous cellular therapies, however, can induce strong 
immune responses and require strict immunosuppression protocols. These 
immunosuppression protocols can compromise the health of the host and can reduce 
the effectiveness of the transplant. One method of foiling the immune response is to 
encapsulate the graft cells in a permselective matrix, which would allow free 
diffusion of the growth factors, cell nutrients and waste products but would prevent 
the components of the host immune system from getting through. Matrices such as 
collagen6, 153, 154 and Matrigel7 have been used for embedding fibroblasts producing 
NGF and Schwann cells respectively before transplantation into the spinal cord. 
Hollow fibers of acrylonitrile-vinyl chloride8 and polyethersulfone9 have been used to 
encapsulate fibroblasts that are genetically modified to produce neurotrophic factors 
and have been used as transplants in the central nervous system. Fibroblasts modified 
to produce CNTF and encapsulated in hollow polypropylene fibers were transplanted 
subcutaneously and were shown to slow down progressive motor neuronopathy in 
mice148. Encapsulation of cells also presents the opportunity of being able to try 
combination therapies by transplanting capsules containing cell lines producing 
different neurotrophic factors or encapsulating antibodies to growth inhibitors. The 
success of encapsulation depends on the survival of the cells in encapsulated form 
and on expression of the therapeutic product after encapsulation (in vitro as well as in 
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vivo). It also depends on the ability of the encapsulation matrix to provide sufficient 
immunoisolation to the encapsulated cells from the host and also to allow free 
diffusion of the therapeutic product out of the matrix. Alginate is an attractive choice 
because of the ease of encapsulation and the mild conditions utilized for 
encapsulation. In addition, it provides the opportunity of being able to provide a 
growth permissive substrate such as laminin, in the form of a coating. We have shown 
that genetically engineered fibroblasts continue to secrete BDNF after encapsulation 
in alginate11. When transplanted in to the injured spinal cord of adult rats without any 
form of immunosuppression, these encapsulated cells survive and also promote 
sprouting of axons in the lesion area. These examples demonstrate the potential for 
encapsulation in the field of spinal cord injury repair and hold a lot of promise for 
developing future therapeutic strategies. 
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3. MATERIALS AND METHODS 
3.1 Materials 
3.1.1 Lipids 
 Egg phosphatidylcholine (PC), phosphatidylglycerol (PG), and cholesterol 
(Chol) were purchased from Sigma Chemical Co., St. Louis, MO. 
Dioleoylphosphatidylcholine (DOPC), rhodamine-labeled phosphatidylethanolamine 
(Rh-PE) and nitrobenzoxadiazole-labeled phosphatidylethanolamine (NBD-PE) were 
purchased from Avanti Polar Lipids, Alabaster, AL. All these chemicals were used as 
received. 
3.1.2 Entrapped Species 
 Bovine serum albumin (BSA) and bovine serum albumin labeled with 
fluorescein isothiocyanate (FITC-BSA) were purchased from Sigma Chemical Co., 
St. Louis, MO. Carboxyfluorescein (CF) was purchased from Molecular Probes, 
Eugene, OR.  
3.1.3 Other Chemicals 
 Low viscosity sodium alginate (Keltone-LV) was a generous gift from ISP 
Alginates, San Diego, CA (formerly the Nutrasweet Kelco Company) and was used 
as obtained. N-[2-hydroxyethyl]piperazine-N'-[2-ethanesulfonic acid] sodium salt 
(HEPES), poly-L-lysine (PLL, MW 15,000-30,000), poly-L-ornithine (PLO, MW 
15,000-30,000), calcium chloride, aluminum chloride and barium chloride were all 
purchased from Sigma Chemical Co., St. Louis, MO. All other chemicals were 
reagent grade. 
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 All solutions were prepared in HEPES buffer (20 mM HEPES, 0.78% NaCl, 
pH 7.5, osmolality 290 mmol/kg) unless otherwise mentioned.  
3.2 Liposome Preparation 
3.2.1 Large Unilamellar Vesicles  
 LUV’s were prepared by the reverse-phase evaporation technique44 with some 
modifications. A detailed description of the procedure is given in Appendix A. For 
protein release studies, BSA was used as the entrapped species whereas 
carboxyfluorescein was used as the entrapped species in leakage experiments. 
Liposome compositions used were pure PC, PC/Chol (7:3), PC/PG/Chol (6:1:3), pure 
DOPC and DOPC/Chol (7:3). All the ratios mentioned above are molar ratios. For 
lipid mixing experiments, PC/Chol and PC/PG/Chol liposomes were prepared with 
0.6 mol% Rh-PE and 0.6 mol% NBD-PE and with HEPES buffer as the entrapped 
species. 
3.2.2 Multilamellar Vesicles  
 Multilamellar vesicles were prepared by the dehydration-rehydration method45 
as described in detail in Appendix B. BSA was used as the entrapped species for 
protein release experiments. Liposome compositions used were PC/Chol (7:3) and 
PC/PG/Chol (6:1:3).   
3.2.3 Entrapped Species 
 For protein release experiments, an aqueous solution of FITC-BSA and BSA 
(1:1 weight ratio, total concentration 25 mg/ml) was used. The protein was dissolved 
in HEPES buffer for the preparation of LUV’s and in distilled water for the 
preparation of MLV’s. Carboxyfluorescein (200 mM) was used as the entrapped 
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species in leakage experiments. The CF was first dissolved in acidic medium in order 
to ensure complete dissolution and the buffer was slowly brought up to pH 7.5 by 
addition of 1 N NaOH. The CF solution was stored in a dark bottle and covered with 
foil to prevent exposure to light.   
3.2.4 Extrusion 
 Liposomes were extruded through polycarbonate membranes using a hand-
held mini extruder (Avanti Polar Lipids, Alabaster, AL). Liposomes were drawn into 
a 1 ml gas-tight syringe and extruded through the polycarbonate membrane into 
another syringe on the other side of the extruder. The extrusion was performed 12 
times back and forth between the two syringes. LUV’s were extruded through a 0.4 
µm membrane. During an intermediate step in the DRV procedure, MLV’s were 
sequentially extruded through 0.4 µm, 0.2 µm and 0.1 µm membranes to obtain 
SUV’s.  
3.2.5 Separation 
 The unentrapped material was removed from the liposomes by gel permeation 
chromatography and/or centrifugation. For gel filtration, a 1.5 cm (diameter) × 50 cm 
(length) Kontes Flex glass column packed with Sepharose-4B or Sephadex-G75 was 
used and HEPES was used as the eluting buffer.  
 LUV’s containing BSA (except those of pure PC) were separated from the 
unentrapped BSA using the Sepharose-4B column followed by centrifugation 
(Sorvall Inc., Wilmington, DE model Ultra 80). Unentrapped BSA in the case of PC 
LUV’s was removed using a Sephadex-G75 column followed by the centrifugation 
step. Liposomes of 0.4 µm size were centrifuged at 20000×g for 2 hours. 
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Unentrapped CF was separated from LUV’s by centrifuging the liposomes twice as 
mentioned above. Unentrapped BSA was separated from the MLV’s by centrifuging 
the liposomes twice at 20000×g for 30 minutes. All centrifugation steps were carried 
out at 12°C after several fold dilution with HEPES buffer to improve separation. 
3.2.6 Phosphate Assay 
 An assay for inorganic phosphorus189 was used to determine the concentration 
of lipid in the liposome preparation. The amount of phosphorus in the liposome 
suspension could be determined and from this the phospholipid concentration was 
calculated. A detailed protocol for the assay is provided in Appendix C.  
3.3 Microencapsulation of Liposomes in Alginate 
 Keltone-LV (sodium alginate) was dissolved in HEPES buffer to obtain a 
2.5% (w/v) solution. The alginate was slowly added to the HEPES buffer under 
vigorous stirring to obtain a good dispersion of the alginate which eased the 
dissolution process. The alginate solution was then filtered through a 0.45 µm 
cellulose acetate bottle top filter to remove any undissolved particulate matter. 
3.3.1 Microcapsule Formation  
 Microencapsulation of liposomes in alginate followed the method of Wheatley 
et al1. Liposomes to be encapsulated were pelleted by centrifugation, resuspended in 
HEPES buffer and then mixed with the stock alginate solution such that a final 
concentration of 1.5% (w/v) alginate was obtained with 10 µmol lipid/ml of solution. 
The liposome-in-alginate suspension was sprayed from a 5 ml syringe (~3.5 ml/min) 
into 400 ml of a solution of the crosslinking cation through a 22G needle in a custom-
made jethead using a Sage syringe pump (Orion Research Inc., Beverly, MA model 
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355). The stream from the jethead was sheared by a coaxial stream of air (~2 slpm), 
causing the formation of droplets of the liposome-alginate mixture. Spherical 
microcapsules were formed due to the crosslinking of the alginate droplets by the 
crosslinking cations. The microcapsules were allowed to harden in the crosslinking 
solution for 1 hour after which they were washed thrice with 200 ml of HEPES buffer 
per wash. A schematic of the microcapsule preparation is shown in Figure 3.3.1. The 
size of the microcapsules was 300-500 µm.  
3.3.2 Microcapsule Coating 
 The microcapsules were coated with either PLL (0.46 mg/ml) or PLO (0.5 
mg/ml) by placing the hardened microcapsules in a solution of the polyamino acid for 
6 minutes under gentle shaking. The volume of the polyamino acid solution used was 
6 times the volume of the amount of 1.5% (w/v) alginate sprayed during the 
encapsulation. The polyamino acid solutions were prepared in HEPES buffer just 
before use and were filtered through a 0.2 µm cellulose acetate bottletop filter. The 
microcapsules were then washed three times with 200 ml of HEPES buffer to remove 
any unreacted polyamino acids. Following this, the microcapsules were contacted 
with 100 ml of a 0.12% (w/v) alginate solution for 15 minutes. Finally, the 
microcapsules were washed thrice with HEPES buffer to remove any unreacted 
alginate and were ready for use in protein release studies.  
3.4 In vitro Release Studies 
3.4.1 Protein Release From Microencapsulated Liposomes 
 The microcapsules prepared as described in the previous section were filtered 
through a 149 µm polypropylene mesh in order to remove undersized microcapsules.  
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Figure 3.3.1 Set up for preparation of alginate microcapsules 
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The microcapsules were then allowed to dry sufficiently so that almost all of the 
water is removed. It is essential not to let the microcapsules drain completely since 
drying can affect their stability. The microcapsules were then weighed out into 
polypropylene sleeves, which were used to facilitate transfer. The sleeves in turn were 
placed into 20 ml glass vials containing 10 ml of HEPES buffer. The capped vials 
were then placed on a rotary shaker (Labline Instruments Inc., Melrose Park, IL 
model 3520) at 200 rpm in an incubator at 37°C. The buffer was replaced at regular 
intervals to mimic infinite sink conditions. The amount of FITC-BSA released was 
determined by measuring the fluorescence of FITC in the collected release buffer on a 
spectrophotofluorometer (Photon Technology International, Monmouth Junction, NJ). 
FITC fluorescence was measured at an excitation wavelength of 495 nm and emission 
wavelength of 513 nm.  
3.4.2 Protein Release from Non-encapsulated Liposomes 
 Release of FITC-BSA from non-encapsulated liposomes was monitored as 
control. Some of the liposomes from the preparations used for microencapsulation 
were used for these control experiments. Liposomes were suspended in HEPES buffer 
at a concentration of 0.3 µmol lipid/ml buffer and 10 ml of suspension was placed in 
20 ml glass vials. The capped vials were placed on a rotary shaker at 200 rpm in an 
incubator at 37°C. A 500 µl aliquot was withdrawn from the vials every 5 days and 
centrifuged to separate the liposomes as a pellet. The supernatant was analyzed for 
released FITC-BSA content as described in the previous section. 
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3.4.3 Determination of Total Amount of Protein Entrapped                                    
 The total amount of protein entrapped in liposomes and in liposome-
containing microcapsules was determined by disrupting them to obtain complete 
protein release. An aliquot of liposomes of known concentration was disrupted by 
adding polyoxyethylene-8-lauryl ether, resulting in a clear solution which was then 
analyzed for FITC-BSA content by measuring the fluorescence. A known weight of 
liposome-containing microcapsules was treated with a 10% (w/v) EDTA solution 
containing 1% (v/v) Triton X-100. The EDTA chelated the crosslinking cations and 
disrupted the microcapsules while the Triton X-100 disrupted the liposomes released 
from the microcapsules. The microcapsules in the EDTA/Triton mixture were 
subjected to sonication until the microcapsules were disrupted. The microcapsule 
debris was separated by centrifugation at 65000×g for 30 minutes and the supernatant 
was analyzed for FITC-BSA content by measuring the fluorescence.  
3.5 Carboxyfluorescein Leakage Study 
 Carboxyfluorescein (CF) leakage assays work on the principle of self-
quenching of CF at high concentrations and an increase in the fluorescence upon 
dilution190. LUV’s were prepared using the reverse-phase evaporation technique. CF 
was used at a concentration of 200 mM in the liposome preparation. A 10 µM 
suspension of the CF-liposomes in HEPES buffer was prepared and aliquots of 20 ml 
in glass vials were placed on a rotary shaker at 200 rpm in an incubator at 37°C. The 
fluorescence (Ft) of the suspension was monitored over time, with the baseline 
fluorescence at time 0 being denoted as F0 and the 100% leakage fluorescence (as 
obtained after treatment with polyoxyethylene-8-lauryl ether) denoted as Fmax. The % 
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leakage of CF from the liposomes was calculated as (Ft- F0)/(Fmax-F0) × 100. A 
similar experiment was conducted where the CF-liposomes were suspended in a 1.5% 
(w/v) alginate solution and CF fluorescence was monitored over time. The 
fluorescence of CF was measured at an excitation wavelength of 492 nm and an 
emission wavelength of 516 nm. It is important to note that the fluorescence of CF is 
very sensitive to pH and, hence, care should be taken to maintain the pH of all 
working solutions at or as close to 7.5 as possible. 
3.6 Lipid Mixing Experiments 
 Lipid mixing experiments are based on the principle of resonant energy 
transfer191 and were used to determine if alginate caused any exchange of lipids 
(observed during membrane fusion) to occur between liposomes. Liposomes 
containing 0.6 mol% NBD-PE and 0.6 mol% Rh-PE were prepared using the reverse 
evaporation procedure. Blank or unlabeled liposomes (without any NBD-PE and Rh-
PE) were also prepared. The entrapped species used in both cases was HEPES buffer. 
Labeled liposomes and blank liposomes were mixed in the molar ratio 1:4 to a total 
concentration of 100µM in HEPES buffer and aliquots of 20 ml were placed on a 
rotary shaker at 200 rpm in an incubator at 37°C. The fluorescence of NBD (Ft) in the 
liposome suspension was monitored over a period of time. The initial residual 
fluorescence of NBD (F0) was measured and the fluorescence of NBD after complete 
lipid mixing (Fmax) was obtained by adding polyoxyethylene-8-lauryl ether to disrupt 
the liposomes and mix the labeled and unlabeled lipids. The % lipid mixing was 
calculated as (Ft- F0)/(Fmax-F0) × 100. A similar experiment was conducted where the 
liposomes were incubated in 1.5% (w/v) alginate and the fluorescence of NBD was 
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monitored over time. The fluorescence of NBD was measured at an excitation 
wavelength of 460 nm and emission wavelength of 534 nm. 
3.7 Differential Scanning Calorimetry 
Differential scanning calorimetry was performed on liposomes in an attempt 
to understand the mechanism of interaction of liposomes with alginate. Calorimetric 
experiments were performed using a differential scanning calorimeter (TA 
Instruments Inc., New Castle, DE model DSC-2010) Blank liposomes of DOPC and 
DOPC/Chol (7:3) were prepared using the reverse phase evaporation procedure. 
Aliquots of 10 µl of liposomes (known concentration) in HEPES buffer were 
transferred into aluminum pans which were then hermetically sealed. Thermograms 
were recorded at a heating rate of 4°C/min, using HEPES buffer as the reference. 
Similar experiments were conducted on liposomes immediately after suspending 
them in 1.5% alginate and also after incubation in 1.5% alginate at 37°C for 24 hours. 
The amount of liposomes used for performing these experiments without alginate or 
in the presence of alginate was maintained the same by diluting the stock liposome 
suspension appropriately.  
3.8 Microscopic Observation of Microcapsules 
The microcapsules were observed under an Olympus IMT-2 inverted research 
microscope at different points during the release studies and pictures were taken using 
an Olympus SC35 camera. A grid of 1 mm on a microscopic glass slide was used for 
size comparison purposes 
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3.9 Encapsulation of Genetically Engineered Fibroblasts 
3.9.1 Culture of Genetically Engineered Fibroblasts 
 Adult Sprague-Dawley fibroblasts that were genetically modified by a 
recombinant retrovirus to secrete BDNF (Fb/BDNF) were obtained from Dr. Itzhak 
Fischer’s laboratory in the Department of Neurobiology and Anatomy at 
MCP/Hahnemann University. The retroviral construct contains the human BDNF 
transgene along with the reporter gene LacZ, which codes for the bacterial enzyme β-
galactosidase. The construction of the retrovirus and characterization of the modified 
fibroblast cells has been reported previously188. 
 Fb/BDNF were cultured in 10 cm tissue culture dishes in Dulbecco’s 
Modified Eagle Medium (DMEM) containing 10% fetal bovine serum (FBS) at 37°C 
and 5% CO2. The cells were passaged at about 70-80% confluency. The expression of 
the transgene is maintained at good levels through approximately 25 passages 
(personal communication). 
3.9.2 Encapsulation of Fb/BDNF in Alginate 
 At about 75% confluency, cells were harvested with 0.25% trypsin and 
washed three times with sterile saline (0.9% NaCl). A stock solution of 2.5% (w/v) 
alginate (Keltone LV) was sterilized by filtration through a 0.45 µm sterile bottle top 
filter. The cells were resuspended in sterile saline and mixed with the sterile alginate 
solution to obtain a final alginate concentration of 1.5% (w/v) and cell concentration 
of 3 × 106cells/ml of solution. Alginate microcapsules containing cells were prepared 
as described in Section 3.3.1. Prior to use, the jethead was sterilized by spraying with 
70% alcohol. The microcapsules were coated with a 0.5 mg/ml solution of PLO 
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followed by coating with a 0.12% (w/v) alginate solution. All solutions were prepared 
in sterile saline (pH 7.5) and all steps involved were carried out in a laminar flow 
hood under sterile conditions. The same encapsulation procedure was used to prepare 
cell-free alginate capsules that served as controls. The capsules were transferred to 10 
cm culture dishes and placed in the incubator. 
3.10 In vitro Evaluation of Microencapsulated Fb/BDNF 
3.10.1 Growth of Fb/BDNF in Alginate Microcapsules 
 The growth of the BDNF-producing fibroblasts was visually observed for 
several days after encapsulation. The encapsulated cells were observed under the 
microscope and micrographs were taken to demonstrate the growth of cells inside the 
alginate microcapsules. 
3.10.2 X-Gal Staining of Encapsulated Cells In vitro 
 After 7 days in culture, capsules containing Fb/BDNF were evaluated for 
expression of the β-galactosidase reporter gene by X-Gal histochemistry192. Capsules 
containing Fb/BDNF were transferred to a 15 ml conical tube, fixed with 0.5% 
glutaraldehyde for 10 minutes and washed three times with PBS. The capsules were 
then incubated with X-Gal reagent (5-bromo-4-chloro-3-indolyl β-D-
galactopyranoside from Molecular Probes, Eugene, OR) at 1 mg/ml final 
concentration and X-Gal mixer in PBS overnight at 37°C. The X-Gal mixer consists 
of 35 mM K3Fe(CN)6, 35 mM K4Fe(CN)6 ⋅ 3H2O, 2 mM MgCl2. After 24 hours, the 
capsules were transferred to a 10 cm culture dish and photographed.  
 In a separate experiment, cells were released from the capsules by disrupting 
the capsules on the fifth day in culture by treatment with 0.2 g/L solution of EDTA in 
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PBS for 20 minutes. Cells released from the capsules were then placed in growth 
medium and examined for β-galactosidase expression by X-Gal histochemistry after 4 
days in culture.  
3.10.3 Freezing and Thawing of Microencapsulated Fb/BDNF 
 Capsules containing Fb/BDNF were pelleted by centrifuging for 5 minutes at 
1000 rpm. The capsules were then resuspended in freezing medium (DMEM + 30% 
FBS + 10% dimethyl sulfoxide) and transferred to cryogenic vials. The tubes were 
placed in a -85°C freezer for 24 hours and then transferred to liquid nitrogen. 
Fb/BDNF alginate capsules, frozen as described above, were thawed by placing the 
vials in a water bath at 37°C. The thawed capsules were transferred to a 10 cm culture 
dish with 20 ml of prewarmed growth medium and placed in an incubator at 37°C. 
After 4 hours, the medium was replaced with fresh prewarmed growth medium to 
remove the dimethyl sulfoxide (DMSO). The cells inside the thawed capsules were 
observed for growth and expression of the β-galactosidase reporter gene by X-Gal 
staining.  
3.10.4 Bioactivity Assay of BDNF Expressed by Microencapsulated Fb/BDNF 
 An E8 chick dorsal root ganglion (DRG) explant assay193 was used to 
determine if the BDNF produced by the encapsulated cells was functionally active. 
Fb/BDNF capsules, growing in culture, were washed three times with sterile saline 
and were placed in fresh media containing 0.1% FBS. After 24 hours, the conditioned 
media was removed for the DRG assay. Conditioned media was also collected from 
non-encapsulated Fb/BDNF cells growing in culture and from cell-free capsules. 
Fertile eggs were purchased from SPAFAS (Preston, CT) and were incubated in a 
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humidified incubator at 37°C for 8 days before use. Eggs containing E8 embryos 
were opened and the embryos were transferred to a sterile culture plate containing 
prewarmed DMEM with 0.1% heat inactivated goat serum. Connective tissue and 
meninges were removed and DRG’s from the lumbar region were gently dissected out 
for the experiment. The DRG’s were placed in 12 well plates containing 600 µl of 
collagen gel and 400 µl of conditioned media from either Fb/BDNF capsules, cell-
free capsules, non-encapsulated Fb/BDNF cells was added to separate wells of the 12 
well plate containing the DRG’s. Unconditioned media (DMEM + 0.1% FBS) was 
used as the negative control and unconditioned media with 450 ng of human 
recombinant BDNF was used as the positive control. DRG outgrowth was observed 
24-48 hours and compared.  
3.11 In vivo Evaluation of Microencapsulated Fb/BDNF 
3.11.1 Surgical Procedures 
 Twenty eight female Sprague-Dawley rats (Taconic, Germantown, NY) 
weighing 200-250 g received a partial hemisection at the C3/C4 segment of the spinal 
cord. The rats were anesthetized with an intraperitoneal injection of acepromazine 
maleate (0.7 mg/kg), ketamine (95 mg/kg) and xylazine (10 mg/kg) and the C4 
segment of the spinal cord was exposed by a laminectomy. The dura was cut in the 
midline and the dorsolateral portion of the right side of the C4 spinal cord was 
removed by aspiration. Either alginate-PLO-alginate capsules containing Fb/BDNF 
(n=22) or cell-free alginate-PLO-alginate capsules (n=6) were then injected into the 
lesion cavity through a 16G needle. About 20-40 capsules were required to fill the 
lesion. The dura was closed with interrupted 10-φ sutures and the muscle and skin 
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were closed with 4-φ sutures. At the time of the injury, all rats received one bolus 
intravenous injection of methylprednisolone (30mg/kg) through the tail vein. After 
surgery, rats were kept on heating pads and observed until fully awake, then returned 
to their home cages. All procedures were carried out in accordance with a protocol 
approved by the MCP/Hahnemann University Institutional Animal Care and 
Utilization Committee and followed the NIH guidelines for the care and use of 
laboratory animals.   
3.11.2 In vivo Expression of Reporter Gene 
 In order to determine whether, the transgene was being expressed in the 
capsules in vivo, the capsules were harvested from the injury site and studied for β-
galactosidase expression. Two (n=3) and four (n=3) weeks after implantation of 
capsules into the lesion cavity, the rats were deeply anesthetized with Nembutal and 
transcardially perfused with 200 ml of saline. The capsules were then harvested from 
the lesion, washed in PBS and then processed for X-Gal staining. Some capsules were 
maintained in culture for one week before staining for β-galactosidase while some 
capsules were disrupted to release the cells and the released cells were stained after 
four days in culture. 
3.11.3 Immunocytochemical Staining of Transplant Tissue 
 Immunocytochemical staining was performed to study the tissue of the 
transplant for sprouting of axons and to evaluate the immune response due to the 
implanted capsules. After 2 weeks and 4 weeks, rats that received Fb/BDNF capsules 
(n=8 for each time point) or cell free capsules (n=3 for each time point) were deeply 
anesthetized with Nembutal and transcardially perfused with 200 ml of saline 
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followed by 500 ml of 4% paraformaldehyde in 0.1M phosphate buffer at pH 7.4. The 
spinal cords were dissected and the transplant region was washed with PBS for 2 
hours, and then placed in 0.1M phosphate buffer containing 30% sucrose for 48-72 
hours at 4°C. The spinal cord tissue was frozen with O.C.T compound and serially 
sectioned at 20 µm on a freezing microtome. The tissue sections were stained with 
primary antibodies followed by secondary fluorescent antibodies. The primary 
antibodies were polyclonal CGRP (1:5000; Peninsula Laboratories Inc., Belmont, 
CA), monoclonal RT-97 (1:100, Boehringer Mannheim GmbH, Germany), polyclonal 
MAP-1B (1:40000; Black et al194), polyclonal MAP-2 (1:10000; Fischer et al195), 
monoclonal ED-1 (1:50; Harlan Bioproducts, Indianapolis, IN) and monoclonal 
GFAP (1:100; Boehringer Mannheim). Fluorescent secondary antibodies (1:200) 
were either FITC or rhodamine conjugated goat-anti-mouse for monoclonal 
antibodies or FITC or rhodamine conjugated goat-anti-rabbit for polyclonal 
antibodies. Slides were then coverslipped with Vectashield containing the nuclear 
counterstain DAPI. 
3.11.4 Image Analysis 
 Stained sections were examined under a Leica DMRBE microscope and 
images were captured using a Photometric Sensys KAF-1400 CCD camera. Images 
were processed on a Macintosh Power PC 8500 with IP Lab (Scanalytics) and NIH 
image analysis software packages.  
3.12 Behavioral Analysis 
 Adult female Sprague Dawley rats (n=12) were studied for functional 
recovery of forelimb use during spontaneous vertical exploration using the cylinder 
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test at different points of time following implantation of alginate capsules at the 
injury site. This test is very sensitive to asymmetries in chronic limb use196. Repeated 
testing does not influence the behavioral score because the weight shifting 
movements of the forelimbs scored in this test are typically used by the animal in its 
homecage. 
 The rats were placed in a clear Plexiglass cylinder (20 cm dia × 30 cm height) 
for 5 minutes. Placing the animals in the cylinder encourages forelimb usage for 
vertical exploration. A mirror was placed behind the cylinder at an angle so that both 
forelimbs could be viewed at all times. The testing session was videotaped and the 
forelimb usage was blindly scored at a later time.  
 The following behaviors were scored: (1) Independent use of the left or right 
forelimb for contacting the wall of the cylinder during a full rear, or to regain center 
of gravity while moving laterally along the wall in a vertical posture; (2) 
Simultaneous or near simultaneous use of both the right and the left forelimb to 
contact the wall of the cylinder during a full rear and for lateral movements along the 
wall.    
 Each behavior was expressed in terms of: (1) percentage of use of impaired 
forelimb; (2) percentage use of the non-impaired forelimb; and (3) percentage 
simultaneous use of both forelimbs. All percentages were relative to the total number 
of impaired, non-impaired or simultaneous limb use observations.  
 Baseline behavior was measured before the surgical procedure was performed 
and all the animals were tested weekly for 5 weeks after surgery. Two-way ANOVA 
(treatment × preferred limb) was performed to test for differences between animal 
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groups and one-way ANOVA was performed to test for differences within a treatment 
group.    
3.13 YIGSR-Alginate Conjugate as a Growth Permissive Surface 
3.13.1 Preparation of YIGSR-Alginate Conjugate 
 YIGSR peptide was purchased from American Peptide Company (Sunnyvale, 
CA). The peptide was covalently attached to the alginate via an amide bond formation 
between the carboxyl groups of the alginate and the amine terminus of the peptide 
using the zero length crosslinker, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide 
(EDC from Sigma Chemicals, St. Louis, MO). A detailed description of the 
preparation of alginate-peptide conjugate is provided in Appendix D. The conjugate 
was prepared using 0.5 mg peptide, 1 mg peptide and 2 mg peptide per gram of 
alginate. 
3.13.2 Culture of NB2a Neuroblastoma Cells 
 NB2a mouse neuroblastoma cells were obtained as a gift from Prof. Thomas 
Shea (University of Massachusetts, Lowell campus). NB2a cells were cultured in 10 
cm culture dishes in DMEM (without L-glutamine) + 10% FBS + 2 mM L-glutamine. 
The cells were passaged at about 75% confluency.    
3.13.3 Preparation of Alginate Discs 
 Flat alginate gels (discs) were used to study of NB2a cells on peptide 
modified alginate surfaces. The discs were prepared using a CaSO4 slurry as 
described by Rowley et al197 with some modifications. A 1% (w/v) solution of 
alginate (modified or unmodified) was prepared in deionized water containing 0.2% 
(w/v) of sodium metaphosphate. This solution was sterilized by filtration through a 
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0.45 µm syringe filter. Alginate (5 ml) was transferred to a 50 ml conical tube and 
100 µl of CaSO4 slurry (0.4 g/ml) was added to it. The contents of the tube were 
shaken vigorously to ensure complete mixing of the alginate and the CaSO4 slurry. 
The mixture was then poured into three wells of a 6-well plate and allowed to gel for 
2 hours after which the discs were ready for use. Alternatively, the mixture was 
poured into a 50 mm crystallization dish and allowed to set. Following complete 
gelation in about 2 hours, small discs (about 5mm dia. × 2 mm thick) were punched 
out of the gels using the wider end of a pasteur pipette and the small discs were used 
for further experiments. 
3.13.3 Adhesion of NB2a on YIGSR-Alginate 
 The adhesion of cells on YIGSR-alginate gels was studied with varying 
amounts of peptide used in the preparation of the conjugate. YIGSR-alginate gels 
were prepared in the wells of 6 well plates as described in the previous section. NB2a 
cells were harvested using 0.25% trypsin, counted and resuspended in serum free 
medium containing DMEM + 10% serum replacement (Gibco BRL, Rockville, MD) 
+ 2 mM L-glutamine. The gels were then seeded with 100, 000 cells in 5 ml of serum 
free medium. They were then placed in an incubator at 37°C and 5% CO2. After 24 
hours, the gels were washed with Hank’s Buffered Salt Solution (HBSS) to remove 
any unattached cells. The gels were then transferred to 15 ml conical tubes and 
treated with 3 ml of 0.25% trypsin for 10 minutes to detach the cells from the alginate 
surface. Standard growth medium (7 ml) was added and the medium containing the 
cells was transferred to counting vials and diluted to 20 ml with HBSS. The cells in 
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the vials were then counted using a Coulter Multisizer II (Coulter Electronic Ltd., 
England). The orifice size used was 100 µm and the manometer volume was 100 µl.  
 Alternatively, three small discs (5 mm × 2 mm) prepared as described in the 
previous section were placed in each well of a 6 well plate and were seeded with 100, 
000 cells in 5 ml of serum free medium. After 24 hours, the discs were washed with 
HBSS, placed in counting vials and treated with 1 ml of 0.25% trypsin for 10 minutes 
followed by addition of 10 ml of 10% (w/v) of EDTA to dissolve the alginate discs. 
After about 30 minutes that are required to dissolve the alginate discs, the cells were 
counted using the Coulter Multisizer. 
 Similar experiments were conducted with unmodified alginate gels and served 
as the negative controls. Unmodified gels coated with laminin served as a positive 
control. Alginate gels were coated with a 25 µg/ml solution of laminin (Gibco BRL, 
Rockville, MD) in HEPES buffer for hour and then washed three times with alginate 
before adding the cells.  
 A detailed protocol for counting cells using the Coulter Multisizer is provided 
in Appendix E.   
3.13.4 Differentiation of NB2a on YIGSR-Alginate 
 NB2a cells were also studied for their ability to differentiate on the modified 
alginate surface. Alginate gels were prepared in the wells of a 6 well plate as 
described in Section 3.13.2 and seeded with NB2a cells as described in Section 
3.13.3. After 24 hours, the gels were washed with HBSS to remove any unattached 
cells and 5 ml prewarmed differentiation medium (serum free medium + 0.1% FBS + 
10 µM dbcAMP) was added to each well. The differentiation medium was changed 
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every day to replenish the dbcAMP supply. The differentiation of the cells was 
monitored visually by observation under a microscope and digital images were 
recorded using a DP-11 digital camera (Olympus Optical Co. Ltd, Japan). 
 Unmodified alginate gels served as the negative control and alginate gels 
coated with laminin served as the positive control. 
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4. RESULTS AND DISCUSSION 
 In this thesis we tested the hypothesis that encapsulation of liposomes in 
alginate would allow the development of a drug delivery system with multiple control 
points allowing altered release characteristics and great flexibility along with 
protecting the liposomes from the host immune system. We also hypothesized that 
encapsulating genetically engineered fibroblasts in alginate would not only eliminate 
the need for immune suppression but also provide the potential for creating a growth 
permissive environment in an injured spinal cord.    
 Release of protein from microencapsulated liposomes was studied as a means 
to developing a delivery system which could deliver proteins over an extended period 
of time in the human body. Such a delivery system would be very useful in the 
administration of protein drugs such as vaccines and hormones.  
 Different parameters of the microencapsulated system were studied. The 
effect of the ion crosslinking the alginate was studied to determine if that altered the 
release of protein from microencapsulated liposomes. Liposome type and liposome 
composition were studied since the physical characteristics, such as permeability of 
liposomes, vary greatly with these parameters. The results from these studies led to 
further experiments including lipid mixing, carboxyfluorescein leakage from 
liposomes and differential scanning calorimetry in order to investigate the nature of 
any possible interaction between the liposomes and the alginate.  
 Genetically engineered fibroblasts producing BDNF were encapsulated in 
alginate and these microcapsules were studied as a means of providing ex vivo gene 
therapy for treating spinal cord injuries. Firstly, the behavior of the encapsulated cells 
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was studied in vitro with respect to their growth and expression of the recombinant 
BDNF. Then, these microencapsulated cells were studied in vivo for their ability to 
promote regeneration of axons in an injured spinal cord. Lastly, the possibility of 
providing a permissive growth surface for neuronal growth in combination with 
delivering BDNF in the form of microencapsulated cells was investigated.  
4.1 Release of FITC-BSA from Microencapsulated Liposomes 
 The protein used to study protein release from microencapsulated liposomes 
was FITC-BSA, a large molecular weight model protein. The FITC label enabled 
detection of very low levels (µg/ml) of the protein in solution with high sensitivity 
using fluorometry.  
PLL was initially used as the permselective outer membrane since it has 
traditionally been used as a coating in alginate microencapsulation systems10. PLL 
with an average molecular weight of 22KDa was used since it has been shown that 
coating alginate microcapsules with a 0.06% (w/v) solution of PLL of this molecular 
weight for 6 minutes provides sufficient protection from the host immune system109. 
However, we found that alginate microcapsules coated with PLL were unstable and 
disintegration of capsules was often observed within a week of incubating them at 
37°C. This instability or breakdown of PLL coated alginate microcapsules has been 
noted by other investigators also198. As an alternative, the use of PLO was 
investigated and it was found that PLO-coated microcapsules were much more stable 
and lasted more than 90 days when incubated at 37°C. PLO differs from PLL in only 
a methylene group and the shorter chain probably results in a tighter coating on the 
alginate. Moreover, it has also been suggested that PLO might have better 
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immunoisolation properties compared to PLL with respect to blocking immunogenic 
substances of the host from entering the microcapsule198. Hence, all the release 
experiments described in this thesis were conducted using alginate microcapsules 
coated with a 0.5 mg/ml (0.05 % w/v) solution of PLO for 6 minutes.   
4.1.1 Release of FITC-BSA from Liposomes Encapsulated in Ca-Alginate 
The first microencapsulated liposome system we studied was PC/Chol LUV’s 
(7:3 molar ratio). The composition of the liposomes was so chosen because PC is one 
of the most common phospholipids found in biological membranes and cholesterol 
was added to enhance the stability with respect to aggregation of liposomes. LUV’s 
were chosen because they have a large entrapped volume enabling more drug to be 
entrapped. Previous studies have shown that encapsulation of LUV’s in calcium 
crosslinked alginate, hereafter referred to as Ca-alginate, resulted in a pulsatile release 
of protein128.  
Figure 4.1.1 shows the release profile for FITC-BSA from PC/Chol liposomes 
encapsulated in Ca-alginate. The release profile shown is the mean obtained from two 
different preparations. The error bars represent the deviations of the different samples 
(n=4 for each preparation) from the mean. Also shown is the release profile for FITC-
BSA from non-encapsulated liposomes, hereafter referred to as controls. This profile 
is an average of three different preparations (n=3 for each preparation).  
It can be seen that FITC-BSA is released very rapidly from the PC/Chol 
liposomes encapsulated in Ca-alginate. About 45% of the entrapped protein is 
released during the first 24 hours and about 82% after three days. Almost all of the 
protein (~95%) is released within the first 10 days of release. It should be noted that  
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Figure 4.1.1 Release of FITC-BSA from PC/Chol (7:3) liposomes encapsulated in 
Ca-alginate at 37°C 
 
It can be seen that release from encapsulated liposomes is much faster than that from 
non-encapsulated ones. An initial “burst” of protein release is observed from the 
encapsulated liposomes during which about 80% of the entrapped protein is released 
in the first three days. (n=8, mean +/- deviations)  
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the rate of release is very rapid during the first three days after which it slows down 
substantially. It can also be seen that the release of FITC-BSA from 
microencapsulated PC/Chol liposomes is much faster than that from non-
encapsulated liposomes. In 10 days, during which the liposomes encapsulated in Ca- 
alginate release most of the entrapped protein, the non-encapsulated liposomes 
release only about 15% of FITC-BSA. Over the period of 30 days studied, the free 
liposomes released only 30-35% of protein. Previous studies have shown that egg 
PC/Chol (1:1) liposomes released FITC-BSA in the form of two distinct “bursts” or 
pulses after encapsulation in alginate128. The first “burst” was observed immediately 
after encapsulation followed by a period of slow release and the second pulse after 
about 30 days. It was during the second pulse that most of the protein was released. 
However, it would be inappropriate to draw a direct comparison with our 
observations because of the different lipid compositions employed and also because 
the liposomes were extruded through a different size (0.6 µm) membrane.  
The release of FITC-BSA from the PC/Chol liposomes encapsulated in Ca-
alginate is very similar to that observed for free protein (myoglobin) encapsulated in 
alginate-PLL microcapsules1. Since alginate allows rapid diffusion of quite large 
molecules and the approximate molecular weight cutoff of the PLO coating that we 
have employed is about 70 kDa, it could be argued that the release of free FITC-BSA 
from Ca-alginate would be a very rapid one and most likely will be a diffusion 
limited process. However, the fact that the release of FITC-BSA from liposomes 
encapsulated in Ca-alginate exhibits the same characteristics is an unexpected 
outcome. More interesting is the fact that the controls do not exhibit such behavior 
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indicating that the encapsulation in alginate causes an alteration in the release 
characteristics of the liposome-entrapped FITC-BSA. Previous studies have 
suggested that alginate inserts into the lipid bilayer causing an increase in the 
permeability of the lipid bilayers128. This will be discussed in more detail in Section 
4.2. The release characteristics of PC/Chol liposomes encapsulated in Ca-alginate, if 
mirrored in vivo, would definitely be an improvement over administration of free 
liposomes which are eliminated from the body in about 24 hours resulting in wastage 
of the entrapped protein and possibly less than therapeutic levels of the protein in the 
blood stream. However, the release of almost all the protein in about 10 days would 
fall short of the requirements for long term delivery of proteins such as vaccines and 
hormones, which is the primary objective in the development of this system. This led 
us to look into the different parameters of the system that could significantly affect 
the release of entrapped protein. 
One of the first things we looked at was the inclusion of a negatively charged 
phospholipid, PG, into the liposome bilayer. Introduction of PG in the lipid bilayer 
results in more stable liposomes since the charge inhibits aggregation and fusion of 
the liposomes. It has been shown that PC/PG/Chol (4:1:5 molar ratio) liposomes, 
when encapsulated in Ca-alginate, did not exhibit release of carboxyfluorescein in the 
form of bursts128. Rather, it was released very slowly and over an extended period of 
time. We decided to use the negatively charged PG to attempt to mimic a similar 
behavior in the release of FITC-BSA from microencapsulated liposomes. The 
liposome composition used was PC/PG/Chol in the molar ratio 6:1:3. Fig 4.1.2 shows 
the release of FITC-BSA from PC/PG/Chol liposomes encapsulated Ca-alginate.  
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Figure 4.1.2 Release of FITC-BSA from PC/PG/Chol (6:1:3) liposomes 
encapsulated in Ca-alginate at 37°C 
 
Similar to PC/Chol liposomes, release from encapsulated liposomes is much faster 
than that from non-encapsulated ones. An initial “burst” of protein release is observed 
from the encapsulated liposomes during which about 70% of the entrapped protein is 
released in the first two days. The rate of protein release is dramatically reduced after 
that and approximately 15-20% of protein is permanently retained in the encapsulated 
liposomes. (n=8, mean +/- deviations)  
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Similar to the case of PC/Chol liposomes encapsulated in Ca-alginate, the release 
profile is characterized by a large initial burst during which almost 70% is released 
during the first two days. During the first 24 hours, about 55% of the protein is 
released and is followed by a rapid reduction in the rate of release. After the first 2 
days, the rate of release is reduced dramatically and only 80% of the protein is 
released even after 10 days. Following day 10, practically no further release of 
protein is observed up to 30 days. Even after 30 days (data not shown), the 
microencapsulated PC/PG/Chol liposomes retain approximately 15-20% of the total 
amount of the protein entrapped. This observation is in stark contrast to the 
observations of Cohen et al128 who observed no burst in the release of 
carboxyfluorescein from PG containing liposomes. They suggested that the lack of 
bursts might be a result of a lesser degree of interaction between the negatively 
charged alginate and the negatively charged PG-containing liposomes. However, our 
observations contradict their observation. Again, it should be noted that a direct 
comparison is not appropriate because of different lipid compositions employed, 
difference in extrusion and different entrapped species (CF and FITC-BSA) used. It is 
possible that the retention of some protein in the encapsulated liposomes might be a 
result of the inherent stability of PG-containing liposomes199. Also, shown in Figure 
4.1.2 is the release of FITC-BSA from non-encapsulated PC/PG/Chol liposomes. As 
in the case of PC/Chol liposomes, the free PG-containing liposomes release only 
about 25% of the entrapped protein over a 30 day period and the rate of release is 
much slower than that of liposomes encapsulated in Ca-alginate. The rapid release of 
protein from both types of liposomes when encapsulated in alginate leads to the 
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conclusion that the encapsulation process alters the permeability of the liposomes. 
 Both PC/Chol and PC/PG/Chol liposomes encapsulated in Ca-alginate were 
visually monitored by observing them under a microscope at different time points 
during the release studies. Figure 4.1.3 shows PC/Chol liposomes encapsulated in Ca-
alginate and Figure 4.1.4 shows PC/PG/Chol liposomes encapsulated in Ca-alginate. 
It was observed that starting from about day 2 (Figures 4.1.3b and 4.1.4b), both types 
of liposomes started showing formation of clumps inside the microcapsules. The 
clumping appeared to be progressive in time as seen from Figures 4.1.3c and 4.1.4c, 
which were taken at day 10 after encapsulation and incubation at 37°C. Takagi et al 
suggested that after encapsulation there was a gradual concentration of liposomes 
encapsulated in alginate towards the center of the beads200. According to them this is 
possibly due to the fact that that the gelation occurred instantly on the surface of the 
droplets and the resulting gel network forced the liposomes to move into deeper 
concentric sections as gelation proceeds to the interior. However, we have noticed 
this phenomenon starting only from 2 days after removing the beads from the gelation 
medium (CaCl2) whereas they cured their liposome-containing microcapsules for 3 
days in CaCl2. In their case the liposomes were exposed to an excess of Ca2+ ions for 
a prolonged period of time. Ca2+ ions are known to cause aggregation and fusion of 
liposomes201. Our hypothesis is that the concentration of the liposomes to the center 
of the beads is due to the presence of Ca2+ ions and not due to gelation forces forcing 
them to move to the interior of the microcapsule. It is not clear whether the process 
involves aggregation or fusion of the liposomes. Since Ca2+ ions are also known to 
cause leakage of contents from liposomes concomitant with inducing liposome  
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Figure 4.1.3 Photomicrographs of PC/Chol (7:3) liposomes encapsulated in Ca-
alginate 
 
Liposomes are uniformly distributed throughout the microcapsule immediately after 
encapsulation (a) but start moving away from the periphery of the capsule starting 
from day 2 (b) and form a concentrated core of liposomes in the center of the 
microcapsule around day 10 (c). This behavior is observed in all types of liposomes 
encapsulated in Ca-alginate. (Bar = 500 µm) 
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Figure 4.1.4 Photomicrographs of PC/PG/Chol (6:1:3) liposomes encapsulated in 
Ca-alginate 
 
Liposomes are uniformly distributed throughout the microcapsule immediately after 
encapsulation (a) but start moving away from the periphery of the capsule starting 
from day 2 (b) and form a concentrated core of liposomes in the center of the 
microcapsule around day 10 (c). This behavior is observed in all types of liposomes 
encapsulated in Ca-alginate. (Bar = 500 µm) 
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fusion201, it could be responsible in part for the rapid release of protein observed from 
the liposomes encapsulated in Ca-alginate. Thus we could say that it was either the 
alginate (as suggested by a previous study) or the presence of Ca2+ ions that caused 
the occurrence of the “burst” effect.  
 In order to determine whether Ca2+ alone was responsible for the rapid release 
of protein from liposome encapsulated in Ca-alginate, we studied the release of FITC-
BSA from liposomes encapsulated in alginate crosslinked with different cations, 
namely Al3+ and Ba2+.  
4.1.2 Effect of Crosslinking Ions on Release of FITC-BSA from 
Microencapsulated Liposomes 
 Release of FITC-BSA from PC/Chol and PC/PG/Chol liposomes encapsulated 
in alginate crosslinked with Al3+ and Ba2+, hereafter referred to as Al-alginate and Ba-
alginate respectively, was studied. A 2% (w/v) solution of AlCl3 or a 2.15% (w/v) 
solution of BaCl2 was used as the source of the crosslinking ions. The concentrations 
were so chosen that the molarities of Al3+ and Ba2+ in the crosslinking solutions was 
the same as the molarity of Ca2+ used to crosslink the alginate previously.  
 Figure 4.1.5 shows the release of FITC-BSA from PC/Chol liposomes 
encapsulated in Al-alginate and Ba-alginate. For comparison purposes, the data from 
Figure 4.1.1 is also shown. The release of FITC-BSA from PC/Chol liposomes 
encapsulated in Al-alginate is again characterized by a huge burst of protein during 
the first three days of release. As in the case of PC/Chol liposomes encapsulated in 
Ca-alginate, approximately 80% of the protein is released during the first three days. 
Interestingly, the rate of release drops off dramatically after the initial burst of three  
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Figure 4.1.5 Release of FITC-BSA from PC/Chol (7:3) liposomes encapsulated in 
Al-alginate and Ba-alginate 
 
As in the case of liposomes encapsulated in Ca-alginate, those encapsulated in Al-
alginate also showed an initial burst of protein release during which about 80% of the 
entrapped protein was released in the first three days. However, the release from 
liposomes encapsulated in Ba-alginate was marked by the absence of the initial burst 
and the protein was released in a comparatively sustained manner. (n=8, mean +/- 
deviations)  
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days and a more gradual release of protein is observed. Over a period of 30 days, 
about 95-98% of the protein is released from PC/Chol liposomes in Al-alginate. In  
contrast, the release of FITC-BSA from PC/Chol liposomes encapsulated in Ba-
alginate is characterized by a gradual release of protein in the first 5 days during 
which approximately 20-30% of the total protein is released. Even after 15 days only 
70% of the protein is released and after 30 days about 85% of total protein is released. 
Beyond 30 days (data not shown) the release of protein is very slow and even after 60 
days about 10% of the protein is still entrapped in the microcapsules. It is important 
to note that the release of protein from PC/Chol liposomes encapsulated in both Al-
alginate and Ba-alginate is faster than that from non-encapsulated liposomes.  
 Figure 4.1.6 shows the release of protein from PC/PG/Chol liposomes 
encapsulated in both Al-alginate and Ba-alginate. For comparison purposes, release of 
FITC-BSA from liposomes encapsulated in Ca-alginate and non-encapsulated 
liposomes (Figure 4.1.2) is also shown. The release of protein from PC/PG/Chol 
liposomes encapsulated in Al-alginate shows a burst during which about 55% of the 
total protein is released during the first three days. This burst is much smaller than the 
burst exhibited by PC/PG/Chol liposomes encapsulated in Ca-alginate. After the first 
three days the release of protein slows down significantly and about 81% of the total 
protein is released in 10 days following which practically no protein release is 
observed. It is interesting to note that the difference in release from liposomes 
encapsulated in Ca-alginate and Al-alginate is much more prominent in the case of 
PC/PG/Chol liposomes as compared to that in the case of PC/Chol liposomes. The 
release of FITC-BSA from PC/PG/Chol liposomes encapsulated in Ba-alginate is a  
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Figure 4.1.6 Release of FITC-BSA from PC/PG/Chol (6:1:3) liposomes 
encapsulated in Al-alginate and Ba-alginate 
 
The effect of crosslinking ions on the release profiles is clearly evident in this case. 
The extent of the initial burst is much reduced in liposomes encapsulated in Al-
alginate as compared to those encapsulated in Ca-alginate. Also, the burst effect is 
completely absent in the case of liposomes encapsulated in Ba-alginate. (n=8, mean 
+/- deviations) 
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very gradual release during which about 50% of the entrapped protein is released 
during the first 12 days. Even after 30 days, only about 80% of the total protein is 
released following which the release of protein tails off rapidly (data not shown). 
Again it should be noted that the release of protein from PC/PG/Chol liposomes 
encapsulated in both Al-alginate and Ba-alginate is faster than that from non- 
encapsulated liposomes. Also, it can be seen that encapsulated PC/PG/Chol liposomes 
permanently retain approximately 15-20% of the drug in all cases. 
 Visual monitoring of the liposomes encapsulated in both Al-alginate and Ba-
alginate revealed an interesting phenomenon. Figure 4.1.7 shows PC/Chol liposomes 
encapsulated in Al-alginate (Figure 4.1.7a) and Ba-alginate (Figure 4.1.7b) 10 days 
after incubation in HEPES buffer at 37°C. It can be seen that unlike the case of 
liposomes encapsulated in Ca-alginate, these liposomes did not exhibit a visual 
clumping or aggregation towards the center of the Al-alginate or Ba-alginate 
microcapsule. Even after 30 days, no occurrence of visual clumping was observed. 
The same was true of PC/PG/Chol liposomes encapsulated in Al-alginate (Figure 
4.1.8a) and in Ba-alginate (Figure 4.1.8b).  
 It is important to note some trends in the release of protein from both types of 
liposomes encapsulated in alginate crosslinked with the different cations. The release 
of protein is fastest from liposomes encapsulated in Ca-alginate, whereas the release 
is slowest from liposomes encapsulated in Ba-alginate. The release from liposomes 
encapsulated in Al-alginate lies in between and this effect is more pronounced in the 
case of PC/PG/Chol liposomes. In all cases, the release from microencapsulated 
liposomes is much faster than that from the corresponding non-encapsulated  
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Figure 4.1.7 Photomicrographs of PC/Chol (7:3) liposomes encapsulated in Al-
alginate and Ba-alginate 
 
Liposomes are uniformly distributed throughout the microcapsule even 10 days after 
encapsulation in Al-alginate (a) and Ba-alginate (c). Liposomes did not concentrate 
towards the center of the microcapsule even 30 days after encapsulation.  (Bar = 500 
µm) 
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Figure 4.1.8 Photomicrographs of PC/PG/Chol (6:1:3) liposomes encapsulated in 
Al-alginate and Ba-alginate 
 
Liposomes are uniformly distributed throughout the microcapsule even 10 days after 
encapsulation in Al-alginate (a) and Ba-alginate (c). Liposomes did not concentrate 
towards the center of the microcapsule even 30 days after encapsulation.  (Bar = 500 
µm) 
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liposomes. This suggests that the liposomes become leaky after encapsulation in 
alginate, irrespective of the crosslinking cation used. This vindicates Ca2+ alone from  
being responsible for the faster release rates and points to the possibility of an 
interaction between the liposomes and the alginate as suggested by some earlier 
work128. The very rapid release of protein from liposomes encapsulated in Ca-alginate 
and Al-alginate is comparable with that expected in the case of protein being 
encapsulated in alginate alone1. The crosslinking ion has a very marked effect on the 
release profile and the effect of crosslinking with Ba2+ is the most dramatic. It is 
known that the size of the Ba2+ ion in solution (1.35 Å) is much bigger than that of 
the Ca2+ ion (0.97 Å) 202. Both the divalent cations would be expected to crosslink the 
alginate in a similar mechanism in the egg-box model. However, the larger Ba2+ ion 
presents the positive charge close to the carboxylate which would be expected to give 
rise to a much tighter gel structure as compared to the Ca2+ ion which interacts to a 
lesser degree with the carboxylate. This would result in slower diffusion of 
substances across Ba-alginate as compared to Ca-alginate. This behavior has been 
also noted by Musa et al83 in case of release of metoclopramide hydrochloride from 
alginate beads and by Lee et al74 in the release of melatonin from alginate beads. On 
the other hand, the Al3+ would be expected to form a three dimensional valent 
bonding structure with alginate83. The three dimensional crosslinking would occur 
across different planes of the gel and would result in a more compact arrangement of 
alginate molecules as compared to Ca2+, giving rise to slightly slower diffusion rates. 
On the other hand, inspite of the three dimensional bonding, the much smaller size of 
the Al3+ cation would probably result in a gel structure that is less compact than that 
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obtained with Ba2+, resulting in diffusion rates that are faster than Ba-alginate. Musa 
et al83 also observed that release of metoclopramide hydrochloride from Al-alginate 
films was in between that from Ca-alginate (most) and Ba-alginate (least). This 
indicates that the crosslinking ion might be the rate limiting factor in this case, which 
points to the possibility of a very rapid interaction between the liposomes and the 
alginate causing the liposomes to spill its contents into the alginate microcapsule 
followed by release of protein by diffusion through the alginate microcapsule and 
across the polycation membrane. The absence of the “burst” in Ba-alginate could then 
be attributed to the stronger binding of Ba2+ ions with the alginate, resulting in a 
much tighter gel network and lower diffusion rates.  Alternatively, the binding of the 
Ba2+ could be more rapid and enduring, limiting the extent of liposome-alginate 
interaction. 
 Clumping of liposomes is observed only in liposome encapsulated in Ca-
alginate (Figures 4.1.3 and 4.1.4) and not in liposomes encapsulated in Al-alginate 
and Ba-alginate (Figures 4.1.7 and 4.1.8). These observations do not go along with 
the theory put forth by Takagi et al200 proposing that the clumping of liposomes 
occurred due to the forcing of liposomes towards the interior of the beads as gelation 
proceeds inwards. If this were truly the case, we would have observed clumping of 
liposomes in Ca-alginate and Ba-alginate also. Irrespective of whether the clumping 
process involves aggregation or fusion, our observations indicate that the occurrence 
of clumping can be directly attributed to the presence of Ca2+.  
 We have shown here that irrespective of the crosslinking cation, the release of 
protein from liposomes encapsulated in alginate is much faster than that from non-
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encapsulated liposomes and that the crosslinking cations could serve as a means to 
regulate the overall release profile. It is important to note that encapsulation of 
liposomes in Ba-alginate eliminates the burst effect and results in a sustained release 
of protein72. Also, the observations seem to suggest the possibility of an interaction 
between the alginate and the liposomes that leads to the faster release of protein upon 
encapsulation. 
 We next turned our attention to the possibility of varying liposome 
composition as a means to regulate protein release from microencapsulated 
liposomes. 
4.1.3 Effect of Liposome Composition 
 In the earlier parts of the thesis we used liposomes composed of PC/Chol and 
PC/PG/Chol encapsulated in Ca-alginate, Al-alginate and Ba-alginate in an effort to 
see the effect of crosslinking ions on the release of FITC-BSA. Egg PC is a natural 
product composed of phospholipids with a mixture of acyl chains of which about one 
thirds is palmitoyl (16:0), about one thirds is dioleoyl (18:1) and the rest is primarily 
stearoyl (18:0) and linoleoyl (18:2). In order to determine the effect of lipid 
composition we encapsulated protein-containing DOPC (18:1) liposomes in Ca-
alginate. To determine if cholesterol had an effect on the release of protein from 
microencapsulated liposomes, we encapsulated PC liposomes in Ca-alginate and also 
DOPC/Chol liposomes in Ca-alginate.  
 Figure 4.1.9 shows the release of FITC-BSA from PC liposomes encapsulated 
in Ca-alginate. The release profile is a mean of two different preparations with the 
error bars representing the maximum deviations observed within all the samples  
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Figure 4.1.9 Release of FITC-BSA from PC liposomes encapsulated in Ca-
alginate 
 
The release profile is marked by the absence of the initial burst seen in PC/Chol (7:3) 
and PC/PG/Chol (6:1:3) liposomes encapsulated in Ca-alginate, which suggests that 
the presence of cholesterol makes the encapsulated liposomes more permeable to the 
protein. Also as seen in the previous cases, the release from encapsulated liposomes is 
much faster than that from non-encapsulated liposomes. (n=8, mean +/- deviations) 
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(n=8) of the different preparations. The control profile is an average of three different 
preparations with three samples used from each preparation. 
 It can be seen that the “burst” of protein release that was observed in the case 
of PC/Chol liposomes encapsulated in Ca-alginate is absent in the case of PC 
liposomes encapsulated in Ca-alginate. During the first 4 days, only about 25% of the 
protein is released from PC liposomes encapsulated in alginate as compared to about 
85% in the case of PC/Chol liposomes. However after day 4, there seems to be a 
slight increase in the rate of release and about 92% of protein is released in 12 days. 
After day 12, however, there is a dramatic reduction in the rate of release and almost  
all of the protein (~98%) is released in 30 days, which in the case of PC/Chol 
liposomes occurred somewhere around day 10. This leads us to suspect that the 
presence of cholesterol in microencapsulated liposomes makes them more leaky as 
compared to those without cholesterol. Such behavior is not exhibited by non-
encapsulated PC liposomes with and without cholesterol. The release profiles from 
free PC and PC/Chol liposomes are identical which shows that the cholesterol 
containing liposomes are not inherently more leaky. This indicates towards the 
possibility of an increased level of interaction of alginate with the lipid bilayer in the 
presence of cholesterol. Such behavior has been observed in the case of an increased 
insertion of cytochrome b5 into POPC bilayers (LUV’s) in the presence of 
cholesterol203. The interaction of alginate with the lipid bilayers will be discussed 
further in Section 4.2. 
 In order to confirm if the presence of cholesterol did make the liposomes more 
leaky, we studied the release of FITC-BSA from DOPC and DOPC/Chol liposomes 
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encapsulated in Ca-alginate. The use of DOPC also added to the data available on the 
effect of liposome composition on drug release. Figure 4.1.10 shows the release of  
FITC-BSA from DOPC and DOPC/Chol liposomes encapsulated in Ca-alginate. The 
release of protein from DOPC liposomes was characterized by a small burst of about 
10% on day 1 followed by a period of slow release and only about 21% protein was 
released after 8 days. However, this was followed by a period of rapid protein release 
in the form of a “burst” and by day 21 about 86% of the total protein was released. 
After 30 days, about 95% of the protein was released and very little protein release 
was detected thereafter. The release of protein from DOPC liposomes exhibited a  
small initial burst and a larger burst after day 8. Significantly, we did not observe a 
delayed burst of protein in any other liposome composition studied thus far. But a  
delayed burst was observed in the case of DOPC/Chol liposomes encapsulated in Ca-
alginate. Until day 6, only about 10% of the total protein was released but after day 6, 
a large pulse of protein release was observed. By day 11, 62% of the protein was 
released and by day 17 almost 95% of the protein had been released. Also, the release 
of protein during the “burst” appeared to be slightly faster in the case of DOPC/Chol 
liposomes than DOPC liposomes. These observations suggest that a delayed burst 
could be obtained 6-7 days after encapsulation by using DOPC and DOPC/Chol 
liposomes and that the timing of these burst could be controlled by varying liposome 
composition. This is in agreement with the observations of Cohen et al128 which 
suggested that the timing of the bursts was dependent on the liposome composition 
and possibly other factors such as alginate concentration. It is important to recognize 
that a delivery system which exhibits a delayed pulse of protein release could be very 
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Fig 4.1.10 Release of FITC-BSA from DOPC and DOPC/Chol (7:3) liposomes 
encapsulated in Ca-alginate 
 
Unlike PC/Chol (7:3) and PC/PG/Chol (6:1:3) liposomes encapsulated in Ca-alginate 
which released a large amount of the protein in an initial burst, DOPC and 
DOPC/Chol liposomes displayed a delayed pulse of protein release around day 6-7 
after which the protein was released rapidly. Release from non-encapsulated 
liposomes was slower than the encapsulated ones.  (n=8, mean +/- deviations) 
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useful for vaccine delivery. Native vaccine and the encapsulated vaccine could be 
administered together which would result in two pulses of vaccine release in the host; 
the first being from the native vaccine immediately after administration, and the 
second would be the delayed pulse from the microencapsulated liposome system.  
 We have also seen evidence that suggests that the presence of cholesterol 
makes the liposomes leakier when encapsulated in alginate. Also, we have seen in 
Section 4.1.1 that addition of PG caused about 15% protein to be permanently 
retained in the microencapsulated liposomes. This confirms that the liposome 
composition plays a very important role in determining the release profile from 
microencapsulated liposomes and that the significant variation observed with 
liposome composition might be a result of differing levels of interaction of the 
different lipid bilayers with alginate. This will be discussed in detail in Section 4.2. 
4.1.4 Effect of Liposome Type 
 We investigated the effect of liposome type on the release of FITC-BSA from 
microencapsulated liposomes. All the release data discussed in this thesis so far was 
from microencapsulated LUV’s. This section will discuss the effect of using MLV’s 
and unextruded REV’s on the release of protein. It is known that MLV’s are more 
stable in terms of leakage since the entrapped species has to diffuse through several 
bilayers45. Our hypothesis was that the release of protein from the different aqueous 
compartments of the MLV’s might give rise to a pulsatile release profile. The method 
chosen for the preparation of MLV’s, the dehydration-rehydration method does not 
involve the use of any solvents. Unextruded REV’s were prepared exactly the same 
way as LUV’s by reverse phase evaporation, the only difference being that they were 
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not extruded prior to use. Unextruded REV’s were studied since they contain 
different types of liposomes with a varied size distribution and would provide a 
“cocktail” of liposomes to be encapsulated.  
 Figure 4.1.11 shows the release profiles of FITC-BSA from PC/Chol and 
PC/PG/Chol MLV’s encapsulated in Ca-alginate. Both the release profiles are very 
similar and track each other very closely. There is no initial “burst” effect observed in 
the release profiles. Both PC/Chol and PC/PG/Chol MLV’s release ~10% of protein 
during the first 2 days following which there appears to be a slight increase in the rate 
of release. By day 9, about 60% of the protein is released from liposomes of both 
compositions. After day 9, the rate of release gradually reduces and by day 30, about 
82% of protein is released from PC/Chol MLV’s whereas those composed of 
PC/PG/Chol release about 75% of their protein content. A significant amount of 
protein (~20%) is retained within the liposomes of both compositions and after day  
30, very little protein release is observed. The absence of an initial burst is significant  
since LUV’s of both PC/Chol and PC/PG/Chol exhibited a large initial burst during 
which a major portion of the entrapped protein was released. The absence of initial 
burst could be explained by the fact that the outermost bilayers in MLV’s enclose 
much smaller aqueous spaces and hence contain a smaller amount of entrapped 
protein. Also, the retention of about 20% of the protein within the MLV’s might be 
due to the fact that the innermost aqueous compartments of the MLV’s are not 
accessible for interaction with alginate which would cause them to leak their contents. 
Visual observation showed that MLV’s also gradually concentrate towards the center  
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Fig 4.1.11 Release of FITC-BSA from PC/Chol (7:3) and PC/PG/Chol (6:1:3) 
MLV’s encapsulated in Ca-alginate 
 
Both PC/Chol and PC/PG/Chol MLV’s exhibited very similar release profiles and did 
not show an initial phase of rapid release as seen with LUV’s of the same 
composition. The protein was released in a gradual manner and only about 80-85% of 
the total entrapped protein was released over 30 days after which no significant 
release was observed. Release from non-encapsulated liposomes was slower than the 
encapsulated ones.  (n=8, mean +/- deviations) 
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of the microcapsule. This was however, much slower in the case of MLV’s than in 
the case of LUV’s and was observed only starting from day 5 to day 7. It can clearly 
be seen that microencapsulated MLV’s offer much more sustained delivery of the 
protein as compared to LUV’s of the same composition. 
 The other type of liposome we studied was unextruded REV’s. Since we have 
observed the existence of a large initial burst of protein from LUV’s encapsulated in 
Ca-alginate and a comparatively sustained release from MLV’s encapsulated in Ca-
alginate, we were interested in studying what kind of release profile would be 
obtained with a mixed population of liposomes. The reverse phase evaporation 
procedure gives rise to a mixed population of liposomes, which vary in size and also a 
significant number of the liposomes are thought to be MLV’s. This mixed population 
is subjected to extrusion to obtain mostly LUV’s with a comparatively narrower size 
distribution. However, in this case, we skipped the extrusion step in order to study the 
release of protein from the mixed population of liposomes. The hypothesis behind 
this was that the alginate would interact with the different types of liposomes 
differently giving rise to a hybrid release profile, which if one examines Figures 
4.1.1, 4.1.2 and 4.1.11 carefully, could very well be a pulsatile release profile, 
consisting of two distinct pulses of protein release. 
 Figure 4.1.12 shows the release of FITC-BSA from unextruded PC/Chol and 
PC/PG/Chol liposomes encapsulated in Ca-alginate. Interestingly, the release profiles 
do show the existence of a small delayed pulse of protein release. About 40% of 
protein is released from PC/Chol unextruded liposomes encapsulated in Ca-alginate 
during the first 10 days which is much less than that observed with PC/Chol LUV’s.  
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Fig 4.1.12 Release of FITC-BSA from PC/Chol (7:3) and PC/PG/Chol (6:1:3) 
unextruded REV’s encapsulated in Ca-alginate 
 
Both PC/Chol and PC/PG/Chol unextruded REV’s exhibited very similar release 
profiles and the initial burst effect was much reduced. However, around day 7, 
unextruded REV’s of both compositions showed a small pulse of protein release 
during which about 30% of the total protein was released in 3 days. Following the 
pulse, the protein release became progressively slower and after about 45-50 days, no 
further protein release was observed. Release from non-encapsulated liposomes was 
slower than the encapsulated ones.  (n=8, mean +/- deviations) 
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This could be attributed to the presence of MLV’s in the liposome population which 
slowed down the overall release of protein. After day 10, the release profile exhibits a  
small pulse of release during which an additional 20% of the protein is released 
within two days. Following day 12, the rate of protein release decreases and about 
80% of the total protein is released in 19 days. By day 50, almost all of the entrapped 
protein was released from the encapsulated PC/Chol unextruded liposomes. Also 
shown in Figure 4.1.12 is the release of FITC-BSA from PC/PG/Chol unextruded 
liposomes encapsulated in Ca-alginate. As in the case of PC/Chol unextruded 
liposomes, there is a small but distinct delayed burst of protein release after day 5. 
Until day 5 about 30% of the entrapped protein is released at a steady rate. However 
after day 5, there is a jump in the rate of release and by day 8 almost 60-65% of total 
protein is released. Following day 8, the rate of release gradually decreases and by 
day 30 about 95% of the protein is released from the encapsulated PC/PG/Chol 
unextruded liposomes. The existence of the delayed pulse of release is more evident 
in the case of PC/PG/Chol liposomes than in the case of PC/Chol liposomes. In case 
of PC/Chol liposomes, the pulse is more easily noticeable by looking at the release 
profiles of individual samples (data not shown) within a preparation. In the averaged 
release profile, the pulse gets diminished due to wide variations observed between 
samples (as seen by the large error bars). We observed that different samples within 
the same preparation exhibited pulses at different points in time. This behavior was 
consistently seen in all preparations of unextruded liposomes of both compositions. 
However, we had not seen this phenomenon in any other liposome type.  This could 
be attributed to the wide variation in the liposomes present in the sample, but it is 
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statistically impossible to have segregation of one type of liposomes in a sample after 
encapsulation, considering the large number of liposomes and microcapsules 
involved. We believe that these liposomes might be extremely sensitive to 
environmental conditions such as temperature in the incubator and shear caused by 
the rotary shaker. The placement of the sample at different spots on the shaker might 
result in the samples being subjected to different conditions. We did not investigate 
the reason for this behavior. Nevertheless, what we have been able to demonstrate 
here is the fact that by encapsulating a mixture of different types of liposomes, it is 
possible to obtain a release profile that is a composite (qualitatively in the least) of the 
profiles obtained by using the individual liposomes. It is plausible that the same could 
be achieved by using mixtures of liposomes of the same type but differing 
phospholipid compositions. 
 Having demonstrated the versatility of this system and the different types of 
release profiles that could be obtained, we investigated the interaction of the alginate 
with the liposomal bilayer leading to the rapid leakage of protein from the liposomes 
after encapsulation. 
4.2 Interaction Between Alginate and Liposomes 
 The nature of the interaction between alginate and liposomes was investigated 
using three different techniques. A lipid mixing assay191 was used to study whether 
the exposure of the liposomes to alginate resulted in fusion of the liposomes. To 
determine whether any interaction of the alginate with the liposomes caused the 
liposomes to become more permeable to solutes we used a carboxyfluorescein 
leakage assay190. Finally, in order to determine the mechanism of any such interaction 
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between the alginate and the liposomes, we performed differential scanning 
calorimetry on the liposomes in the presence and absence of alginate. Each of these 
techniques and the results will be discussed individually in the following sections. 
4.2.1 Lipid Mixing Assay 
 Lipid mixing experiments using liposomes containing phospholipids that are 
fluorescently labeled with NBD and rhodamine (Rh) were performed to determine if 
the presence of alginate caused fusion of liposomes. This lipid mixing assay works on 
the principle of resonant energy transfer and was performed as described by Struck et 
al191. This approach is based on the interactions which occur between two 
fluorophores if the emission wavelength of one fluorophore, the energy donor (NBD), 
overlaps with the excitation wavelength of the second fluorophore, the energy 
acceptor (Rh) and the two probes exist physically close to each other. The efficiency 
of fluorescence energy transfer between the two probes is directly dependent on their 
physical separation in space. Fusion is always accompanied by a mixing of the lipids 
of the fusing vesicles. The fusion of a vesicle containing the labeled phospholipids 
with a vesicle without any fluorescent phospholipids results in a decrease in the 
amount of fluorescent lipid present per unit of unlabeled lipid. The spatial separation 
between the energy donor and the energy acceptor increases leading to a decrease in 
the efficiency of energy transfer. The fluorescence of the energy-donating 
fluorophore (NBD) increases and, hence, monitoring of the fluorescence of the donor 
fluorophore is used to detect and track the occurrence of fusion. Such an assay has 
been used in several studies of liposome fusion such as fusion induced by the type 1 
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fusion peptide of HIV204 and also fusion induced by hemagglutinin of the influenza 
virus205. 
   PC/Chol liposomes containing NBD-PE and Rh-PE were mixed with 
unlabeled PC/Chol liposomes in the molar ratio 1:4 to a final concentration of 100 
µM. The mixing of lipid was measured by monitoring the fluorescence of NBD and 
the results are shown in Figure 4.2.1. The experiments were carried out for a period of 
only 48 hours since this is the period where the burst effect is observed and most of 
the protein is released from PC/Chol liposomes. It can be seen that only about 15% 
lipid mixing was observed in liposomes in the absence of the alginate after 48 hours. 
Also, it is seen that the lipid mixing observed in the presence of alginate (~20% over 
48 hours) is not much different from that observed in the absence of alginate. Figure 
4.2.2 shows the lipid mixing observed for PC/PG/Chol liposomes in the absence and 
presence of alginate. The lipid mixing observed in this case is lower than that in the 
case of PC/Chol liposomes which is expected due to the negative charge on the PG-
containing liposomes. However, in this case too, the lipid mixing observed (~7-8%) is 
very similar in the presence as well as absence of alginate. If alginate was causing 
fusion of the liposomes then the lipid mixing observed in the presence of alginate 
would have been significantly higher than what we observed. This led to the 
conclusion that the presence of alginate does not induce fusion of liposomes. This 
eliminated fusion of liposomes as the cause of the rapid release of entrapped protein 
from liposomes encapsulated in alginate.             
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Figure 4.2.1 Lipid mixing experiments with PC/Chol (7:3) liposomes in the 
presence of alginate 
 
Lipid mixing was monitored in PC/Chol LUV’s using resonant energy transfer 
between NBD-PE and Rh-PE to determine if alginate caused fusion of the liposomes. 
No significant difference in lipid mixing was observed between liposomes in buffer 
and those suspended in 1.5% (w/v) alginate solution. 
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Figure 4.2.2 Lipid mixing experiments with PC/PG/Chol (6:1:3) liposomes in the 
presence of alginate 
 
Lipid mixing was monitored in PC/PG/Chol LUV’s using resonant energy transfer 
between NBD-PE and Rh-PE to determine if alginate caused fusion of the liposomes. 
The lipid mixing observed in liposomes in the presence as well in the absence of 
alginate was very similar indicating that alginate does not cause the liposomes to 
undergo fusion.  
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4.2.2 Carboxyfluorescein Leakage Assay 
 Carboxyfluorescein fluorescence dequenching has been used as a tool for  
monitoring the permeability properties of liposomes206 and to study transfer of 
aqueous contents during liposome-cell interactions190. Carboxyfluorescein (CF) 
exhibits the property of self-quenching which is commonly observed in fluorescent 
systems. In dilute solutions, the fluorescence of CF is directly proportional to the 
concentration of the dye (and the number of dye molecules) in solution. As the 
concentration is raised above about 10 mM, the fluorescence yield per molecule 
decreases rapidly because of interactions between the CF molecules. Dilution of a 
concentrated solution causes dequenching and an increase in the fluorescence. 
Liposomes (LUV’s) were prepared using the REV method with 200 mM CF as the 
entrapped species. Such a high concentration of CF was used to ensure that the 
fluorescence of CF was quenched when all of it was inside the liposomes. This was 
checked by preparing a very dilute suspension of the CF-containing liposomes (10 
µM) and recording the baseline fluorescence and then recording the fluorescence after 
addition of detergent. As soon as detergent was added, causing disruption of the 
liposomes, the fluorescence of CF showed a sharp increase to a very high level 
compared to the baseline. This indicated that the CF was released from the liposomes 
and dilution into the surrounding buffer caused an increase in fluorescence. It is 
important to note that the fluorescence of CF is very sensitive to variations in pH and 
care should be taken to maintain the pH of the leakage medium as close to pH 7.5 as 
possible. The very low concentration of liposomes was used for two reasons: (1) to 
minimize any background arising from light scattering effects; and (2) to ensure that 
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the CF released into the surrounding buffer after liposome disruption was not still 
quenched.  
 Figures 4.2.3 and 4.2.4 show the leakage of CF from PC/Chol and 
PC/PG/Chol LUV’s respectively in the presence and absence of 1.5% alginate. 
PC/Chol LUV’s released about 15% of the entrapped CF in 4 days whereas during the 
same time PC/Chol LUV’s suspended in 1.5% alginate released about 35% of 
entrapped CF. PC/PG/Chol liposomes released about 12% of entrapped CF in the 
absence of alginate while in the presence of 1.5% alginate these liposomes released 
approximately 20% of the entrapped CF. These results indicate an increased 
permeability of liposomes of both compositions in the presence of alginate resulting 
in slightly faster leakage of CF from the liposomes. However, the leakage of CF 
observed from liposomes of both types is far from the burst effect observed in the 
case of release of FITC-BSA when liposomes containing the protein were 
encapsulated in Ca-alginate and Al-alginate. However, these results are comparable  
with the release of FITC-BSA from liposomes encapsulated in Ba-alginate. This 
suggests that in addition to the alginate, there might be other factors that contribute to 
the burst effect. These factors could be either the presence of protein in the liposomes 
or the crosslinking cations. It is possible that the presence of BSA in the liposomes  
results in an increased interaction with the alginate or causes aggregation or fusion of 
liposomes as has been suggested in the case of interaction of human serum albumin 
with SUV’s207. However, increased insertion of alginate in presence of protein is 
unlikely since Feeser208 observed that although liposomes containing FITC-BSA 
released protein faster in the presence of alginate, the release was marked by the  
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Figure 4.2.3 Carboxyfluorescein leakage from PC/Chol (7:3) LUV’s in the 
presence of alginate 
 
Carboxyfluorescein leakage was monitored from PC/Chol liposomes to determine if 
the presence of alginate causes the liposomes to become permeable, allowing leakage 
of entrapped material. The leakage of CF from PC/Chol liposomes is significantly 
higher in the presence of alginate than in plain buffer suggesting that alginate 
increases the permeability of the liposomes. However, the increase in permeability is 
not so drastic that it would lead to the burst effect as seen in Figure 4.1.1.   
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Figure 4.2.4 Carboxyfluorescein leakage from PC/PG/Chol (6:1:3) LUV’s in the 
presence of alginate 
 
Carboxyfluorescein leakage was monitored from PC/PG/Chol liposomes to determine 
if the presence of alginate causes the liposomes to become permeable, allowing 
leakage of entrapped material. Almost twice the amount of CF was released from 
PC/PG/Chol liposomes in the presence of alginate than in plain buffer. However, as 
in the case of PC/Chol liposomes, the increase in permeability observed is not so 
drastic that it would lead to the burst effect as seen in Figure 4.1.1.   
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absence of the rapid initial burst. The scenario of fusion in the presence of BSA is 
discounted by the fact that we have observed that non-encapsulated liposomes 
released protein slower than those encapsulated in alginate. Moreover, it has also 
been suggested that the interaction of human serum albumin with liposomes is much 
enhanced in the case of SUV’s than in the case of LUV’s (as is the case in this study) 
or MLV’s207. All this seems to point towards the crosslinking cations as the additional 
factor that contributes to the burst effect. It is conceivable that the crosslinking cation 
acts on the liposomes in a co-operative fashion with the alginate. The degree of this 
possible co-operative interaction results in the presence or absence of the burst of 
protein release. In this scenario, Ca2+-induced fusion of liposomes (with leakage of 
contents) along with the interaction with alginate would result in an initial burst of 
protein release. It has been also shown that Al3+ can cause lateral phase separation in 
liposomes209. This can destabilize the liposomes and add to the leakage of protein due 
to the interaction with alginate. There is not much evidence of any such action of Ba2+ 
on liposomes and, hence, the slower release observed with liposomes encapsulated in 
Ba-alginate.    
4.2.3 Differential Scanning Calorimetry 
 Differential scanning calorimetry (DSC) is a powerful tool used in a variety of 
fields including membrane science and polymer science. In the context of liposomes, 
thermal analysis is used to study phase transition behavior of liposomes which is very 
important for applications of liposomes for drug delivery210. It is also used to study 
interactions between drugs and liposomes as a model to investigate the mechanism of 
action of drugs on biological membranes211. DSC has also been used to study the 
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interactions of proteins212 and polymers213 with liposomes as a model for biological 
membranes. Seki et al213 and Papahadjopoulos et al212 classified interactions of 
liposomes with molecules such as proteins, drugs and molecules into three major 
classes: (1) surface adsorption only, which involves a shift in the phase transition to 
lower temperatures without affecting the enthalpy of transition (∆H); (2) insertion 
into the liposome bilayer, resulting in a decrease of transition enthalpy without 
affecting the phase transition temperature and; (3) complete disruption of the lipid 
bilayer resulting in the reduction of the transition enthalpy to zero.  
 Since the transition peak of egg PC (-5 to -15°C) overlaps the transition of 
water, we used LUV’s made of pure DOPC (-20°C) to investigate the mechanism of 
interaction of alginate with liposomes. In order to investigate the effect of cholesterol 
on the interaction between liposomes and alginate, we also performed DSC on 
DOPC/Chol (7:3) liposomes. Also, DSC was performed on only alginate in solution 
(data not shown) and it was confirmed that the alginate did not exhibit any transition 
peaks in the same region or in the vicinity of the transition peak for DOPC. 
Thermograms were recorded at a heating rate of 4°C/min and the environment in the 
calorimetric chamber was kept inert by a nitrogen purge.  
 Figure 4.2.5a shows the thermograms recorded for DOPC liposomes alone 
and for DOPC liposomes suspended in a 1.5% (w/v) alginate solution. Thermograms 
for liposomes suspended in alginate were recorded immediately after mixing. DOPC 
liposomes exhibited a transition temperature of -16.73°C with a transition enthalpy of 
about 42 J/g. DOPC liposomes that were suspended in alginate showed no significant 
change in the transition temperature (-16.93°C) but the transition enthalpy was  
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Figure 4.2.5 Differential scanning calorimetry of DOPC and DOPC/Chol 
liposomes suspended in alginate 
 
Both DOPC liposomes (a) and DOPC/Chol liposomes (b) exhibit a decrease in 
transition enthalpy in the presence of alginate, indicating insertion of alginate into the 
lipid bilayer. The transition enthalpy did not seem to change further after incubation 
at room temperature or at 37°C for 24 hours, indicating a very rapid interaction 
between the liposomes and the alginate. 
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reduced by about 18% to 34.5 J/g. Similar behavior was noted with DOPC/Chol 
liposomes (Figure 4.2.5b). Thermograms of DOPC/Chol liposomes alone showed a 
transition temperature of -20.5°C and a transition enthalpy of about 14.5 J/g. While 
the transition temperature did not change significantly in the presence of alginate, the 
transition enthalpy of DOPC/Chol liposomes in the presence of alginate dropped to 
about 9.75 J/g which represents a reduction of more than 30%.  
 In order to determine whether time and/or temperature had any effect on the  
observed interaction, thermograms were recorded from liposomes suspended in 
alginate and incubated at room temperature as well as at 37°C for 24 hours. However, 
no further difference in transition temperature or transition enthalpy was observed 
(data not shown). Table 4.2.1 represents a summary of the results obtained from 
thermal analysis of liposome-alginate interactions. 
  
 
Table 4.2.1 Summary of observations from DSC experiments 
 
Liposome 
composition 
Without alginate In presence of 1.5% 
alginate 
DOPC Tm= -16.73°C, ∆H= 42 J/g Tm= -16.93°C, ∆H= 34.5 J/g 
DOPC/Chol  Tm= -20.5°C, ∆H= 14.5 J/g Tm= -20.62°C, ∆H= 9.75 J/g 
DPPC (from ref. 128) Tm= 44.58°C, ∆H= 22.93 J/g Tm= 44.5°C, ∆H= 6.51 J/g 
 
 
 
 The reduction of transition enthalpy observed in the presence of alginate for 
both DOPC and DOPC/Chol liposomes suggests that the liposome-alginate 
interaction involves an insertion of alginate into the lipid bilayer. This observation is 
 122 
in agreement with that of Cohen et al128 who observed a 70% decrease in the 
transition enthalpy of DPPC liposomes in the presence of 1.5% alginate. The 
difference in the extent to which the transition enthalpy is reduced for different 
liposome compositions also indicates that the degree of interaction between 
liposomes and alginate is dependent on liposome composition. A larger reduction in 
transition enthalpy would lead to more leaky liposomes. It appears that the presence 
of saturated phospholipids as well as cholesterol increases the interaction. Egg PC 
contains several acyl chains, approximately one-third of them being oleoyl and one 
third of them being palmitoyl. Based on this and our observations, one would expect 
that the reduction of transition enthalpy of egg PC on interaction with alginate would 
be much greater than that of DOPC alone, which would lead to more leaky PC 
liposomes (Figure 4.1.9). The presence of cholesterol would compound the effect and 
it would be a reasonable explanation of the large initial “burst” observed in the case 
of PC/Chol (Figure 4.1.1)and PC/PG/Chol (Figure 4.1.2) liposomes. As mentioned 
earlier, an increased and tighter insertion of cytochrome b5 into LUV's has been 
observed in the presence of cholesterol (up to 30% cholesterol) 203. The exact 
mechanism of this unexpected phenomenon is not known but the authors suggested 
that the loose insertion of the membrane-anchoring domain of the cytochrome b5 into 
cholesterol containing membranes results in local packing defects which could 
conceivably facilitate the transition from loose binding to tight binding. However, no 
experimental evidence was provided for this speculation.  
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4.3 In vitro Evaluation of Encapsulated Genetically Engineered Fibroblasts 
 Fibroblasts that were genetically engineered to produce BDNF were 
encapsulated in alginate to develop a source of the neurotrophic factor that could be 
implanted directly at the site of the spinal cord injury. The aim of the encapsulation 
process was to protect the genetically engineered cells (Fb/BDNF) from the host 
immune system and to allow the BDNF to diffuse out of the microcapsule directly 
into the host injury site. Before implanting these encapsulated cells into an animal 
model, it was necessary to examine the behavior of the encapsulated cells in vitro, 
with respect to their growth and expression of the transgene for BDNF. The ability of 
the microcapsules to release the secreted BDNF was also looked at as was the 
physical integrity of the microcapsules over a period of time. 
 BDNF-producing fibroblasts were obtained from Dr. Fischer’s laboratory at 
MCP/Hahnemann University, who had modified adult Sprague Dawley fibroblasts 
with a recombinant retrovirus to secrete BDNF. The retroviral construct (Figure 
4.3.1) contains the human BDNF transgene along with a reporter gene which enables 
easy monitoring of transgene expression. The reporter gene used was LacZ, which 
codes for the bacterial β-galactosidase enzyme. The LTR’s and the IRES sequence in 
the retroviral construct allow for expression of the transgene and the reporter gene 
through transcription of a polycistronic mRNA. The construction of the recombinant 
retrovirus and the transfection of the fibroblasts with the retrovirus have been 
discussed in detail by Liu et al188. Using slot blot analysis, they calculated the 
secretion rate of BDNF from the modified fibroblasts as 12.8 ng per million cells per 
24 hours.  
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4.3.1 Growth of Fb/BDNF in Alginate Microcapsules 
 Fb/BDNF were encapsulated in alginate as described in Section 3.9.2. 
Initially, we suspended the cells to be encapsulated in growth medium and mixed the 
suspension with the alginate stock solution to obtain required concentrations of the 
cells and the alginate. However, when we sprayed the cell-alginate mixture into 
CaCl2, the microcapsules formed were very highly irregular in terms of shape and 
size when compared to the very spherical microcapsules formed in the case of 
liposome encapsulation. We realized that the proteins in the serum interacted with the 
alginate and hindered the formation of spherical microcapsules. In order to avoid this, 
in all further experiments we suspended the cells in saline before mixing them with 
alginate. To obtain sufficient therapeutic level of BDNF secretion, we wanted to 
encapsulate the cells at as high concentrations as possible. As a start, we encapsulated 
the cells at concentrations of 106 cells/ml of alginate, 2 × 106 cells/ml of alginate, 3 × 
106 cells/ml of alginate and 4 × 106 cells/ml of alginate. Figure 4.3.2 shows light 
micrographs of the Fb/BDNF encapsulated at all these concentrations immediately 
after encapsulation. The microcapsules containing the cells were placed in culture and 
observed at different times to examine growth of the cells inside the capsules and 
physical integrity of the microcapsules. Microcapsules prepared with all the 
concentrations of Fb/BDNF exhibited growth of cells inside the capsules. However, 
the capsules prepared with the highest concentration of Fb/BDNF exhibited some loss 
of microcapsule integrity after about 7 days in culture. Hence, for all future 
experiments we decided to encapsulate Fb/BDNF at a concentration of 3 × 106 
cells/ml of alginate since it was observed that at this concentration, there was  
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sufficient room for the cells to proliferate and there was minimal loss of microcapsule 
integrity, if any.  
 Figure 4.3.3 shows the growth of Fb/BDNF encapsulated in alginate at a 
concentration of 3 × 106 cells/ml of alginate. The cells inside the microcapsules 
mostly appeared as individual cells as shown in Figure 4.3.3a, but upon culture in 
medium for a few days, they began to form large spheres of cells. Such behavior of 
fibroblasts growing in alginate cells has been observed previously95. The spherical 
aggregates or “fibrospheres” become clearly visible by about 5 days after 
encapsulation (Figure 4.3.3b). The Fb/BDNF continued to grow and multiply within  
the capsules as indicated by increase in the size and number of the fibrospheres over a 
two week period (Figure 4.3.3c). 
 Proliferation and survival of primary cell lines such as pancreatic islets10 and 
hepatocytes99 and the PC12 cell line214 after encapsulation in alginate has been 
reported previously. To examine the viability of the encapsulated Fb/BDNF, some 
capsules were disrupted by treatment with EDTA in order to release the spherical 
aggregates and study their behavior in culture. The released spheres attached to the 
culture plate (Figure 4.3.4a) and within 2 days, the attached spheres began to grow 
and proliferate as shown in Figure 4.3.4b.This proves that the Fb/BDNF encapsulated 
inside the alginate microcapsules were viable and capable of proliferating under 
normal growth conditions when released from the capsules.  
4.3.2 X-Gal Staining of Encapsulated Fb/BDNF  
 In order for the proposed strategy of ex vivo gene therapy to be successful, a 
primary consideration is whether the Fb/BDNF can retain expression of the transgene 
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after encapsulation. It has been previously shown that genetically engineered  
fibroblasts continue to secrete growth factors and other proteins/peptides12, 95, 215-217 
after encapsulation in alginate. To examine whether the Fb/BDNF continued to 
express the transgene after encapsulation in alginate, the encapsulated cells were 
stained for β-galactosidase reporter gene as described in Section 3.10.2. Figure 4.3.5 
shows the β-galactosidase staining observed in encapsulated cells 2 days, 2 weeks 
and 4 weeks after encapsulation. The number and size of the fibrospheres that stained 
for β-galactosidase increased with time indicating again that the encapsulated cells, 
similar to non-encapsulated cells, continued to grow and express the transgene. Also 
the cells that were released from the capsules by treatment with EDTA were stained 
for β-galactosidase expression. Figure 4.3.6 shows the β-galactosidase staining 
observed in cells 4 days after they were released from the capsules. Figure 4.3.6a 
shows that the released sphere showed a high density of cells that were positive for β-
galactosidase. Also cells that had migrated away from the sphere (Figure 4.3.6b) 
showed extensive staining for β-galactosidase expression. The reporter gene staining 
observed in the cells released from the alginate microcapsules was very similar 
(qualitatively) to that observed in Fb/BDNF that had not been encapsulated which 
shows that the encapsulation procedure did not affect transgene expression. 
4.3.3 In vitro Bioactivity of BDNF Secreted from Encapsulated Fb/BDNF 
 Once it was known that the transgene was being expressed in the encapsulated 
cells, it was important to determine whether the recombinant BDNF was able to 
diffuse through the microcapsule into the external medium. Also it was important to 
determine whether the BDNF secreted was biologically active. This was achieved by  
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Figure 4.3.5 Reporter gene expression in encapsulated cells in vitro 
 
The encapsulated cells were stained for reporter gene β-galactosidase at 2 days (a); at 
7 days (b) and; at 4 weeks after encapsulation. The staining for β-galactosidase 
increased with time in accordance with the growth of the capsules. (Brightfield, Bar = 
250 µm)  
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Figure 4.3.6 Reporter gene expression in cells released from the capsules 
 
Encapsulated cells released by disrupting the capsules were stained for β-
galactosidase expression after 4 days in culture. The cells expressed β-galactosidase 
in the spheres that had attached to the culture surface (a) and even in the cells that had 
migrated away from the sphere (b). (Brightfield, Bar = 100 µm) 
 
 
a 
b
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using an E8 chick dorsal root ganglion (DRG) explant assay. This method has been 
previously described193 and has been used by Liu et al188 to study the bioactivity 
BDNF secreted from Fb/BDNF growing in culture by observing the neurite 
outgrowth from the DRG’s. DRG’s were dissected from day 8 chick embryos and 
used for the assay. Conditioned media was collected from Fb/BDNF capsules, cell-
free capsules and from adherent Fb/BDNF in culture and added to the wells of a plate 
containing DRG’s embedded in a collagen gel. Unconditioned media was used as the 
negative control and unconditioned media containing 450 ng of human recombinant 
BDNF was used as the positive control. Figure 4.3.7 shows the effect of the different 
media on the DRG’s. Unconditioned media (Figure 4.3.7a) and conditioned media 
from cell-free capsules (Figure 4.3.7c) did not induce any neurite outgrowth from the 
DRG’s, which was expected since the media would not contain any BDNF. In 
contrast, neurite outgrowth was observed from DRG’s to which conditioned media 
from encapsulated Fb/BDNF (Figure 4.3.7d), conditioned media from non-
encapsulated Fb/BDNF (Figure 4.3.7e) and unconditioned media containing 
recombinant human BDNF (Figure 4.3.7b) had been applied. Neurite outgrowth is 
indicated by the processes extending from the DRG’s as shown by arrows and not by 
the non-specific Schwann cell proliferation observed in Figures 4.3.7a and 4.3.7c. 
These results show that the BDNF secreted by the encapsulated Fb/BDNF is able to 
diffuse through the alginate matrix and the semipermeable PLO coating to the 
external medium and that the released BDNF remains biologically active such that it 
promotes neurite outgrowth in the DRG explant assay.  
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4.3.4 Freezing and Thawing of Microencapsulated Fb/BDNF 
 We examined the feasibility of freezing the encapsulated cells for storage 
purposes. It would be of great significance for treatment purposes, if the encapsulated 
cells to be transplanted would be readily available. We studied the freezing and 
thawing of encapsulated cells in the freezing medium consisting of 60% DMEM + 
30% FBS + 10% dimethyl sulfoxide which is routinely used to freeze several 
different types of cells for long term storage. The encapsulated cells were frozen in 
this medium and then stored in liquid nitrogen. The frozen encapsulated cells were 
thawed, transferred to normal growth medium and examined for physical integrity of 
the microcapsules as well as for transgene expression inside the encapsulated cells. 
Visual examination of the microcapsules did not show any loss of integrity and most 
of the capsules appeared to be intact. They were maintained in culture and stained for 
β-galactosidase expression. Figure 4.3.8a shows the reporter gene staining observed 
in encapsulated cells 48 hours after staining. The growth characteristics of the 
encapsulated cells did not appear to be affected by the freezing and thawing process. 
The size of the fibrospheres increased up to 3 weeks in culture and they displayed 
strong staining for β-galactosidase expression as shown in Figure 4.3.8b. A 
comparison of Figure 4.3.5 and Figure 4.3.8 shows that there is no visible difference 
between freshly prepared capsules in culture and thawed capsules with respect to 
appearance and β-galactosidase staining. These observations show that the 
encapsulated cells survive the freezing and thawing process and continue to express 
the transgene even after thawing. This can have enormous implications on the storage 
and availability of encapsulated cells for implanting immediately following an injury.  
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Figure 4.3.8 Reporter gene expression in encapsulated cells thawed after storage 
in liquid nitrogen 
 
Alginate capsules containing cells were frozen in regular freezing medium and were 
stored under liquid nitrogen. The capsules were then thawed, placed in culture and 
stained for β-galactosidase expression at 2 days (a) and; 3 weeks (b) after thawing. It 
can be seen that the cells continue to express the reporter gene and the size of the 
stained spheres increases with time. The ability to freeze the cells in encapsulated 
form with retention of transgene expression could have great implications for clinical 
purposes. (Brightfield, Bar = 250 µm)   
 
 
A 
B 
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Similar results have been reported for porcine pancreatic islet cells218, rat 
hepatocytes219, and human kidney 293 cells150. However, all these cells were primary 
cell lines that had not been genetically modified to secrete a therapeutic recombinant 
product. We believe that our results provide the first example in which a genetically 
modified cell line that had been encapsulated in alginate maintained transgene 
expression after freezing and thawing11. The ability to freeze a highly characterized 
genetically modified cell line encapsulated in a polymer matrix that protects the cells 
from the host immune system should greatly increase the clinical and experimental 
applications of this therapeutic approach.  
4.4 In vivo Studies 
 The in vivo performance of the encapsulated cells was studied in a rodent 
model of spinal cord injury. Adult Sprague Dawley rats were given a partial 
hemisection on the C3/C4 level. Figure 4.4.1 shows a schematic of the injury 
model188. We examined the survival of the encapsulated cells in vivo and also their 
ability to express the transgene at the injury site. Also the ability of the encapsulated 
cells to promote sprouting of axons in the graft area was evaluated as was the immune 
response evoked by the transplantation of the encapsulated cells.  
4.4.1 Survival and Transgene Expression of Encapsulated Fb/BDNF in vivo 
 It has been previously shown that unencapsulated fibroblasts transplanted into 
an injured spinal cord are rejected in the absence of heavy immune suppression145. 
We studied the ability of the alginate-PLO-alginate microcapsule system to protect 
the cells from the host immune system by examining the survival of the encapsulated 
cells and β-galactosidase expression in the encapsulated cells after transplantation  
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Figure 4.4.1 Schematic of experimental model of spinal cord injury 
                      (adapted from ref. 188) 
 
Animals received a partial hemisection at the C3-C4 level which resulted in 
disruption of axons in the area. The drawing shows a cross section of the spinal cord 
and the lesion cavity created by the hemisection is shown as the shaded area. 
Immediately after the creation of the lesion cavity, the animals received transplants of 
Fb/BDNF capsules or empty capsules.  
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into the injured spinal cord of rats that had not been immune suppressed. All the rats 
in this study received one bolus dose of methylprednisolone to minimize the 
inflammatory response due to the injury itself. However, none of the animals were 
subjected to chronic immune suppression. Encapsulated Fb/BDNF were transplanted 
into the lesion cavity in the spinal cord created by the partial hemisection procedure 
and were harvested 2 and 4 weeks after transplantation. Capsules harvested at 2 
weeks showed an increase in the size and the number of the spheres compared to 
those at the time of transplantation. β-galactosidase was expressed in the harvested 
capsules (Figure 4.4.2a) but the level of expression appeared to be reduced as 
compared to that observed before transplantation (Figure 4.3.4a). The harvested 
capsules were returned to culture for one week after which they showed a dramatic 
increase in staining for β-galactosidase (Figure 4.4.2b). Similar behavior was 
observed in capsules harvested at 4 weeks after transplantation. The harvested 
capsules contained large spheres of Fb/BDNF (Figure 4.4.2c) but they stained very 
weakly for β-galactosidase (Figure 4.4.2d). After one week in culture these cells 
demonstrated a dramatic increase in staining for the reporter gene (Figure 4.4.2e). 
These results suggest that there is a down-regulation of the transgene in vivo. 
However, the results also show that the down-regulation is reversible as evident from 
the increase in staining observed after maintaining the harvested capsules for one 
week in culture. The harvested capsules were disrupted and the released cells were 
allowed to grow and were stained for reporter gene expression. The growth and 
reporter gene expression of these cells after 3 days in culture (Figure 4.4.2f) was  
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similar to that observed with Fb/BDNF that had been released from capsules grown 
only in vitro (Figure 4.3.5). These results suggest that the Fb/BDNF inside alginate 
microcapsules survived in the host spinal cord, continued to express the transgene, 
although at a lower level, and were not subjected to any permanent damage by the 
host immune system. These results are similar to results by other investigators who 
showed that genetically engineered cells encapsulated in alginate survived in vivo. 
We believe that our study provides the first instance of survival of alginate 
encapsulated cells in to the injured spinal cord. 
 The encapsulated Fb/BDNF exhibited a down-regulation of the gene in vivo 
by 2 weeks. However, it was also seen that the down-regulation was reversed when 
the capsules were harvested and placed in culture. One way to explain this would be 
that the Fb/BDNF within the capsules did not survive too well after they were 
transplanted into the injured spinal cord leading to the diminished staining for the 
reporter gene. The surviving cells proliferated inside the capsules once they were 
harvested and placed in culture and the new cells expressed the transgene leading to 
an increase in staining for β-galactosidase. However, the harvested capsules were 
already filled with cells in vivo and the cell density inside the capsules did not appear 
to increase after they were placed in culture. This observation suggests that the above 
explanation for transgene down-regulation is probably incorrect. It is possible that the 
down-regulation of the transgene observed in vivo is due to soluble factors that were 
able to permeate through the alginate matrix since the encapsulated cells did not have 
any direct contact with the host spinal cord tissue. Since the host immune response 
was not suppressed, these soluble factors are likely to be inflammatory cytokines 
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secreted by activated macrophages, microglia or astrocytes which are present in the 
injury area as early as a few days after grafting162. The smaller size of the cytokines 
would permit their diffusion in and out of the alginate matrix since the parameters of 
the coating employed allows free diffusion of substances smaller than 70 kDa84. 
Several cytokines such as interferon-γ, transforming growth factor-β, interleukin-1β 
and tumor necrosis factor-α have been shown to decrease expression of transgene 
viral constructs in genetically modified fibroblasts in vitro220, 221. These studies also 
showed that the down-regulation was reversed upon removal of the cytokines. Liu et 
al188 showed that transgene expression is significantly down-regulated after one 
month in unencapsulated Fb/BDNF that were transplanted in to the injured spinal 
cord with immunesuppression. This suggests that there may be factors other than 
cytokines that are involved in down-regulation. We have observed that the transgene, 
although down-regulated is expressed up to 4 weeks in vivo. It has been suggested 
that expression of a neurotrophin for 2 weeks to one month after grafting may be 
sufficient for treatment of spinal cord injury since it may be adequate for 
regeneration188. On the other hand, it has also been shown that long term exposure to 
neurotrophic factors can have adverse side effects such as pain222, and thermal 
hyperalgesia223. These side effects would be avoided by the control of neurotrophin 
delivery due to the down regulation.  
4.4.2 Histology of Transplant Tissue. 
 The integrity of the capsules and the survival of the encapsulated Fb/BDNF 
were examined by looking at sections of the transplant tissue. Figure 4.4.3 shows 
Nissl-stained sections of the transplant tissue using cresyl violet which stains all cells  
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Figure 4.4.3 Photomicrographs of encapsulated Fb/BDNF at 4 weeks after 
transplantation into the injured spinal cord of a rat 
 
Nissl-stained parasagittal sections of the transplant area showing that capsules are 
abundant (a) and the encapsulated Fb/BDNF grow as sheets (arrows) along the inner 
walls (b) and as spheres (arrows) inside the capsules (c). (Scale Bar = 500 µm in A, 
100 µm in B, C) 
A 
C 
B 
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nuclei. The sections of the transplant tissue showed an abundant number of capsules 
(Figure 4.4.3a) which were surrounded by a matrix of non-neuronal cells that filled 
the lesion cavity. These cells were particularly dense in the immediate surroundings 
of the capsule walls. The capsules appeared to be intact as suggested by the 
continuous appearance of the capsule periphery (Figure 4.4.3a). β-galactosidase 
staining on sections of the transplant tissue showed no staining outside the capsules 
indicating that no Fb/BDNF had escaped from the capsules. Also, it was observed 
that the encapsulated Fb/BDNF grew as spheres inside the capsules (Figure 4.4.3c) 
and also in the form of sheets that were attached to the inner periphery of the capsules 
(Figure 4.4.3b). These observations are consistent with the observations of genetically 
modified fibroblasts encapsulated in alginate and implanted in the peritoneum of 
mice144. It is important to note that the capsules in the sectioned tissue do not appear 
to be as filled with cells as the capsules harvested from the lesion site. We believe 
that this is due to a loss of the alginate, in which the Fb/BDNF cells are embedded, 
during tissue processing.  
4.4.3 Immunohistochemical Analysis of the Transplant Area 
 Information about the response of the host’s immune system to the 
implantation of the encapsulated cells was obtained by immunocytochemical stains, 
the results of which are shown in Figure 4.4.4 and Figure 4.4.5. It is important to 
remember here that all the experiments were performed without any form of immune 
suppression. Figures 4.4.4 shows staining of sections of the transplant tissue with an 
antibody for glial fibrillary acidic protein (GFAP), to determine if the transplanted 
capsules elicited an astrocyte reaction. At 4 weeks after grafting, no consistent  
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Figure 4.4.4 GFAP staining for astrocyte response to the alginate capsules 
transplanted in to the injured spinal cord 
 
Darkfield photomicrographs of parasagittal sections. The staining was performed at 4 
weeks after transplantation and is counterstained with DAPI. Strong GFAP staining is 
observed at the periphery of the injury site in transplants of empty capsules (a) as well 
as transplants of Fb/BDNF capsules (b). Hardly any staining is observed in the central 
regions of the transplant area. (Scale Bar = 200 µm) 
 
a
b 
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difference was observed in GFAP staining between the spinal cords containing empty 
capsules (Figure 4.4.4a) and those containing encapsulated Fb/BDNF (Figure 4.4.4b).  
Astrocytes appeared to be concentrated at the periphery of the lesion site and in some 
cases around the capsules closer to the lesion periphery. However, no astrocyte 
presence was generally detected in the central graft area. Similar results were seen 
with stains for ED-1 to detect the presence of glial cells and macrophages which also 
attack the transplant as a response from the host immune system. There was no 
consistent difference between the staining observed in transplants of cell free capsules 
(Figure 4.4.5a) and those of encapsulated Fb/BDNF (Figure 4.4.5b) and once again 
the staining appeared to be mostly limited to the periphery of the grafted area. Overall 
the staining for immune response appeared to resemble that seen after an injury to the 
adult rat spinal cord224. This suggests that the transplantation of alginate 
microcapsules (with or without cells) does not evoke a strong immune response. 
These observations are similar to those obtained in GFAP staining associated with 
dopamine-secreting PC12 cells encapsulated in alginate and implanted in to the 
striatum of adult rats as a treatment for Parkinson’s disease214. 
 To determine whether the transplantation of the encapsulated Fb/BDNF 
created an environment that was permissive to axonal growth, we stained the 
transplant tissue using RT-97 and MAP-1B (microtubule associated protein 1B) 
antibodies for the presence of axons and a MAP-2 (microtubule associated protein 2) 
antibody for the presence of host dendrites. After 2 weeks, small amount of RT-97 
staining was observed in the spinal cord tissue along the periphery of capsules located 
at the edges of the lesion site (Figure 4.4.6a). The RT-97 staining was much increased  
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Figure 4.4.5 ED-1 staining for the presence of glial cells and macrophages in the 
lesion area after transplantation of alginate capsules 
 
Darkfield photomicrographs of parasagittal sections. The staining was performed at 4 
weeks after transplantation and is counterstained with DAPI. No consistent difference 
is observed in transplants of empty capsules (a) and those of Fb/BDNF capsules (b). 
Staining is mostly limited to the peripheral regions of the lesion area and very little 
staining is observed in the central regions of the graft. (Scale Bar = 200 µm)         
 
 
a 
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Figure 4.4.6 RT-97 staining for axonal growth in the lesion area after 
transplantation of encapsulated Fb/BDNF 
 
Darkfield photomicrographs of parasagittal sections counterstained with DAPI. At 2 
weeks, a very small amount of RT-97 staining is observed in the central regions of the 
graft (a) but axons immunoreactive for RT-97 are greatly increased at 4 weeks post-
transplantation (b). In contrast, RT-97 staining was limited to the edges of the lesion 
area in transplants of empty capsules. (Scale Bar = 200 µm)               
 
a 
b 
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at 4 weeks after transplantation and the staining extended to capsules located further 
inside the lesion area (Figure 4.4.6b). In order to enhance the visibility of the  
increased staining, the graft area in Figures 4.4.6a and 4.4.6b was marked off and the 
modified pictures are presented in Figures 4.4.7a and 4.4.7b respectively. The lengths 
of the axons staining for RT-97 within the central area of the graft were measured and 
found to increase from about 244 µm at 2 weeks to about 2000 µm at 4 weeks. That 
represents about an 8 fold increase in the length of axons staining for RT-97. Staining 
for RT-97 was observed at the margins of the transplant area with empty capsules but 
not in the central regions of the transplant. MAP-1B staining was observed in the 
transplant area only after 4 weeks (Figure 4.4.8a) and even at that time it was limited 
to the immediate neighborhood of capsules located close to the edge of the lesion 
area. No staining for MAP-1B was observed in transplants of cell free capsules. 
Exactly similar results were obtained with MAP-2 staining where some staining was 
observed at 4 weeks along the periphery of capsules containing Fb/BDNF (Figure 
4.4.8b) at the border of the injury area but none observed in transplants of empty 
capsules. These observations show that host axons and dendrites can penetrate into 
the transplant area and that the staining for the axons and dendrites increases with 
time. This suggests that the transplantation of encapsulated Fb/BDNF provides an 
effective method of delivering BDNF locally at the injury site and also seems to 
create an environment that is permissive for the growth of neurons. 
 However, the source of the axons observed in the transplant area is not 
known. The axons could be regenerating axons from within the transplant area or 
sprouting intact axons originating from the rostral and caudal portions of the spinal  
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Figure 4.4.7 RT-97 staining for axonal growth in the lesion area after 
transplantation of encapsulated Fb/BDNF (enhanced) 
 
For clarity, the transplant area has been marked off by the dotted line. RT-97 
immunostaining was traced within the transplant area to provide a measure of the 
amount of staining present in the section. The staining increased from 244 µm at 2 
weeks to about 2000 µm at 4 weeks post-transplantation. (Scale Bar = 200 µm)         
 
a 
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Figure 4.4.8 Staining for other markers of neuronal growth in transplants of 
encapsulated Fb/BDNF 
 
Darkfield photomicrographs of parasagittal sections stained with DAPI. At 4 weeks 
post-transplantation, axons immunoreactive for MAP-1B (a) and dendrites 
immunoreactive for MAP-2 were observed closely associated with the outer wall of 
the capsules. In some cases, staining for CGRP was observed in the peripheral 
regions of the transplant area. Staining for these markers was not observed at 2 weeks 
after transplantation. (Scale Bar = 100 µm)            
a
b 
c 
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cord or from the dorsal roots. Staining for calcitonin gene related peptide (CGRP), a 
marker for small and medium sized dorsal roots225, was observed in some transplants 
of encapsulated Fb/BDNF as shown in Figure 4.4.8c. However, the staining was 
observed mostly in the peripheral regions of the injury site and not in the central 
regions of the graft as observed with RT-97 staining. This suggests that the axons that 
penetrated in to the central portions of the transplant were more likely to originate 
from the central rather than dorsal roots. Using anterograde and retrograde tracing 
techniques, Liu et al188 showed that transplants of unencapsulated Fb/BDNF cells into 
the lesion site promoted regeneration of axotomized rubrospinal tract neurons and 
regenerating axons penetrated through and around the transplants in 
immunesuppressed rats.  
 Previous reports have shown axons growing into grafts of freeze dried 
alginate gel in peripheral nerves of cats226, peripheral nerves of rats227 and transected 
rat spinal cord228, 229. However, we did not observe any staining for axons and 
dendrites inside the capsules. The difference, we believe, is a result of the PLO 
coating applied to the alginate microcapsules used in our study which prevented the 
axons from penetrating into the alginate matrix. Moreover, the freeze dried alginate 
gel used in the studies mentioned above was covalently crosslinked with 
ethylenediamine (as compared to ionically crosslinked in our studies) which results in 
a more porous gel which is subject to some degree of swelling in aqueous media. The 
more porous nature of the freeze dried gel was likely the reason for the ability of 
axons to penetrate in to the gel. We observed staining for axons mostly along the 
outer wall of the capsules. One way to explain this would be that the alginate capsule 
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surface provided a growth permissive and favorable surface for the growing axons. 
However, this explanation is contradictory to the fact that alginate by itself is not 
known to have bioadhesive activity. We believe that the reason for the growth of 
axons close to the capsule periphery could be the existence of a gradient of 
concentrations of the BDNF that is secreted from the encapsulated cells. It is 
conceivable that there exist higher concentrations of BDNF close to the capsule walls 
and that the concentration decreases as distance from the capsule increases. Krewson 
et al230 observed a steep concentration gradient of NGF in the brain of rats when 
delivered from an implant of ethylene-vinyl acetate copolymer.  
4.5 Behavioral Analysis  
 Hemisection at the C3/C4 level results in asymmetry in forelimb use. 
Hemisected rats without any treatment rarely used the forelimb ipsilateral to the 
injury (in this case, the right forelimb). The cylinder test is highly sensitive to chronic 
asymmetry in limb use196. When placed in a cylinder, normal rats spontaneously 
reared and explored the wall of the cylinder either using just one forelimb at a time 
(~50%) or both forelimbs (~50%). We calculated the percentage total usage of the 
injured (right) forelimb which included the usage of the right  
forelimb alone and the usage of both forelimbs together.  
 During a rear, if only one limb is placed on the wall first then it is counted as 
an independent movement for that limb provided that the other limb does not contact 
the wall within 0.5 seconds. After the first limb is placed on the wall, a delayed 
placement of the other limb on the wall while the first limb is still placed on the wall 
is counted as an additional movement but categorized as simultaneous use of both 
 154 
limbs. If only one forelimb is placed on the wall and the wall is laterally explored 
using that forelimb then all movements are counted as independent movements for 
that forelimb until the other forelimb contacts the wall for support. If the rat explores 
the wall laterally alternating both limbs on the wall then each such limb movement is 
counted as an additional movement but categorized as simultaneous use of both 
forelimbs. For another independent limb movement to be scored, both forelimbs must 
be removed from the wall. When both forelimbs are removed from the wall and the 
rat begins wall exploration again, then the movements are again counted as 
independent or simultaneous as described above.    
 Four groups of animals were studied for behavioral analysis: (1) Animals that 
received transplants of Fb/BDNF in alginate capsules without immunesuppression 
(n=12); (2) animals that received empty capsules without immunesuppression (n=12); 
(3) animals that received Fb/BDNF in gelfoam with immunesuppression (n=6) and 
(4) animals that received Fb/BDNF in gelfoam without immunesuppression (n=6) as 
transplants at the lesion site. Baseline behavior was measured before the surgery and 
all the animals were tested weekly for 5 weeks after the surgery. 
 Figure 4.5.1a shows a normal rat moving along the wall of the cylinder. It can 
be seen that the rat is supporting its body weight with the right forelimb while moving 
the left forelimb. Figure 4.5.1b shows an injured rat and it can be seen that forelimb 
use is impaired and the rat is unable to support its whole body weight on the right 
forelimb.  
 Figure 4.5.2 shows the results of the cylinder test for all the test groups. The 
baseline behavior, measured before the surgery, was very similar for all the test  
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Figure 4.5.1 Photographs showing forelimb use by rats in a cylinder test 
 
The animals were placed in a cylinder to analyze forelimb use before and after the 
transplantation of the encapsulated cells. A healthy rat can support its body weight 
using the right forelimb (a) whereas after the surgery the right (impaired) forelimb is 
rarely used to contact the wall of the cylinder (b). 
a 
b 
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Figure 4.5.2 Functional recovery of right (impaired) forelimb use after 
transplantation of encapsulated Fb/BDNF  
 
Total use of right forelimb (independent as well as simultaneous) is shown in groups 
of animals receiving different transplants (mean +/- standard error). It can be seen that 
animals receiving transplants of encapsulated Fb/BDNF without immune suppression 
(n=12) and those receiving transplants of Fb/BDNF in gelfoam with 
immunesuppression (n=6) showed significant recovery in terms of total right forelimb 
use (almost up to baseline levels) in 5 weeks. In contrast, animals receiving 
transplants of empty capsules (n=12) and those receiving Fb/BDNF in gelfoam (n=6) 
without immunesuppression showed much reduced levels of recovery. The group of 
animals that received transplants of Fb/BDNF in gelfoam with immunesuppression 
showed no right forelimb function at week 1 (*).  
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groups and all animals used the right forelimb about 75% of the time (independent as 
well as simultaneous use). Immediately following surgery, the total use of the right 
forelimb was greatly diminished to about 10-15% of total limb use. Moreover, there 
was hardly any independent use of the right forelimb.  
 Over the 5 week period, animals that received transplants of Fb/BDNF in 
gelfoam with immunesuppression and Fb/BDNF encapsulated in alginate without 
immunesuppression showed the most recovery and the total right forelimb usage was 
restored to almost baseline levels. The recovery of function appeared to be 
progressive in time and the two groups appeared to track each other very closely, 
except for week 1. After week 2, none of the animals in these groups demonstrated 
independent use of the injured forelimb whereas by week 3 they demonstrated about 
5% independent use of the injured forelimb and by week 4 they showed 
approximately 10% independent use of the same forelimb (data not shown). The lack 
of any right forelimb function after 1 week in the group receiving Fb/BDNF in 
gelfoam with immunesuppression can be attributed to the fact that the chronic 
administration of cyclosporin A reduces the innate capacity of the animals to recover 
from the injury and also reduces the overall healthiness of the animals. However after 
week 1, these animals demonstrated significant functional recovery and the results are 
consistent with those obtained by Liu et al188.  
 The animals that received transplants of Fb/BDNF in gelfoam without 
immunesuppression demonstrated the least amount of recovery, only up to about 30% 
total right forelimb use, which could be attributed to the inability of the Fb/BDNF to 
survive at the lesion site in the absence of immunesuppression, as has been 
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demonstrated earlier145. Animals that received transplants of empty capsules without 
immunesuppression showed an intermediate recovery of up to 50% total right  
forelimb use. This could be because even though these animals did not receive any 
BDNF, it is possible that the surface of the alginate capsules provides a permissive  
substrate for the growth of regenerating axons. It has recently been shown that freeze 
dried alginate hydrogel can serve as a bridge for resected peripheral nerves226, 227 and 
transected spinal cords228, 229. The fact that animals receiving transplants of 
unmodified fibroblasts and of gelfoam alone did not elicit any significant functional 
recovery in the right forelimb188 adds to the plausibility of this reasoning. It is also 
important to note that the animals that received Fb/BDNF in gelfoam without 
immunesuppression or empty capsules did not show significant independent use of 
the right forelimb even after 5 weeks (data not shown). The trends of functional 
recovery with time are more clearly evident in Figure 4.5.3 which is the same data as 
Figure 4.5.2 but represented as a line plot. These results clearly demonstrate recovery 
of injured forelimb use in animals that received transplants of Fb/BDNF encapsulated 
in alginate in the absence of immunesuppression and that the functional recovery 
observed is comparable to that observed in animals that received transplants of 
Fb/BDNF in gelfoam with immunesuppression. Liu et al suggested that the 
progressive recovery of function in the animals could be attributed at least in part to 
the regeneration and reinnervation by axons of the rubrospinal tract promoted by the 
delivery of BDNF and that there may be additional factors that contribute to the 
recovery of function188.  
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Figure 4.5.3 Trends of functional recovery observed in different groups of 
animals 
 
The data in Figure 4.5.2 showing total use of right forelimb is plotted in a different 
way here for easier visibility of the trends observed (mean +/- standard error). The 
total right forelimb use in animal groups receiving Fb/BDNF capsules without 
immunesuppression and Fb/BDNF in gelfoam with immunesuppression tracks each 
other closely except for week 1. The recovery observed in the other two groups is 
much lower. The difference in recovery between groups receiving Fb/BDNF capsules 
and empty capsules is statistically significant (p<0.05) at weeks 3 and 5 and that 
between Fb/BDNF capsules and Fb/BDNF without immunesuppression is statistically 
significant (p<0.05) week 3 onwards.  
 
 
0
10
20
30
40
50
60
70
80
90
Baseline Week 1 Week 2 Week 3 Week 4 Week 5
Time
Fb/BDNF in gelfoam + CSA
Empty Capsules
Fb/BDNF + Capsules
Fb/BDNF in gelfoam no CSA
%
 to
ta
l u
se
 o
f r
ig
ht
 fo
re
lim
b
 160 
4.6 Modification of Microcapsule Surface 
 An interesting property of the alginate hydrogels is that they can be coated 
with substances such as proteins and peptides. We used this property to coat the 
alginate microcapsules with PLO in order to provide immunoisolation properties. The 
same property could be used to coat the microcapsules with extracellular matrix 
proteins such as laminin and or L1 that are known to be permissive for axonal growth. 
The configuration of the microcapsule then would be alginate-PLO-growth 
permissive protein where the PLO coating would provide protection from the host 
immune system and the coating of the growth permissive protein would provide a 
favorable surface for the axons to grow on.  
 Laminin is an extracellular matrix protein found in basement membranes and 
is both a structural as well as a biologically active component. The laminin molecule 
(MW ~ 850, 000) is a cross shaped structure with three short arms and one long arm. 
Laminin consists of three distinct chains called A, B1 and B2. Several studies have 
shown that laminin enhances axonal growth in vitro231, 232. Several domains and 
amino acid sequences from laminin that are believed to promote neurite outgrowth 
have been isolated such as the heparin binding domain233, P1543 peptide234, YIGSR 
peptide235, IKVAV peptide235 and the p20 peptide236. In vitro studies using these 
domains and peptides involved attaching them on glass coverslips via 
aminosilanes237, or on gold coated films of fluoropolymers such as PCTFE238. 
Moreover, no studies had been reported on the safety or effects on nerve regeneration 
of these peptides in vivo until Itoh et al239 used collagen fibers coated with the YIGSR 
peptide to demonstrate their ability to promote peripheral nerve regeneration in vivo. 
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 In recent years, alginate has been investigated for use as scaffolds in tissue 
engineering102. Covalently crosslinked freeze dried alginate hydrogels have been 
investigated for their effectiveness in wound healing100, 101 and as bridges for resected 
peripheral nerves226, 227 and the transected spinal cord228, 229. Alginate hydrogels with 
covalently coupled peptides have been studied as synthetic extracellular materials197, 
240 and as a tissue bulking agent241. 
 We investigated the possibility of creating a growth permissive surface on the 
BDNF-delivering microcapsules in an effort to enhance the regeneration of the axons 
in the injured spinal cord.  
 We first investigated the use of laminin as a coating material. Initial attempts 
to coat the alginate hydrogel with laminin brought some interesting observations. We 
first attempted to coat Ca-alginate microcapsules directly with laminin. However, we 
saw that coating the Ca-alginate microcapsules with laminin (even at concentrations 
as low as 1 µg/ml) resulted in a complete dissolution of the microcapsules. On the 
other hand such behavior was not observed when Ba-alginate or Al-alginate capsules 
were coated directly with laminin. This suggests that the laminin sequestered the Ca2+ 
from the Ca-alginate microcapsules leading to their dissolution. This is in agreement 
with previous observations that showed that calcium interacted with laminin and 
enhanced the formation of large polymers of laminin242. We next decided to test 
whether application of an intermediate PLO coating helped in preventing the 
dissolution of capsules upon application of laminin. We found that a PLO coating 
followed by coating with laminin did in fact prevent dissolution of the microcapsules. 
However, we realized that conducting in vitro experiments with microcapsules was 
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very difficult with respect to observation of cell attachment on the highly curved 
surface of the microcapsules and also in terms of handling the microcapsules in 
culture.  In order to overcome this problem and to test in vitro if the laminin coating 
was effective in promoting neurite outgrowth we used a method to prepare alginate 
hydrogel discs (described in Section 3.13.3) rather than microcapsules. The discs 
were also very convenient in terms of handling and manipulation for in vitro studies.  
 NB2a mouse neuroblastoma cells were chosen as the cell line to be used for in 
vitro studies. This cell line was chosen because it is a well accepted model of 
differentiation and can differentiate in response to various factors such as retinoic 
acid and dibutyryl cyclic AMP. Upon differentiation, these cells adopt a neuron like 
phenotype with cessation of proliferation, development of neurites, and increased 
staining for the markers MAP-2 and p21. Similar to studies using primary neurons, 
laminin also promotes neurite outgrowth from these cells. Also, these cells are much 
easier to grow and maintain in culture than primary neuronal cell lines.  
 Alginate discs were prepared using the CaSO4 slurry method197 and coated 
with a 25 µg/ml solution of laminin for 2 hours. These Ca-alginate hydrogel discs did 
not dissolve upon application of the laminin coating as did the capsules, probably 
because of the excess amount of Ca2+ used in the preparation of the hydrogel. NB2a 
neuroblastoma cells were seeded on the coated alginate surface. The number of cells 
attached to the laminin coated surface was counted using the Coulter Multisizer 
(discussed in Section 4.6.1). Also differentiation experiments were performed on the 
cells attached to the laminin coated surface. Figure 4.6.1a shows NB2a cells attached 
to laminin coated hydrogels 24 hours after seeding. The attached cells appeared to be  
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Figure 4.6.1 Differentiation of NB2a on Ca-alginate surface coated with laminin 
 
NB2a cells attached on laminin coated Ca-alginate surfaces (a) and showed very little 
neurite outgrowth after differentiation for 7 days with 10 µM dbcAMP. The loss of 
neurite-outgrowth promoting activity could be a result of binding of excess Ca2+ from 
the alginate gel. (Bar = 100 µm)   
A 
B 
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numerous and in some places in the form of clumps. Differentiation of the cells was 
observed for 7 days. However, even though the cells attached to the coated alginate 
surface a very small number of the cells showed signs of differentiation and very little 
neurite outgrowth was observed (Figure 4.6.1b). NB2a cells showed extensive neurite 
outgrowth within 4 days when seeded on regular tissue culture plates coated with a 25 
µg/ml solution of laminin (Figure 4.6.2). In fact, neurite outgrowth was observed 
starting from 2 days after attachment. This showed that while laminin did promote 
neurite outgrowth of the NB2a cells under standard conditions, coating the alginate 
discs with laminin did not seem to promote this behavior. One way to explain this 
could be that while the laminin coating on alginate allowed adhesion of cells, the 
regions that promoted neurite outgrowth were obscured and not available for 
interaction with the cells. This is conceivable because laminin is known to have 
several cell adhesion sites242, 243. It is interesting to note however, that when a laminin 
coating was applied to a covalently crosslinked alginate hydrogel, NB2a cells showed 
signs of differentiation beginning from the very first day after seeding (Figure 4.6.3). 
This leads us to conclude that the loss of neurite promoting activity of laminin when 
coated on Ca-alginate gels is a result either of the presence of excess Ca2+ or due to 
the obscuring of the relevant sites on the molecule.   
 We investigated another way of modifying the alginate microcapsule surface 
to make it growth permissive. Peptides such as the YIGSR peptide of laminin have 
been shown to promote neurite activity are easily available and can be covalently 
linked to alginate. Alginate in its native form does not possess bioadhesive properties 
but the conjugation of a biologically active peptide can change that. Rowley et al197  
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Figure 4.6.2 Differentiation of NB2a on laminin coated tissue culture surface 
 
NB2a cells were seeded on laminin coated tissue culture surface and differentiated 
with 10 µM dbcAMP. The cells started differentiating within 2 days (a) and showed 
extensive neurite outgrowth at 7 days (b). (Bar = 100 µm) 
 
A 
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Figure 4.6.3 Differentiation of NB2a on laminin coated covalently crosslinked 
alginate 
 
NB2a cells seeded on a covalently crosslinked alginate hydrogel coated with laminin 
and treated with 10 µM dbcAMP showed signs of differentiation starting from the 
first day after seeding. (Bar = 100 µm) 
 
A 
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showed that covalent attachment of GRGDY peptide to alginate hydrogels allowed 
for the attachment and proliferation of C2C12 skeletal myoblasts. Also, an alginate 
hydrogel linked with a synthetic peptide derived from bone morphogenetic protein 
(BMP) has been shown to induce ectopic bone formation in vivo240.  
 We evaluated the use of a YIGSR-alginate conjugate as a means to provide a 
growth permissive surface. YIGSR peptide was covalently linked to alginate using  
carbodiimide chemistry244. EDC, a water-soluble, zero length crosslinker was used to 
form amide linkages between the amine terminus of the peptide and the carboxyl 
groups on the alginate. The reaction was carried out under slightly acidic conditions 
(pH 6.5) since EDC is more reactive under those conditions. Sulfo-NHS was added to 
stabilize the highly reactive intermediate formed between the EDC and the carboxyl 
groups of alginate. Addition of sulfo-NHS greatly reduces hydrolysis of the 
intermediate and increases the efficiency of the conjugation244. EDC equivalent to 5% 
uronic acid activation was used in order to minimize side reactions associated with 
increasing amounts of EDC. One of the most common side reactions associated with 
the use of EDC in large amounts is the internal rearrangement of the O-acylurea 
activated ester of the EDC to an N-acylurea which would then become stably 
incorporated onto the alginate245. The amount of the N-acylurea covalently linked to 
the alginate increases with increasing amounts of EDC added during the conjugation 
process197. This could adversely affect the gelling properties of the polymer and could 
have undesirable effects in vitro as well as in vivo. The reaction scheme is shown in 
Figure 4.6.4. We studied the YIGSR-alginate conjugate in terms of its ability to allow 
cell adhesion and to promote neurite outgrowth from NB2a cells.    
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4.6.1 NB2a Adhesion on YIGSR-Alginate Surfaces 
 Adhesion of NB2a cells was quantified by dissociating the attached cells from 
the YIGSR-alginate gels by treatment with trypsin and counting them using a Coulter 
Multisizer. This was done to determine the effect of modifying the alginate on cell 
adhesion on alginate hydrogels. Unmodified Ca-alginate discs were used as the 
negative control and alginate gel discs coated with laminin were used as the positive 
control. We also studied the effect of varying the amount of peptide added per gram 
of alginate during the conjugation process. In other words, we evaluated the effect of 
surface density of the conjugated YIGSR peptide on cell adhesion, since varying the 
amount of peptide added during the conjugation reaction would be expected to 
change the number of peptide molecules per alginate molecule and present different 
surface densities of the peptide on the surface of the gel.   
 YIGSR peptide was conjugated to the alginate gel at ratios of 0.5 mg/g 
alginate, 1 mg/g alginate and 2 mg/g alginate. The peptide ratios were so chosen 
depending on the minimum peptide density required for cell adhesion. Rowley et al197 
suggested that a ratio of 1 mg GRGDS peptide/g alginate was about 2.5 orders of 
magnitude higher than that required for cell adhesion. Figure 4.6.5 shows the 
variation of NB2a adhesion on YIGSR-alginate gel discs prepared in the wells of the 
plate in situ. In every experiment the different gels were seeded with 100, 000 cells. 
As expected, since alginate by itself does not possess bioadhesive properties, a very 
small number of cells (~1.5%) attached to the unmodified alginate gels. These could 
be cells that had settled down on the gel surface and did not get removed during the 
washing of the gel. However, we see an increase in cell attachment when cells are  
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Figure 4.6.5 Adhesion of NB2a on YIGSR-alginate surfaces with varying peptide 
densities 
 
NB2a cells were seeded on gels prepared from YIGSR-alginate conjugates with 
peptide-alginate ratios of 0.5 mg/g, 1 mg/g and 2 mg/g alginate. After 24 hours, 
attached cells were removed by trypsinization and counted using Coulter Multisizer. 
Unmodified alginate gels were used as the negative controls while alginate gels 
coated with laminin were used as the positive control. There is a significant increase 
in cell attachment on gels of YIGSR-alginate as compared to unmodified alginate 
gels. Cell attachment increases dramatically between peptide-alginate ratios of 0.5 
mg/g and 1 mg/g. However, the increase is not as dramatic with gels of YIGSR-
alginate with peptide-alginate ratio of 2 mg/g.  
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seeded on gels of the YIGSR-alginate conjugate. There is a dramatic increase in the 
number of cells attached between input peptide ratios of 0.5 mg/g alginate and 1 mg/g 
alginate. While about 9.5% of the cells attached on gels made with the lowest peptide 
ratio, about 44% of the cells attached on the YIGSR-alginate gels with input peptide 
ratio of 1 mg/g alginate. This, we believe is a result of the increased peptide density 
on the surface of the gel. However, while there is a further increase in the number of  
cells attached (~63%) with an input peptide density of 2 mg/g alginate, the increase is  
nearly not as dramatic. The drastic increase in cell attachment between peptide 
density of 0.5 mg/g alginate and 1 mg/g alginate might be the result of a critical 
minimum ligand density required for cell attachment. Alginate gels that were coated 
with laminin showed about 60% cell attachment.    
 During the dissociation of the NB2a cells from the alginate hydrogels, we 
observed some breakdown of the of the alginate gel along its edges into small 
particles and this particulate matter could interfere with the counting of cells giving 
false readings. To determine whether the trend observed in NB2a cell attachment with 
varying input peptide density as shown in Figure 4.6.5 was accurate, we used an 
alternative method in which the cells were seeded on small discs of the alginate gel 
and following attachment and treatment with trypsin to dissociate the cells, the gels 
were dissolved by treatment with 10% (w/v) EDTA. After complete dissolution of the 
gels in about 30 minutes, the cells were counted. The results are shown in Figure 
4.6.6. The trend observed was similar as in Figure 4.6.5. There was a dramatic 
increase in cell attachment between peptide ratios of 0.5 mg/g alginate and 1 mg/g  
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Figure 4.6.6 Adhesion of NB2a cells on YIGSR-alginate surfaces with different 
peptide densities (modified method) 
 
These experiments were conducted on small disks of gels of modified alginate. The 
disks were dissolved by treatment with EDTA and the cells were counted using 
Coulter Multisizer. The trends observed in this case are very similar to those observed 
with the original method as shown in Figure 4.6.5. The attachment of NB2a cells 
increases dramatically between peptide-alginate ratios of 0.5 mg/g and 1 mg/g but not 
as much at a peptide-alginate ratio of 2 mg/g.  
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alginate but the increase was not as dramatic with an input peptide ratio of 2 mg/g 
alginate.  
 These observations show that the covalent grafting of YIGSR peptide on the 
alginate backbone imparts bioadhesive properties to alginate hydrogels. The YIGSR 
peptide has been identified as one of the major sites of cell adhesion in laminin and 
cell adhesion studies have demonstrated that the specific binding of cells to the 
YIGSR peptide is mediated by a non-integrin binding protein243. This non-integrin 
binding protein with a molecular weight of 68 kDa has been characterized in several 
cell types including skeletal muscle cells and neuronal cell lines246, 247.   
4.6.2 NB2a Differentiation on YIGSR-Alginate Surfaces 
 The ability of the YIGSR-alginate surface to promote neurite outgrowth in the 
attached NB2a cells was studied by treating the cells with 10 µM dbcAMP for 7 days. 
It has been shown that dbcAMP induces differentiation of neuroblastoma cells via 
activation of protein kinase A248. After allowing the cells to attach to the YIGSR-
alginate surface, the gels were washed with Hanks buffered salt solution and 
differentiation medium (seeding medium + 10 µM dbcAMP) was added. The 
differentiation medium was changed every day in order to replenish the dbcAMP 
supplied to the differentiating cells. Differentiation was studied on gels of YIGSR-
alginate with different amounts of peptide conjugated to it. Figure 4.6.7 shows the 
differentiation of NB2a cells on YIGSR-alginate with 0.5 mg peptide/g alginate. In 
Figure 4.6.7a the cells are attached on the modified alginate surface after seeding (day 
0 of differentiation) and Figure 4.6.7b shows the cells after differentiation for 7 days. 
It can be seen that no or very minimal neurite outgrowth is observed in almost all of  
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Figure 4.6.7 Differentiation of NB2a on YIGSR-alginate surface with low peptide 
density 
 
NB2a cells attach on the modified alginate surface with peptide-alginate ratio of 0.5 
mg/g (a) but a very small amount of neurite outgrowth is observed after 
differentiation for 7 days (b). (Bar = 100 µm) 
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the attached cells. With 1 mg peptide/g alginate, the NB2a cells attached on YIGSR-
alginate (Figure 4.6.8a) had a slightly larger fraction of the cells showing neurite 
outgrowth (Figure 4.6.8b) and some of the cells even had significant neurite 
outgrowth (Figure 4.6.8c). Figure 4.6.9 shows differentiation of NB2a cells on the 
highest peptide density studied. The cells attached on the modified alginate surface 
(Figure 4.6.9a) extend neurites that are considerably longer (Figures 4.6.9b-f) as 
compared to the alginate gels with lower peptide densities. Moreover, a much larger 
fraction of the cells showed neurite extension as compared to the modified alginate 
gels with lower peptide densities. Also, there was evidence of some branching of the 
neurites produced in this case. In contrast, cells attached to the unmodified alginate 
gels showed no neurite extension (data not shown). In fact the number of cells 
attached to the alginate surface seemed to decrease with time and could be a result of 
the removal of loosely attached cells during the washes applied between changes of 
medium. These results indicate that the YIGSR-alginate conjugate can provide a 
surface that is permissive to neurite outgrowth in neuroblastoma cells. Also, the 
observation of a significant amount of neurite outgrowth on YIGSR-alginate with the 
highest peptide density seems to suggest that peptide density plays an important role 
in inducing differentiation of the neuroblastoma cells. While we saw a dramatic 
increase in cell attachment between the conjugates prepared with 0.5 mg peptide/g 
alginate and 1 mg peptide/g alginate (Figure 4.6.5), a significant amount of neurite 
outgrowth was observed only in the case of the conjugate prepared with 2 mg 
peptide/g alginate. This suggests that while a lower peptide density might be 
appropriate for cell adhesion, a higher peptide density is required for the attached 
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Figure 4.6.8 Differentiation of NB2a on YIGSR-alginate surface with medium 
peptide density 
 
NB2a cells attached on the modified alginate surface with peptide-alginate ratio of 1 
mg/g (a) show significant neurite outgrowth after differentiation for 7 days (b and c) 
as compared to Figure 4.6.7b. Moreover, a larger fraction of the attached cells 
developed neurites. (Bar = 100 µm) 
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Figure 4.6.9 Differentiation of NB2a on YIGSR-alginate surface with high 
peptide density 
 
NB2a cells attached on modified alginate surface with peptide-alginate ratio of 2 
mg/g (a) showed extensive neurite outgrowth (b-f) after differentiation for 7 days as 
compared to that observed on surfaces with low and medium peptide-alginate ratios. 
A large number of the cells developed neurites and the number of neurites developed 
per cell was also higher. (Bar = 100 µm) 
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Figure 4.6.9 Differentiation of NB2a on YIGSR-alginate surface with high 
peptide density (continued) 
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cells to differentiate. It has been shown that an RGD ligand spacing of 440 nm is 
sufficient for cell attachment but a ligand spacing of 140 nm is required for other 
functions such as motility and stress fiber formation249.  It is conceivable that a 
similar requirement leads to the observation of increased neurite outgrowth at a  
higher peptide density.                             
 We have shown here that covalent attachment of the YIGSR peptide to the 
alginate backbone allows adhesion of NB2a neuroblastoma cells on the surface of 
gels made from this YIGSR-alginate conjugate. We have also shown that the covalent 
attachment of the peptide to the alginate promotes differentiation of the 
neuroblastoma cells and that the peptide density on the alginate surface plays an 
important role in differentiation. This YIGSR-alginate conjugate can be used as a 
growth permissive surface in combination with encapsulated FB/BDNF in the form of 
a coating on the microcapsule surface.              
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5. CONCLUSIONS 
 This thesis evaluated the use of alginate microcapsules for the delivery of 
therapeutic proteins using two different methods: (1) encapsulation of protein 
containing liposomes in alginate and (2) encapsulation of genetically engineered cells 
that produce BDNF for treatment of spinal cord injuries. These two methods were 
studied together because of the similarities between liposomes and cells and the 
common requirement of a mild encapsulation method for both.  
 The release of FITC-BSA from microencapsulated liposomes was studied 
with an aim to characterize this delivery system such that the effect of the different 
parameters of the system could be determined. Initial studies conducted with PC/Chol 
and PC/PG/Chol liposomes encapsulated in Ca-alginate showed that the protein was 
released very rapidly during the first 3-5 days followed by a dramatic reduction in the 
rate of release. In an attempt to eliminate the initial “burst” of protein release we 
encapsulated these liposomes in Al-alginate and Ba-alginate. We observed that the 
crosslinking ions significantly affected the nature of the release profile. Liposomes 
encapsulated in Al-alginate did show a burst effect, however, it was much reduced in 
the case of PC/PG/Chol liposomes. However, both types of liposomes showed no 
burst of protein release when encapsulated in Ba-alginate. This is the first time that an 
encapsulated liposome system with no burst effect has been developed. In addition, 
we also noted that PG-containing liposomes permanently retained about 15% of the 
entrapped protein. We also found that the liposome composition had a marked effect 
on the release of protein from microencapsulated liposomes. Studies with PC 
liposomes and liposomes composed of DOPC and DOPC/Chol indicated that the 
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presence of cholesterol increased the rate of protein release from liposomes 
encapsulated in Ca-alginate. Also, we noticed that liposomes of DOPC and 
DOPC/Chol showed a pulse of protein release at about day 7 after which the protein 
was released rapidly. With these results we demonstrated the potential of this system 
for use as a vaccine delivery device. We also investigated the effect of liposome type 
on the release profile. MLV’s encapsulated in Ca-alginate showed a gradual release 
of protein and did not exhibit the initial burst of protein release. Unextruded REV’s, 
which are a mixed population of MLV’s and REV’s displayed the capability of 
achieving pulsatile protein release. However, large deviations in the release profile 
were seen which, we believe, could be a result of environmental factors.  
 The release of protein was always faster from liposomes encapsulated in 
alginate (irrespective of the crosslinking ions) than non-encapsulated liposomes. This 
indicated that the encapsulation of the liposomes in alginate made them more 
permeable. We investigated the possibility of interactions between the liposomes and 
the alginate. Lipid mixing experiments suggested that the presence of alginate did not 
cause fusion of liposomes. However, carboxyfluorescein leakage experiments showed 
that the liposomes did become more permeable to carboxyfluorescein in the presence 
of alginate, indicating an interaction between the liposomes and the alginate. Finally, 
this was confirmed by differential scanning calorimetry which showed that the 
alginate is inserted into the liposome bilayer and that the extent of this interaction was 
dependent on the phospholipid composition.     
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 Fibroblasts that were genetically engineered to produce BDNF (Fb/BDNF) 
were encapsulated in Ca-alginate and in vitro behavior of the encapsulated cells was 
examined. The encapsulated cells continued to grow and express the transgene as 
determined by staining for β-galactosidase reporter gene expression. A DRG explant 
assay performed on conditioned media from capsules containing cells showed 
sprouting of neurites from the DRG’s indicating that the BDNF was released from the 
capsules in an active form. Capsules containing cells were frozen and stored under 
liquid nitrogen and then thawed. The encapsulated cells, when placed in culture 
continued to express the reporter gene. This was a significant observation since 
storage of cells in encapsulated form would ensure immediate availability and could 
have implications for clinical applications and this, we believe, was the first time that 
a genetically modified cell line that had been encapsulated in alginate was shown to 
survive and maintain transgene expression after freezing and storage. 
 The encapsulated cells were implanted into the injured spinal cord of rats 
without immunesuppression and the Fb/BDNF survived and continued to express the 
transgene in vivo. There was no consistent difference in the immune response 
between rats that received transplants of encapsulated cells and those that received 
transplants of empty capsules. The immune response observed seemed to be similar 
to that seen in the case of a spinal cord injury, suggesting that the transplantation of 
the encapsulated Fb/BDNF and the alginate did not elicit a significant immune 
response. Also, the encapsulated cells were protected from the host immune system. 
Staining for markers of neuronal growth showed axonal sprouting in the transplant 
area in the case of encapsulated Fb/BDNF. The axonal sprouting (as indicated by RT-
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97 staining) observed in the transplant area increased from 2 weeks after 
transplantation to 4 weeks post-transplantation. MAP-1B and MAP-2 staining was 
observed in the transplant area only after 4 weeks. Moreover, transplants of empty 
capsules showed sprouting only in the peripheral regions of the lesion site. This was 
also the first instance in which cells encapsulated in alginate had been used for ex 
vivo gene therapy in spinal cord repair and were shown to survive after implantation 
into the injured spinal cord.  
 Finally, we investigated the possibility of providing a growth permissive 
surface on the outside of the microcapsule which would allow sprouting of axons in 
the transplant. Alginate was modified by covalently attaching YIGSR peptide at 
different ratios of peptide to alginate. Differentiation experiments were conducted in 
vitro with NB2a neuroblastoma cells and the surface was shown to be permissive for 
neurite outgrowth from these cells.          
 In this thesis, it has been demonstrated that alginate and peptide-modified 
alginate continue to be excellent candidates for consideration in drug delivery 
systems. Specifically, alginate microcapsules can be used as a vehicle to modulate 
drug release from lipid vesicles while providing them immunoisolation from the host. 
On similar lines, genetically engineered cells encapsulated in alginate can be used as 
a “cell factories” for production of therapeutic products for localized delivery after 
implantation into the injured spinal cord.  
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6. RECOMMENDATIONS 
 Further studies are needed to extend the work presented in this thesis. Some of 
the recommendations are presented below. 
Microencapsulated Liposomes for Drug Delivery: 
1. Co-encapsulate liposomes of different compositions to investigate if a hybrid 
release profile can be obtained. If liposomes which demonstrate a pulse at distinct 
times are co-encapsulated in alginate, a hybrid release profile could display 
independent pulses of protein release from the microencapsulated liposomes.  
2. Determine whether the protein released from the microencapsulated liposomes is 
active over the entire expected time course of release. This can be done by using 
an enzyme whose activity can be determined by assays such as a colorimetric 
assay. 
3. Investigate the dependence of alginate-liposome interaction on the presence of 
crosslinking ions.  
4. Encapsulate liposomes in hydrogels that do not require cations for crosslinking. 
5. Animal studies to test for in vivo protein delivery profiles and potential for use as 
vaccine.   
Ex vivo Gene Therapy for Spinal Cord Injuries: 
1. Determine whether encapsulation in alginate has any effect on the rate of 
secretion of BDNF by the genetically engineered fibroblasts. 
2.  Determine the source of the axons observed in the transplant area. This can be 
done by anterograde and retrograde tracing using labeled markers.  
3. Investigate the factors involved in down-regulation of the transgene in vivo.  
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4. Examine the long term survival of the encapsulated cells in vivo and the effect of 
the long term presence of the microcapsules in the spinal cord. 
5. Optimize the alginate-peptide conjugate to obtain maximum effectiveness in vitro 
and also conduct thorough studies on the usefulness of the conjugate in vivo. 
6. Study the effect of conjugating other peptides such as IKVAV peptide to alginate 
and compare the performance of these conjugates in vitro in terms of neurite 
outgrowth. Also, examine whether a combination of different peptides conjugated 
to the alginate can enhance the potential of supporting neurite outgrowth.  
7. Examine different geometries of the encapsulated cells such as cylindrical tubes 
or strings with or without peptide-alginate conjugate. 
8. Examine the combination delivery of different neurotrophic factors by co-
encapsulating cell lines secreting these factors. Also, antibodies to inhibitors of 
neuronal regeneration could be delivered along with the neurotrophic factors.  
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Appendix A 
Protocol for preparing REV’s 
 
 
 
 
1. All glassware should be rinsed with deionized water and ethanol in that order 
and dried under a stream of argon. 
2. Cholesterol is weighed out into a 50 ml round bottom flask with a 24/40 
ground joint. Phospholipids (obtained as a solution in chloroform) are then 
added to the flask and the cholesterol is allowed to dissolve in the chloroform 
by gentle swirling. 
3. The flask is then attached to a rotary evaporator (Buchi Laboratoriums-
Technik AG, Switzerland model RE-111) and nitrogen is purged through the 
flask to maintain an inert atmosphere. A vacuum of about 700 mm Hg is 
applied to evaporate the chloroform and to form a thin film of lipid/cholesterol 
mixture on the walls of the flask. 
4. HEPES buffer (25 ml) containing 0.1 g sodium bisulfite is added to a 
separatory funnel. Diethyl ether (3 ml per 66 µmol lipid) is then added to the 
funnel. The HEPES and the ether are mixed together by gentle swirling and 
then allowed to separate. This step removes any free radicals present in the 
ether.  
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5. The aqueous fraction is removed and the ether is added to the lipid film in the 
round bottom flask. The flask is subjected to gentle swirling to dissolve the 
lipid in the ether. It is important to let all of the lipid dissolve in the ether 
before proceeding to the next step.  
6. The aqueous phase (1 ml per 66 µmol lipid) containing the material to be 
entrapped is then added to the lipid solution.  
7. The flask is covered with a rubber septum with an 18G and a 26G needle 
fitted through it. A polypropylene tube is attached to the 26G needle such that 
the free end of the tube is immersed in the liquid. Argon is slowly bubbled 
into the liquid through the tubing to maintain an inert atmosphere inside the 
flask. The 18G needle acts as an exit for the gas. Care should be taken not to 
bubble the argon too vigorously to cause rapid evaporation of the ether. 
8. The two-phase mixture is then subjected to sonication in a bath sonicator 
(Laboratory Supplies Co. Inc., Hicksville, NY model G112SP1G). Ice is 
added to the water in the bath sonicator to maintain the temperature of the 
sonication process around 4°C. The sonication is performed with gentle 
swirling of the flask to make sure that the contents of the flask are uniformly 
subjected to the sonication process. This is continued till a stable emulsion of 
the aqueous phase in the ether phase is formed (~2-3 minutes). 
9. The flask with the two-phase emulsion is attached to the rotary evaporator and 
a nitrogen purge is maintained through the flask. A small magnetic stir bar is 
put into the flask in order to help mixing of the contents. The contents of the 
flask are slowly exposed to a low vacuum (~200 mm Hg) and the ether begins 
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to evaporate. Also care should be taken not to apply too high a vacuum to 
cause boiling of the ether. Subjecting the flask to the vacuum rapidly can 
cause splashing of the contents.  
10. Evaporation of the ether causes a cooling of the contents and a paper tissue 
soaked with water at room temperature can be applied to the flask to reduce 
this effect. This is continued till a semisolid gel is formed in the flask. The 
flask is then removed and the contents are stirred to break the gel. 
11. The contents are then subjected to a slightly higher vacuum (~300-350 mm 
Hg) and maintained at that level for about 15 minutes. The gelled material 
gradually converts into a smooth suspension as the ether is removed. The flask 
is then removed and the contents mixed again. 
12. The vacuum is thus increased in steps until it finally reaches 700 mm Hg 
where it is maintained for about 30 minutes to evaporate all of the remaining 
ether. The liposomes are now ready for extrusion after which the entrapped 
material is separated by gel permeation chromatography and/or centrifugation. 
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Appendix B 
Protocol for preparation of DRV’s 
 
 
 
 
1. All glassware should be rinsed with deionized water and ethanol in that order 
and dried under a stream of argon. 
2. Cholesterol is weighed out into a 50 ml round bottom flask with a 24/40 
ground joint. Phospholipids (obtained as a solution in chloroform) are then 
added to the flask and the cholesterol is allowed to dissolve in the chloroform 
by gentle swirling. 
3. The flask is then attached to a rotary evaporator (Buchi Laboratoriums-
Technik AG, Switzerland model RE-111) and nitrogen is purged through the 
flask to maintain an inert atmosphere. A vacuum of about 700 mm Hg is 
applied to evaporate the chloroform and to form a thin film of lipid/cholesterol 
mixture on the walls of the flask. 
4. Distilled water (1 ml per 33 µmol lipid) is added to the thin film of lipid in the 
flask in order to hydrate it and form MLV’s. The mixture is stirred to speed up 
the hydration process. Nitrogen is purged through the flask in order to 
maintain an inert atmosphere inside the flask. The stirring is continued for 2 
hours. The stirring should not be so vigorous that heat is generated leading to 
a warming of the phospholipid dispersion in the flask. 
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5. The MLV’s thus formed are extruded through polycarbonate membranes in 
order to convert them to SUV’s. The MLV’s are extruded several times 
through membranes with pore sizes 0.4 µm, 0.2 µm and 0.1 µm in that order.   
6. The SUV’s are then mixed with an equal volume of a solution of the material 
to be entrapped (in distilled water) in another 50 ml round bottom flask. The 
mixture is stirred for about 15 minutes under a nitrogen purge to ensure proper 
mixing. 
7. The mixture of SUV’s and the material to be entrapped is then flash-frozen in 
a freezing mixture of dry ice and isopropanol. The flask is gently swirled 
around in the dry ice-isopropanol mixture so that the mixture in the flask is 
frozen on the walls of the flask in the form of a thin shell which aids in the 
hydration of the mixture further in the preparation. 
8. The mixture is then lyophilized in a bench top freeze dryer (Virtis Inc., 
Gardner, NY model 3.3 XL) operating at -75°C and a vacuum of about 20 
millitorrs. Freeze drying is usually completed within 4-5 hours but it is 
desirable to continue the freeze drying overnight. 
9. Following freeze drying, the preparation is rehydrated with distilled water. 
The amount of distilled water added in this step is very critical to the amount 
of solute entrapped in the MLV’s. Distilled water was added in the amount of 
1 ml per 4 ml of SUV’s used.  
10. The mixture is gently vortexed in order to speed up mixing of the contents and 
to aid hydration of the preparation. The preparation was left to stand for 30 
minutes after which it was diluted with HEPES buffer (higher osmolality) in 
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order to prevent leakage of entrapped material. The unentrapped material is 
then separated by centrifugation.  
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Appendix C 
Protocol for Phosphate Assay 
 
 
 
 
1. A 10% ascorbic acid solution is prepared in deionized water (0.88g in 50 ml). 
This solution should be stored in a dark colored bottle and preferably covered 
with aluminum foil to prevent exposure to light. The solution can be used until 
it develops a pale yellow color. A 0.08 M solution of ammonium molybdate is 
prepared in deionized water (0.5g in 50 ml) and also a 20% solution of 
perchloric acid in deionized water is prepared. 
2. A phosphorus standard solution (Sigma Chemical Co., St. Louis, MO) is used 
as the reference for measuring phosphate concentrations. Pipette out various 
amounts of the phosphorus standard solution containing 25 to 125 nmol of 
phosphorus into test tubes. Care should be taken to pipette accurate amounts 
since this is used as the standard curve. 
3. Dilute the various amounts of the phosphorus solution to 200 µl using HEPES 
buffer followed by addition of 300 µl of 20% perchloric acid. Also, tubes 
containing just 200 µl of HEPES and 300 µl of perchloric acid serve as 
blanks. These mixtures are then digested on a hot plate at 180-210°C for 30 
minutes.  
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4. The test tubes are allowed to cool and 3 ml of deionized water, 200 µl of 
ammonium molybdate and 100 µl of ascorbic acid in that order are added to 
each of the tubes including the blanks. 
5. The tubes are vortexed to mix the contents and then placed in a boiling water 
bath for 15 minutes during which a blue color develops depending on the 
amount of phosphorus present. 
6. The tubes are allowed to cool to room temperature and the absorbance of the 
blue solutions is read against the colorless/pale yellow blanks at a wavelength 
of 830 nm on a UV/Vis spectrophotometer (Hitachi Instruments Inc., San 
Jose, CA model U-2000). 
7. For determining the phosphate contents of unknown liposome samples, 
various dilutions (total volume made up to 200 µl with HEPES) of liposome 
samples are prepared. Steps 3 through 6 are repeated and the phosphate 
concentration is determined by comparing the absorbance of the unknown 
samples against the standard curve.  
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Figure C-1 Standard curve for Phosphate Assay 
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Appendix D 
Protocol for preparation of alginate-YIGSR conjugate 
 
 
 
 
1. All glassware should be rinsed with deionized water and alcohol in that order 
and dried under a stream of argon.  
2. Alginate (Manugel® DMB, a high G-content alginate) is dissolved in MES 
buffer (0.1 M MES + 0.3 M NaCl, pH 6.5) to obtain a 1% (w/v) solution. The 
pH should not be higher than 6.5 since it affects the efficiency of the 
conjugation process using carbodiimide as the crosslinker. 
3. Once all the alginate is dissolved, 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide (EDC) is added to activate the carboxylic acid groups on the 
alginate. The amount of EDC added is such that 5% of the uronic acid groups 
in the alginate are activated (assuming equimolar conversion, 50 mg EDC/g 
alginate). 
4. Addition of EDC is followed by the addition of N-hydroxysulfosuccinimide 
(sulfo-NHS) in the molar ratio 1:2 to EDC (28 mg sulfo-NHS/g alginate). The 
addition of sulfo-NHS stabilizes the intermediate formed between the EDC 
and the carboxyl group in the alginate. 
5. The solution is stirred for 15 minutes to allow the activation of the carboxyl 
groups to proceed following which the appropriate amount of YIGSR peptide 
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is added. The peptide conjugation is carried out for 20 hours under gentle 
stirring. The stirring should not be so vigorous that the heat generated warms 
the alginate solution.  
6. Several pieces of Spectra/Por dialysis tubing (molecular weight cut off: 3500) 
are soaked in deionized water for at least 2 hours to remove preservatives such 
as glycerine and sodium azide. The water should be replaced a few times to 
ensure complete removal of the preservatives. 
7. The alginate-YIGSR conjugate is transferred to the dialysis tubes using a 20 
ml syringe and the tubes are sealed with closures.  
8. The dialysis tubes are then placed in a large volume of deionized water to 
remove unreacted EDC, sulfo-NHS and unreacted peptide. The dialysis is 
carried out for 4 days with the water being replaced everyday. 
9. The purified alginate-YIGSR conjugate is transferred to 50 ml polypropylene 
centrifuge tubes and frozen at -85°C followed by freeze drying at -75°C and a 
vacuum of about 20 millitorrs to obtain the conjugate in a dried fibrous form. 
The freeze drying process takes about 3 days.  
10. The alginate-YIGSR conjugate is weighed and stored in a -20°C freezer for 
future use.  
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Appendix E 
Protocol for counting cells using Coulter Multisizer 
 
 
 
 
1. Turn on the computer and start the Coulter Multisizer Accucomp application. 
Under the Acquire menu select NEW SAMPLE. Fill out the necessary 
information click OK and select COLLECT FROM MULTISIZER from the 
Acquire menu.  
2. Before turning on the Coulter, make sure that the 100 µm orifice tube is 
attached on the sampling stand. If not, replace the existing orifice tube with 
the 100 µm orifice tube. Replace the vial of detergent with a new vial filled 
with fresh isotonic solution. 
3. Fill the jar of isotonic solution on the sampling stand. Screw the lid on the 
vacuum jar and push down the button on the lid.  
4. Turn on the sampling stand with the knobs at RESET and FILL positions. 
Then turn on the data processing unit and allow it to warm up for about 20 
minutes.  
5. Once the orifice tube fills up with isotonic solution and isotonic solution is 
seen being pumped into the vacuum jar, turn the lower knob to the CLOSE 
position.  
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6. On the data processor screen, type in the date and move the cursor to SETUP. 
Select MANUAL and press the SETUP button to check whether the 
manometer volume is set to the correct value (100 µl). Also change the 
manometer volume using the knob on the sampling stand.  
7. Check whether the Kd value is recorded correctly for the 100 µm orifice. If 
not, on the main screen, move the cursor to the Kd value. Input the new value 
(930.0) and press CAL. This will record the correct value.  
8. Move the cursor to BLANK on the screen. When the light on the vacuum unit 
comes on, press FULL. The screen will change to the count display screen. 
9. Before counting any sample, press RESET to clear any previously stored data. 
Turn the top knob to COUNT top to count the background. Once the 
background is counted, turn the knob to RESET. 
10. Press the SETUP button and move the cursor to SAMPLE. Then move the 
cursor to the BLANK SUBTRACT and change the value to YES.  
11. Replace the vial of isotonic solution (blank) with the sample cell suspension to 
be counted. Gently shake the vial to obtain a uniform suspension. Turn the top 
knob to COUNT. Once the sample is counted, turn the knob to RESET.  
12. Press PRINT to send the data to the computer where you can save it. 
13. Repeat the counting procedure as necessary.  
14. To shut down, turn the top knob to RESET and the bottom knob to CLOSE 
and shut down the sampling stand.  
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15. Release the vacuum by lifting the button on the vacuum jar. Replace the 
isotonic solution in the other jar with detergent and turn on the sampling 
stand. 
16. Turn the bottom knob to FILL and allow detergent to be filled in the orifice 
tube. Turn off the sampling stand.  
 
Precautions: 
1. Always make sure that the orifice on the orifice tube is completely immersed 
in isotonic solution or sample. If not, air bubbles created will cause a lot of 
interference with the counting process.  
2. If the orifice tube gets clogged, use one of the cleaning brushes to gently clean 
the orifice. If that does not help, refer to manual for other cleaning 
instructions.  
3. Keep an eye on the vacuum jar that collects the liquid draining from the 
orifice tube. Empty the jar once it is filled close to the top. Always shut down 
the sampling stand before releasing the vacuum.  
4. Make sure that the electrode near to the tip of the orifice tube does not touch 
the orifice tube. This can give rise to erroneous counts.  
5. It is good practice to flush the orifice tube with fresh isotonic solution 
between samples to remove any traces of the previous sample. 
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Appendix F 
Calculations for preparation of YIGSR-alginate conjugate 
 
 
 
 
Calculations were based on the molecular weight of the individual uronic acid units in 
alginate.  
Reactant Molecular Weight 
Mannuronic/Guluronic Acid 194 
EDC 191.7 
Sulfo-NHS 217.1 
YIGSR peptide 594.7 
 
The number of uronic acid residues (carboxyl groups available for activation) in 1 g 
of alginate were calculated as 1/194 = 5.155 × 10-3 moles 
 
Assuming one mole of EDC is required to activate one mole of carboxylic acid 
groups, amount of EDC required to activate carboxyl groups present in 1 g of alginate 
= 5.155 × 10-3 moles ≈ 0.9882 g 
 
⇒ Amount of EDC required to activate 5% of the carboxylic acid groups present in 1 
g of alginate = 0.9882 g × 0.05 = 0.04941 g ≈ 50 mg (2.5775 × 10-4 moles of EDC) 
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Sulfo-NHS is added in the molar ratio 1:2 to EDC ⇒ Amount of sulfo-NHS added 
per g of alginate = (2.5775 × 10-4 moles × 217.1)/2 = 28 mg  
 
Number of moles of YIGSR peptide per mg = 0.001/594.7 = 1.6815 × 10-6 moles                                       
This ensures that the reactive carboxylic acid groups available for reaction with the 
peptide are in large excess.  
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